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Abstract 
Drug delivery technology is currently advancing faster than at any time in 
biotechnology history. The challenge of drug delivery is to achieve a controlled 
release of therapeutic agents over an extended period. Controlled release 
potentially offers significant advantages over conventional dosage forms, by 
eliminating both under- and overdosing while maintaining a desired range of drug 
concentrations. An existing drug regimen for induced calving produces a 
declining blood profile that does not mimic the naturally occurring, gradually 
increasing, cortisol blood level around parturition effectively, causing animal 
health issues.  Likewise, while the existing progesterone controlled release 
systems for oestrous control successfully synchronise oestrus, it is however, 
associated with reduced fertility and as such other drugs have to be administered 
to improve the fertility during oestrus. Therefore, there is a need for a drug 
delivery system that is capable of delivering multiple drugs at various times and 
patterns. This research aimed to investigate, characterize, identify steroids with 
high absorption rates through vaginal mucosa and evaluate the potential of an 
electronic drug delivery system for the delivery of steroids for either the control of 
the bovine oestrous cycle or induced calving. 
In order to identify steroids with high absorption rates across the vaginal mucosa, 
an in vitro permeation method was developed to screen selected steroids for their 
ability to permeate artificial and biological membranes. The steroids were pre-
formulated to enhance their solubility and permeation through these membranes. 
Analytical UV and HPLC assays to characterise the pure and formulated steroidal 
compounds were also developed and validated. An assessment of an intravaginal 
Electronically Modulated Intravaginal Device (EMID) for the control of the 
bovine oestrous cycle or induced calving was carried out. Five different release 
assessment methods were investigated and critically evaluated in order to identify 
the most appropriate release assessment method for the EMID. These were: 1) the 
Drug Dissolution Test, 2) a weight loss method, 3) the dispensed weight method, 
4) the determination of piston travel distance method, and 5) the rod expulsion 
from the EMID method. The methods investigated were critically evaluated in 
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terms of ease of use and automation, reproducibility and cost/time savings. 
Optimisation of various components and construction materials of the EMID were 
also investigated. Animal trials were carried out using the original EMID 
(manufactured from polypropylene polymer) and modified inserts (manufactured 
from high density polyethylene polymer) to determine their retention rate in the 
animals. Accelerated stability testing of progesterone in suspension, oestradiol-
17β tablets, cloprostenol as a powder blend and the driving mechanism of the 
EMID were examined. 
The flux of the steroids was evaluated through poly-ε-caprolactone and excised 
cow mucosa membranes using side-by-side permeation cells.  
Results indicated that progesterone followed by dexamethasone acetate and 
dexamethasone valerate showed higher permeability values through vaginal 
mucosa compared to dexamethasone or its other analogues. The weight loss 
method of the EMID proved to be an easy and appropriate method to measure the 
release rate from the EMID. A high density polyethylene polymer was identified 
as the most ideal body material for the insert compared to polypropylene body. 
Also double O-ring silicone, Elastollan WYO 1388-5 and solid silicone pistons 
were found to be amongst the best pistons tested and all performed well compared 
to other piston materials. There was a low retention rate with either the original 
EMID or the modified inserts. Further modification of retention wings of the 
EMID did not improve the retention rate, but a good blood profile response was 
obtained from cows treated with the complete EMID containing formulated 
progesterone. The formulations and driving mechanism were found to be stable 
under the tested conditions.   
Therefore, the EMID has potential for commercial application of induced calving 
or oestrous control per vaginum administration, reliant on improvement of its 
retention mechanism.  
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Abstract 
Drug delivery technology is currently advancing faster than at any time in 
biotechnology history. The challenge of drug delivery is to achieve a controlled 
release of therapeutic agents over an extended period. Controlled release 
potentially offers significant advantages over conventional dosage forms, by 
eliminating both under- and overdosing while maintaining a desired range of drug 
concentrations. An existing drug regimen for induced calving produces a 
declining blood profile that does not mimic the naturally occurring, gradually 
increasing, cortisol blood level around parturition effectively, causing animal 
health issues.  Likewise, while the existing progesterone controlled release 
systems for oestrous control successfully synchronise oestrus, it is however, 
associated with reduced fertility and as such other drugs have to be administered 
to improve the fertility during oestrus. Therefore, there is a need for a drug 
delivery system that is capable of delivering multiple drugs at various times and 
patterns. This research aimed to investigate, characterize, identify steroids with 
high absorption rates through vaginal mucosa and evaluate the potential of an 
electronic drug delivery system for the delivery of steroids for either the control of 
the bovine oestrous cycle or induced calving. 
In order to identify steroids with high absorption rates across the vaginal mucosa, 
an in vitro permeation method was developed to screen selected steroids for their 
ability to permeate artificial and biological membranes. The steroids were pre-
formulated to enhance their solubility and permeation through these membranes. 
Analytical UV and HPLC assays to characterise the pure and formulated steroidal 
compounds were also developed and validated. An assessment of an intravaginal 
Electronically Modulated Intravaginal Device (EMID) for the control of the 
bovine oestrous cycle or induced calving was carried out. Five different release 
assessment methods were investigated and critically evaluated in order to identify 
the most appropriate release assessment method for the EMID. These were: 1) the 
Drug Dissolution Test, 2) a weight loss method, 3) the dispensed weight method, 
4) the determination of piston travel distance method, and 5) the rod expulsion 
from the EMID method. The methods investigated were critically evaluated in 
  
iii 
terms of ease of use and automation, reproducibility and cost/time savings. 
Optimisation of various components and construction materials of the EMID were 
also investigated. Animal trials were carried out using the original EMID 
(manufactured from polypropylene polymer) and modified inserts (manufactured 
from high density polyethylene polymer) to determine their retention rate in the 
animals. Accelerated stability testing of progesterone in suspension, oestradiol-
17β tablets, cloprostenol as a powder blend and the driving mechanism of the 
EMID were examined. 
The flux of the steroids was evaluated through poly-ε-caprolactone and excised 
cow mucosa membranes using side-by-side permeation cells.  
Results indicated that progesterone followed by dexamethasone acetate and 
dexamethasone valerate showed higher permeability values through vaginal 
mucosa compared to dexamethasone or its other analogues. The weight loss 
method of the EMID proved to be an easy and appropriate method to measure the 
release rate from the EMID. A high density polyethylene polymer was identified 
as the most ideal body material for the insert compared to polypropylene body. 
Also double O-ring silicone, Elastollan WYO 1388-5 and solid silicone pistons 
were found to be amongst the best pistons tested and all performed well compared 
to other piston materials. There was a low retention rate with either the original 
EMID or the modified inserts. Further modification of retention wings of the 
EMID did not improve the retention rate, but a good blood profile response was 
obtained from cows treated with the complete EMID containing formulated 
progesterone. The formulations and driving mechanism were found to be stable 
under the tested conditions.   
Therefore, the EMID has potential for commercial application of induced calving 
or oestrous control per vaginum administration, reliant on improvement of its 
retention mechanism.  
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1 Introduction to induced calving and oestrous 
control 
Induced calving and oestrous control are farm management tools used to achieve 
the following: 1) to make cows calve prematurely, 2) to bring a large number of 
animals into oestrus at a predetermined time, 3) to reduce the calving period of the 
herd to the shortest period possible, and 4) to achieve high conception rates at the 
end of the mating period (Nation, 1997; Holmes & Garcia, 1999; Compton, 
2005a). In New Zealand, seasonal calving is a prevailing zootechnical strategy 
used to synchronise the time of calving with the increase in pasture growth and 
the decrease in feed demand at the drying-off season with the reduction in pasture 
growth. Oestrous synchronisation is used to induce oestrus in a large proportion of 
a herd within a short period in order to eliminate the need of the oestrus detection, 
a process that is normally difficult and time consuming (Jemmeson, 2000). Both 
induced calving and oestrous synchronisation involve administering hormones to 
control either the pregnancy or reproductive cycle of cattle. In the case of induced 
calving, hormones are administered using intramuscular injections whereas for 
oestrus synchronisation, hormones can be administered either by intramuscular 
injections or through the use of intravaginal devices or subcutaneous implants. 
The existing drug delivery systems used for induced calving lead to health issues 
for the animals such as high mortality rates of the newborn calf and the maternal 
cow endometrial disease due to retained foetal membranes (Stevens et al., 2000). 
Drug delivery systems for oestrous synchronisation are designed to deliver a 
single drug at one time, however, for oestrous synchronisation to be effective, 
several drugs must be administered to improve fertility. A review of the New 
Zealand dairy farming industry with respect to current induced calving and 
oestrous synchronisation protocols are elaborated herein.  
1.1 The New Zealand dairy farming industry 
The majority of New Zealand dairy cows calve once a year, in a concentrated 
pattern in late winter-early spring (Nation, 1997; Holmes & Garcia, 1999). This 
seasonal calving allows the increase in the herd’s feeding requirements after 
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calving to coincide with the increase in pasture growth during springtime. At this 
time, the cows need extra energy to cope with the commencement of lactation and 
the resumption of the reproductive cycle. The lactation period usually lasts about 
300 days in a year to allow for a dry period of at least 60 days before next calving 
(Holmes & Garcia, 1999). However, there are a significant number of cows that 
calve later than the desired calving time, and conceive late in the breeding season, 
thereby making it difficult to bring these cows forward to the optimal calving 
season (Welch, 1973; Welch et al., 1979; Compton, 2005b).  Late calving cows 
are more likely to be dried off while they are still milking heavily and, therefore, 
would have a shorter lactation period and result in a poorer return for the farmer. 
In order to control the uneven calving time among the cows in the same herd and 
to make the lactation period coincide with the availability of pasture, production 
induced calving was introduced into New Zealand in 1973.  
1.2 Induced calving 
The normal gestation period of dairy cattle ranges between 278 and 290 days 
(Allen et al., 1976). However, this period may be shortened by terminating the 
pregnancy through drug intervention. Therefore, the incidence of late calving 
cows can be reduced by prematurely induced calving (Welch et al., 1979). These 
cows can then be brought back in synchronisation with the rest of herd to the 
normal conception date of the following season. This practice enables seasonal 
calving patterns to be maintained among dairy herds and gives the late calving 
cows the opportunity to become pregnant in time to calve naturally at an optimal 
time. Other possible reasons for induced calving include: 1) grouping calving at a 
precise time to ensure adequate care and shelter, 2) extending the mating season, 3) 
reducing calf size and incidence of dystocia (difficult labour) and 4) terminating 
undesired pregnancy for medical reasons (Allen at al., 1976; Gordon, 1996). 
1.2.1 Practical aspects of induced calving 
Parturition has been induced using exogenous pharmacological agents while 
mimicking the hormonal changes during the last few days of cow pregnancy 
(Adams, 1969). Administration of synthetic corticosteroids to the pregnant cow 
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results in expulsion of the foetus from as early as two months before the end of 
the pregnancy. A similar situation to natural parturition can be seen if 
dexamethasone is injected into pregnant cows to induce parturition (Kindahl et al., 
2004). Corticosteroids alone or in combination with prostaglandins are also used 
for the induction calving (Refsdal, 2000). For instance, parturition can be induced 
reliably in a cow by administration of a single glucocorticoid (e.g., 
dexamethasone) treatment of the animals after about day 255 and, less reliably, as 
early as day 235 of gestation (Gordon, 1996). Historically, corticosteroids have 
been used systematically in over 80% of New Zealand dairy herds to control the 
birth, to induce premature parturition during the third trimester of pregnancy, and 
to condense calving patterns into periods of 6-12 weeks (Macmillan, 2002). 
Corticosteroid preparations used to induce premature calving are divided into two 
categories depending on the time they take to induce calving, i.e., short-acting and 
long-acting (McGowan et al., 1975). The short-acting drugs (i.e., dexamethasone 
and flumethasone) induce parturition within two to three days after administration, 
but have two major disadvantages: firstly the number of animals which respond to 
the treatment varies markedly from herd to herd, secondly the animals that do 
respond have a high incidence of retained placenta. The longer acting drugs (e.g., 
dexamethasone trimethylacetate) are more widely used and are usually insoluble 
forms of the short acting drugs (McGowan et al., 1975). They induce calving 
approximately 15 days after injection. Some reports have suggested that the 
problem of undesired side effects such as retained placenta are worse with short-
acting formulations (Peters & Poole, 1992). When it is desirable that calving 
should be induced in cows within the last two or three weeks of gestation, a single 
injection of a number of short-acting preparations (corticosteroids administered as 
a free alcohol or soluble ester) of dexamethasone and flumethasone have shown to 
produce reliable and predictable results (Gordon, 1996).  
Calving induction and the use of corticosteroids (e.g., long- and short-acting 
corticosteroids) or/and cloprostenol (prostaglandin analogue) to induce parturition 
is well documented in the literature (Adams, 1969; Agrawal et al., 1993; Allen & 
Herring, 1976; Barth et al., 1978; Beardsley et al., 1976; Davis et al., 1979; Evans 
& Wagner, 1976; Fairclough et al., 1975; Fairclough et al., 1981b; Fulkerson & 
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McDowell, 1975; Garverick et al., 1974; Hansen & Christiansen, 1971; Jackson, 
1979; MacDiarmid, 1979; McFeely & Ganjam, 1976; Morton & Butler, 1995; 
Murray et al., 1981; Murray et al., 1982; Murray et al., 1984; Nasser et al., 1994; 
O'Farrell & Crowley, 1974; Kaker et al., 1984; Peters & Poole, 1992; Schmitt et 
al., 1975; Terblanche et al., 1976; Terblanche & Labuschagne, 1980; Wagner et 
al., 1974; Welch, 1973; Welch et al., 1973; Welch et al., 1977; Welch et al., 
1979).  
Induction of parturition by injections of prostaglandin F2α (PGF) alone or its 
analogue has been suggested to be non-physiological as the foetal cortisol levels 
obtained from the induced calving cows were not ideal to mimic the blood 
profiles obtained from the naturally calving cows (McGowan et al., 1975; 
Königsson, 2001). 
1.2.2 Effect of induced calving on milk production 
Induced calving can have both direct and indirect effects on subsequent milk 
production. The direct effect can be seen by comparing the difference in 
subsequent milk production between induced and non-induced cows that calve at 
the same time. The indirect effect is the difference in subsequent milk production 
due to altered calving dates (Morton & Butler, 1995a). While studies found 
induced calving increased milk production by increasing the number of days in 
milk, the induced cows produced 9% less than cows that calved naturally on the 
same day (Morton & Butler, 1995a). 
1.2.3 Effect of induced calving on reproductive performance 
One of the biggest challenges that New Zealand dairy farmers face is to improve 
the reproductive performance of their herds (Compton, 2005a). Induced calving 
minimises the adverse effects of declining reproductive performance in dairy 
herds on the sustainability of seasonally concentrated calving (Macmillan, 2002). 
Results of induced calving on cows reproductive performance found no effects of 
induced calving on 3-week submission rates (Morton, 2000). In contrast, results 
from Morton & Butler, (1995b) and McDougall, (2001) indicate an 8.3% 
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reduction in the induced cows’ 28-day pregnancy rate. The induced late calving 
cows however, got back into calf much sooner after calving than their earlier 
calving herd mates (Stevens et al., 2000). This means that the difference in 
calving dates between induced and late calving cows is shorter in the subsequent 
season.  
1.2.4 Animal welfare issues arising from induced calving 
Induced calving has now become an animal welfare issue due to high calf 
mortality rates, the stress it places on the cow and associated animal health 
problems (Stevens et al., 2000). For instance, the problem of retained foetal 
membranes (RFM) is associated with induced calving. Table  1.1 presents the 
effects of calving induction on RFM, stage of pregnancy and the formulation used.  
The incidence of clinical disease and mortality of induced cows were high relative 
to their non-induced herd mates (Morton & Butler, 1995c). The corticosteroids 
used for induction, suppress the immune system of the cow and may reduce its 
ability to combat disease. Additionally, corticosteroids may cause high mortality 
rates in induced calves compared with naturally born calves (75% versus 7%, 
respectively) (Morton & Butler, 1995d). Calf mortality rates vary considerably 
depending on the timing of induction and the drug regimen used. 
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Table  1.1. Rate of RFM incidences extracted from the literature due to the induced calving. 
Formulation  Phase of 
gestation 
RFM 
rate 
Reference 
Dexamethasone or flumethasone Last 1-2 weeks 54% 
(Wagner et al., 
1974) 
Opticortenol (dexamethasone trimethylacetate) with 
or without prednisolone 
Last 1-6 
weeks 8.5% 
(O'Farrell et 
al., 1974) 
PGF analogue (Cloprostenol) Last 5 weeks 
5.7-
28.2% (Day, 1977) 
Opticortenol and bethamethasone in different 
combinations 2 weeks 16% 
(Welch et al., 
1977) 
Dexamethasone Last week 52% (Chew et al., 1978) 
Opticortenol/dexamethasone isonicotinate Close to calving 25% 
(Welch et al., 
1979) 
A mixture of 20 mg dexamethasone phenylpropionate 
and 10 mg dexamethasone phosphates 1st shot and  
± 0.5 mg of cloprostenol (after 10-11 days) as 2nd shot 
Last 2 
weeks 53% 
(Kaker et al., 
1984) 
Opticortenol (1st shot) and cloprostenol (2nd shot) Last 5-12 weeks 15% 
(Morton & 
Butler, 1995d) 
Dexamethasone isonicotinate and dexamethasone 
sodium phosphate 
Close to 
calving 8.6% 
(Verkerk et al., 
1997) 
 
1.2.4.1 Other dexamethasone applications and its misuses in livestock 
animals 
Although dexamethasone is frequently used for the induction of parturition, it is 
also used in cattle either alone or in combination with antibiotics for the treatment 
of inflammatory diseases (Toutain et al., 1982; Calvarese et al., 1994). In addition, 
dexamethasone is the most abused corticosteroid (De Wash et al., 1998).  
Dexamethasone is used illegally as a growth promoter and has been administered 
to cattle through livestock food or by injection, in order to achieve mass gains. 
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Similarly, corticosteroids such as betamethasone or its esters have been detected 
in injection sites. This is unfortunate because the consumption of meat 
contaminated with injection sites can be a considerable threat to human health. 
Public opinion rejects the use of growth promoter substances such as 
corticosteroids in animal fattening (Antignac et al., 2001). Consequently, 
analytical techniques have been developed, in order to control their illegal use as 
growth promoters in meat producing animals and to insure food safety. The use of 
growth promoters has never been allowed in Europe and maximal residue levels 
have only been established for dexamethasone, which are 0.75 ng/mL in liver, 0.5 
ng/mL in muscle and 0.3 ng/mL in milk. 
1.2.4.2 Dexamethasone residue in milk and plasma 
The levels of dexamethasone in the milk of lactating cows shows the same 
profiles as the levels in plasma, but the concentration of dexamethasone in milk 
decreases more rapidly compared to the plasma concentrations because of the 
shorter half-life of dexamethasone in milk compared to the plasma (Dilova et al., 
1999). Dilova et al. (1999) showed that the clearance of dexamethasone from the 
milk was 5 days. In another study, the concentration of dexamethasone in both 
milk and plasma of cows treated with 25 mg dexamethasone trimethyl acetate 
containing radiolabelled molecules showed similar profiles (Fairclough et al., 
1981a). The concentration of dexamethasone in both milk and plasma were still 
detectable at around 0.05 ng/mL, 30 days post injection.  
Another study showed that dexamethasone traces were still detectable from 
plasma and affected cortisol levels of the treated cows up to 52 days post injection 
(Toutain et al., 1982). Even though the drug concentrations were below the 
maximal residue levels permitted, there was still some concern relating to the 
residue risk of some long acting corticosteroids. Consequently, the New Zealand 
Food Safety Authority (NZFSA) defined meat and milk-withholding periods, 35 
and 12 days, respectively, where there has been the use of long acting 
corticosteroids (NZFSA, 2006). Finally, social or marketing pressures have 
limited the use of calving induction, which is now discouraged on animal welfare 
grounds and has possible consequences for the marketing of New Zealand dairy 
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products (Macmillan, 2002). This reflects that the modern induced calving does 
not control the drug residue of long-acting corticosteroids after calving, and 
consequently, there are animal health concerns due to the undesired side effects 
arising from the treatment. Corticosteroid release needs to be controlled during 
and after treatment in order to maintain the desired drug blood responses to mimic 
naturally occurring profiles around parturition. Safer induced calving in which the 
prevailing undesired side effects are reduced to minimum is yet to be developed. 
As discussed earlier, the induced calving involves termination of pregnancy and, 
therefore, a brief discussion of recent advances in the physiology and 
endocrinology of bovine pregnancy and parturition is further discussed in the 
following sections. 
1.2.5 Introduction to endocrinology of cattle reproduction 
After reaching the age of puberty, cows are either cycling, pregnant or recovering 
from pregnancy to recycle again. Several hormones produced by the 
hypothalamic-pituitary-ovarian axis and the uterus, control cattle reproduction 
(Gordon, 1996). The hypothalamus, pituitary gland and ovary coordinate the 
reproductive cycle by secreting hormones directly into the blood. The 
hypothalamus secretes Gonadotrophic Releasing Hormone (GnRH), which in turn 
stimulates the anterior pituitary to secrete two gonadotrophic hormones (Follicle 
Stimulating Hormone, FSH and Luiteinizing Hormone, LH). LH and FSH control 
ovarian functions. FSH initiates maturation of ovarian follicles while LH induces 
ovulation and luteinization of corpus luteum (CL) cells known as granulosa and 
thecal cells. At the ovaries, the follicles produce oestrogens (primarily oestradiol-
17β) and CL produces progesterone. Both oestradiol-17β and progesterone 
regulate the reproductive cycle through a series of feed back mechanisms acting 
on the hypothalamus and pituitary gland. The uterus produces PGF which causes 
luteolysis at the end of the oestrous cycle or pregnancy (Kindahl et al., 2004; Goff, 
2004). The luteolysis process can be prevented by production of antiluteolytic 
signals, such as interferon factors produced in the presence of the embryo (Mann 
et al., 1998; Ivell et al., 2000). The interferon factors prevent PGF release from 
the endometrial epithelial cells, therefore CL function is maintained and 
progesterone is released during the pregnancy.  
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1.2.5.1 Physiology and endocrinology of bovine pregnancy and 
parturition 
Steroidal hormones associated with cow pregnancy are mainly progesterone and 
oestrogens (Kindahl et al., 2002). The progesterone level, which is used to 
indicate the stage of a cow’s reproductive cycle, is near zero during oestrus. When 
a cow conceives, the progesterone levels rise and remain high for the rest of the 
gestation period preventing further reproductive cycles occurring during 
pregnancy (Kindahl et al., 2002; Peters & Lamming, 1983). If conception does 
not happen, the progesterone level increase, reaches a peak level, and then 
declines to near zero as the cow returns to oestrus once again. Progesterone plays 
the dominant role in the maintenance of pregnancy. Progesterone originates from 
the CL and, later on in pregnancy, is supplemented by further progesterone from 
the placenta and maternal adrenal glands (Kindahl et al., 2004). It is a known fact 
that the bovine adrenal glands contribute to progesterone production and are 
capable of maintaining pregnancy following an ovariectomy at 215 days of 
gestation (Wendorf et al., 1983). The concentration of oestrogens in bovine blood 
plasma remain low during the early period of pregnancy and increase gradually 
throughout mid- to late gestation (Hirako et al., 2003). Oestrogens, which are 
mainly produced from the placenta and ovaries in the maternal cow during 
gestation, start to increase between days 70 and 265 of pregnancy (Kindahl et al., 
2004). Oestrogens play an essential role in the maintenance of pregnancy and the 
initiation of parturition. Oestrogens have several derivatives and the major 
biologically active compounds are oestradiol-17β, oestrone and oestriol. Oestrone 
sulphate, oestrone in its conjugated form, is the major oestrogen that occurs in the 
pregnant cow. Oestrone sulphate blood level begins to increase around day 50 of 
pregnancy and gradually increases until day 80 (Hirako et al., 2003). However, 
oestradiol-17β and oestrone blood levels remain low until day 80. Oestrone 
sulphate levels are monitored during pregnancy and foetal wellbeing (Kindahl et 
al., 2004).  
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1.2.5.1.1 Hormonal blood profiles of the foetus and maternal cow at late 
pregnancy and around parturition 
Maintenance of pregnancy in the cow is dependent upon the balance of several 
hormones maintained by interactions between the cow, the placenta and the foetus 
(Kindahl et al., 2002). At late pregnancy and around parturition, the decreased 
levels of progesterone prior to the time of parturition and the increased levels of 
oestradiol-17β and PGF on the day of parturition appear to be crucial 
(Kornmatitsuk et al., 2002). A gradual reduction of progesterone concentration is 
seen in the last 2-3 days prior to parturition followed by an even more rapid 
decline in progesterone until delivery, a process known as pre-partial luteolysis 
(Fairclough et al., 1981b). PGF plasma levels increase in late pregnancy and the 
highest levels are reached during parturition (Königsson, 2001). Hypothetical 
profiles of the foetal and maternal hormonal changes around calving period of 
cattle are shown in Figure  1.1. Initially, the foetal cortisol levels start to rise 
significantly at less than four days before parturition (Fairclough et al., 1981b). 
The cortisol rise continues in the next two days and then reaches a maximum level 
the day before parturition. PGF levels on the other hand start to rise only two days 
before parturition, and the progesterone level starts to drop dramatically just 
several hours before parturition and the oestrogen levels continue to rise until on 
the day of parturition (Figure  1.1).  
 
Figure  1.1. Hypothetical foetal cortisol and maternal hormone changes around calving  
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1.2.5.1.2 Mechanism of naturally occurring parturition 
Parturition is a natural event that involves stress and pain for the cow (Hydbring et 
al., 1999). Cortisol is a naturally occurring stress hormone that is produced by the 
adrenal gland and released during stress and pain (Kindahl et al., 2004). It is 
generally accepted that the signal for the initiation of parturition originates in the 
foetus and not the maternal cow (Taverne et al., 2002). A functionally intact foetal 
hypothalamus-pituitary-adrenal axis (HPA) dictates the initiation of spontaneous 
parturition (Young et al., 1996). The mechanism of this trigger is not well 
understood, but it might be due to stress caused by the foetus reaching its critical 
size and the lack of space in the uterus. This stress exerts considerable pressure on 
the foetal hypothalamus to release corticotrophin releasing hormone (CRH). CRH 
and adrenocorticotrophic hormone (ACTH) together with cortisol are involved in 
the initiation of parturition in the foetus (Kindahl et al., 2004). ACTH is secreted 
from the anterior pituitary in response to CRH from the hypothalamus. ACTH 
stimulates secretion of cortisol from the adrenal cortex. A typical diagram 
representing a hypothesis for the mechanism of initiation of parturition in the cow 
is shown in Figure  1.2. The release of cortisol induces the 17α-hydroxylase 
enzyme in the placenta to start the conversion of progesterone to oestrogen 
(Kindahl et al., 2004). Therefore, the level of progesterone falls and oestrogen 
increases in the blood. Cortisol also regulates PGF synthesis (Kindahl et al., 2004) 
such that cortisol induces enzymes, which promote PGF synthesis (Goff, 2004).  
 
Figure  1.2. Representation of the mechanism of initiation of parturition in the cow. 
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In the meantime, the reproductive organs of a pregnant cow undergo discrete 
changes during gestation. The vulva enlarges, becoming noticeable around the 
seventh month of gestation. The cervix remains tightly closed and is sealed by a 
mucus plug. Relaxation of the pelvic ligaments occurs gradually during gestation 
and becomes more noticeable with approaching parturition (Gordon, 1996).  
Relaxin, together with oestrogen compounds, soften the cervix, opens the birth 
canal, and stimulates the release of PGF from the endometrium (Kindahl et al., 
2004). Softening of the cervix is due to changes in collagen fibres. These changes 
lead to loss of the mucus plug followed by dilation and opening of the cervix as 
well as the stretching of the vagina, which in turn causes neural impulses to the 
brain through ascending pathways and stimulates the secretion of oxytocin from 
the pituitary gland, causing the uterine smooth muscles to contract. This makes 
the uterus become more excitable and starts contractions to propel the foetus into 
the vaginal canal (Kindahl et al., 2004). Therefore, sequential events, some of 
which are cervical ripening and dilatation, activation of uterine musculature, 
attainment of the appropriate posture by the foetus, expulsion of the foetus and 
detachment and expulsion of the placenta, make up the process of natural 
parturition (Gordon, 1996). The placental detachment process initiates several 
weeks before parturition and reaches completion prior to the day of parturition 
(Königsson, 2001). The final detachment occurs along the interface borders 
between the foetal and the maternal parts of the placenta. 
1.2.5.2 Parturition failures 
Complex foetal endocrine dysfunction can lead to growth retardation of the foetus 
(Hafner et al., 1991). For instance, hypoplasia of the anterior pituitary gland and 
adrenal cortex dysfunction suggest that a failure in the initiation of parturition 
results from a foetal deficiency of ACTH and cortisol hormone (Figure  1.2). The 
lack of foetal brain development can cause prolonged pregnancy since the 
hypothalamus does not release CRH which triggers the release of ACTH from 
pituitary (Wintour et al., 1996). In addition, surgical disconnection of the pituitary 
from the hypothalamus (hypophysectomy) prevents parturition (Poore at al., 
1999). Furthermore, some studies have found that an ingestion of certain species 
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of teratogenic plants (i.e., Lupinus formosus and Lupinus arbustus) during 
specific gestational periods harm the unborn calf, which leads to birth defects and 
the need for cows induction (Panter et al., 1998; Keeler et al., 1976). 
1.2.5.3 Drug intervention to prolong or to shorten pregnancy 
Pregnancy can be prolonged or shortened through drug intervention. For example, 
when pregnant cows are given norgestomet, a progesterone analogues, ear 
implants, the pregnancy was prolonged and within 36-47 hours after the removal 
of the implants, the expulsive stage of calving will start (Janszen et al., 1990). 
This is due to progesterone withdrawal, which is a prerequisite for the normal 
parturition process. On the opposite end of the spectrum, an intrafoetal infusion of 
dexamethasone can shorten pregnancy and induce premature parturition in cattle 
at six weeks before full term (Fairclough et al., 1981b). A study showed that 
dexamethasone infusions are more effective when given to the foetus rather than 
the maternal cow. Intrafoetal infusion of prostaglandin can also induce premature 
parturition in sheep and does so by activating the foetus HPA axis (Young et al., 
1996). An infusion of ACTH to hypophysectomised foetuses can also induce 
labour (Figure  1.2). Similarly, an infusion of cortisol to foetus can lead to 
premature parturition (Ingram et al., 1999). Feeding pine needles to pregnant 
cows in late gestation causes incidences of premature parturition due to a change 
of cortisol, progesterone and oestrogens metabolism (Short et al., 1993). In fact, 
the feeding of pine needles shortened pregnancy by about two weeks and induced 
a premature normal rise in cortisol and estradiol-17β associated with parturition 
(Short et al., 1989). Foetal cortisol triggers the parturition process and causes 
dramatic changes of oestradiol-17β, PGF and progesterone levels in the maternal 
cow. The levels of cortisol and other hormones in both foetus and the maternal 
cow close to parturition will be elaborated in the following section. 
1.2.5.4 Foetal cortisol, oestrone and oestradiol-17β levels during normal 
calving 
Fairclough and others (1975) investigated plasma cortisol concentrations in the 
foetus and the maternal cow near full term. Foetal cortisol levels increased 
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progressively from around 10 ng/mL, 9 days before term, to a maximum 60-100 
ng/mL at parturition. This six to eight fold increase in foetal cortisol 
concentrations over the last 10 days of pregnancy was also reported in other 
studies. For instance, McGowan et al. (1975) found that the foetal cortisol levels 
were less than 10 ng/mL three weeks before normal parturition, then rose to a 
peak of up to 80 ng/mL on the day of parturition. In another study, it was found 
that foetal cortisol rose slowly from 5.0 ± 0.7 ng/mL at 20 days to 9.3 ± 3.0 ng/mL 
at 10 days before term and then progressively increased to a mean of 74 ng/mL 
(Hunter et al., 1977), whereas, the foetal oestrone and oestradiol-17β 
concentrations showed little or no change toward term and were both less than 50 
pg/mL. 
1.2.5.5 Maternal cortisol, oestrone, oestradiol-17β and PGF levels of 
normal calving 
The maternal cortisol levels remained below 20 ng/mL up to the day of parturition 
(Fairclough et al., 1975; McGowan et al., 1975). The maternal utero-ovarian 
oestrogen levels rose slowly from 20 to 10 days pre-partum and then increased 
more rapidly reaching peak levels of 2.9 ± 0.6 ng/mL for oestrone and 1.4 ± 0.3 
ng/mL for oestradiol-17β, 1 to 4 days before delivery (Hunter et al., 1977). The 
maternal progesterone concentrations declined towards term and showed a rapid 
decrease over the last 36-48 hours before calving. This was concomitant with a 
gradual rise of PGF until the last 24 hours where there was a dramatic increase, 
reaching peak levels (5.7 ± 0.6 ng/mL) during labour. During normal parturition, 
cortisol concentrations increase and continue to rise during foetal expulsion, peak 
until levels are altered when the calf is born. Levels return to preparturition values 
one day after calving (Hydbring et al., 1999).  
1.2.6 Hormonal blood levels associated with induced calving 
Kaker et al. (1984) investigated hormonal profile changes between induced and 
spontaneous calving cows during and after the induction of parturition using 
dexamethasone with or without the aid of PGF and found: 1) there were no major 
differences in progesterone, oestradiol, and prostaglandin concentration between 
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the induced and non-induced cows before or after the treatment, 2) treated cows, 
which retained foetal membranes, had lower progesterone values one to two days 
before calving compared to their non-induced counterparts, and 3) PGF 
concentrations steadily increased in the treated cows in contrast to the dramatic 
increase that occurred in non-induced cows in the last two days of pregnancy. The 
study concluded that the pre- and post-partum hormonal profiles and fertility were 
similar in induced and non-induced cows. Perhaps this similarity between the two 
groups was because the cows were almost close to their normal calving time and, 
therefore, the induction programme would have no major impact on them. In both 
spontaneous and induced calving, maternal plasma progesterone levels fall before 
oestrogen levels rise suggesting that the induced treatment might mimic the 
physiological mechanisms by which the foetus induces parturition in cattle. 
However, cortisol, the trigger hormone or the dexamethasone levels, were not 
monitored in this study. In another study, the effect of the infusion of 
dexamethasone into foetal calves, which induced premature parturition in six 
cows (at day 240 of gestation) on the maternal and foetal hormonal changes were 
investigated (Fairclough et al., 1981b). Three infusion rates of 0.1, 1.0 or 10 
mg/day, which induced calving in 12, 9 and 3 days, respectively, were tested. The 
maternal hormonal changes observed for all cows were similar. Progesterone 
levels declined and both oestrogen and PGF concentrations increased before 
parturition. The foetal plasma cortisol levels were reduced by the higher infusion 
rates (1.0 or 10 mg/day) during the entire infusion. At the lower infusion rate (0.1 
mg/day), there was a rise in foetal cortisol concentration from 5 to 60 ng/mL 
during the last 2-3 days before parturition. This level of cortisol is similar to that 
found at naturally occurring delivery as previously discussed. Dexamethasone had 
no effect on the foetal oestrogen levels at the lowest infusion rate, but at the rate 
of 1.0 mg/day or greater there was a marked rise in the foetal plasma levels of 
oestrogen. The study also showed that the effect of dexamethasone infusion on 
hormonal changes was dose dependent (Fairclough et al., 1981b). 
1.2.6.1 The pharmacokinetics of dexamethasone in cows 
The pharmacokinetics of dexamethasone were studied in four non-lactating dairy 
cows all of which received dexamethasone and dexamethasone isonicotinate via 
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the intravenous or the intramuscular route (0.1 mg/kg) (Toutain et al., 1982). 
Following intravenous administration, the half-lives were similar (5.6 and 4.9 
hours, respectively) for dexamethasone and dexamethasone isonicotinate. The 
peak plasma concentrations reached maximum values within one-minute post 
injection and bioavailability was approximately 75%-80%. The drug was largely 
distributed in the tissues and only a fraction of the intravenous dose reached the 
systemic circulation as intact drug (Toutain et al., 1982). The plasma 
concentrations of both formulations showed a very rapid and high blood response 
(very sharp initial concentrations can be toxic to the animal subjects) with ranges 
from 500 to 600 ng/mL, followed by a three phase declining profile. The first and 
second phases were rapid (0-16 and 16-60 minutes, respectively) whereas the final 
phase was prolonged and showed the elimination of the drug up to 24 hours later. 
This study found that the two formulations produced similar results, 1) showing 
dexamethasone isonicotinate releases dexamethasone as the active compound, and 
2) the ester bond hydrolysis was very rapid and complete since the dexamethasone 
concentration in plasma reached the highest level within one minute. Like wise, 
following intramuscular administration of dexamethasone or dexamethasone 
isonicotinate (0.1 mg/kg) in the same number of cows, the half-lives showed no 
significant difference between the two formulations (6.6 and 6.1 hours). For both 
formulations the plasma concentrations initially increased, the peak plasma 
concentrations (ranges between 42 and 44ng/mL) were reached at 3 to 4 hours 
post injection and bioavailability was approximately 70%. The plasma 
concentrations reached a plateau level and subsequently the concentrations 
decreased as observed at the post intravenous injection. Both the intravenous and 
intramuscular dexamethasone injections showed different plasma profiles. The 
dexamethasone was available in the blood circulation immediately after the 
intravenous administration, whereas with the intramuscular administered 
dexamethasone, absorption took place before the drug was available in the blood 
circulation. The half-lives of dexamethasone absorption range between 1.5 and 
2.0 hours for the two formulations, respectively. The plasma concentration of 
dexamethasone in cows following the administration of dexamethasone esters 
showed that plasma dexamethasone concentrations were elevated for 3-4 and 7-8 
days following intramuscular injection of soluble short-acting and insoluble long-
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acting dexamethasone esters, respectively (Fairclough et al., 1981a). For instance, 
the plasma concentration of dexamethasone in cows injected intramuscularly with 
either 20 mg of dexamethasone trimethyl acetate or tributyl derivative reached 
peak levels of 0.6-1.1 ng/mL of dexamethasone in 2-6 days then declined to 
undetectable levels (<0.15 ng/mL) 14 days after the injection, whereas the equal 
dose of dexamethasone sodium phosphate resulted in the plasma concentrations of 
dexamethasone which increased sharply to maximum levels of 24-70 ng/mL 
within 2-20 minutes and fell to undetectable levels (<0.15 ng/mL) after 3 days. In 
the case of dexamethasone tributyl acetate the plasma concentration between the 
treated cows showed a similar pattern with maximum levels of 0.7-1.1 ng/mL 
occurring 1-7 days following the injection. In the case of dexamethasone sodium 
phosphate treatment the plasma concentration between the treated cows showed a 
considerable variation with a peak value ranging from 22-70 ng/mL. This study 
demonstrated that the insoluble ester formulations of dexamethasone could lead to 
a sustained release of dexamethasone into systemic circulation from intramuscular 
injections. 
Dexamethasone pharmacokinetics in sheep using two injectable dexamethasone 
formulations-water suspension of dexamethasone associated with albumin 
microspheres (AM) and water-alcohol solution of dexamethasone were studied 
(Dilova et al., 1999). Following intramuscular injection of a water suspension 
containing dexamethasone-AM (at 1 mg active substances/kg of animal body 
weight), a plateau of plasma concentration of 23-25 ng/mL was observed within 
the animal blood levels between 72-120 hours post injection, and then 
subsequently the concentration decreased. Dexamethasone blood levels showed a 
gradual decrease until six days post injection. In contrast, the blood plasma 
concentration of dexamethasone obtained after injection of 1 mg dose/kg of 
animal body weight containing water or alcohol solution, which reached a short 
time peak of 55-59 ng/mL at about 3 hours post injection and then concentration 
decreased drastically and returned to the baseline concentration within several 
hours. This study demonstrated that a sustained release of dexamethasone for a 
period of a week could be achieved when dexamethasone is associated with MA. 
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1.2.6.2 Current dexamethasone delivery systems for inducing calving 
and its shortfalls 
To imitate the natural slow rise of cortisol during parturition, a two-injection 
schedule has been developed for current induction protocols (Verkerk et al., 1997). 
The current treatment is based on injection of late pregnant cows with insoluble 
esters of dexamethasone from which the drug is released over two weeks after the 
injection and followed by a further boost injection of soluble dexamethasone. The 
initial priming dose of a long- acting steroid, followed some days later by 
injection of a short- acting formulation, was developed to produce a reliable and 
predictable response. Between the two injections the treated cows may or may not 
respond to the first long acting steroid. The first injection, an intramuscular 
injection of a long acting depot corticosteroid such as of 21 mg dexamethasone 
isonicotinate (Voren AP, Boeringer-Ingelheim (NZ) Ltd; I1) initiates the 
induction process. Cows that have adequate udder development and vulva 
enlargement after 10-15 days receive a further intramuscular injection, of 20 mg 
dexamethasone sodium phosphate (Dexadresin V, Pharmaco (NZ) Ltd; I2), which 
results in parturition typically within 3-4 days. If udder development is not 
adequate, an additional I1 is administered. During the treatments, all relevant 
information is recorded, and all cows receiving I2 are examined at 3-5 days post-
partum to determine the presence of retained foetal membranes (Verkerk et al., 
1997).  
Presently, limited data exists on dexamethasone pharmacokinetics in plasma due 
to current calving practices. However, studies demonstrated dexamethasone blood 
levels followed by the intramuscular injection of insoluble (long-acting) or soluble 
(short-acting) dexamethasone esters differed from cortisol levels found during 
natural delivery. For instance, the long-acting preparations produced increase of 
plasma dexamethasone concentrations in the treated cows within a week 
following the intramuscular injection then declined to undetectable levels within 
two weeks after the injection (Fairclough et al., 1981a). The short acting 
preparations resulted in the plasma concentrations of dexamethasone, which 
increased sharply to reach maximum levels within a short time and fell to 
undetectable levels after 3 days. An ideal dexamethasone preparation for induced 
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calving should produce dexamethasone plasma levels that slowly increase, 
continue to rise around parturition and peak when the calf is born. Finally, the 
concentration of dexamethasone in plasma should return to preparturition levels 
after calving.  
Based on the foregoing studies, dexamethasone formulations need to be 
frequently administered by injection or infusion in order to maintain the desired 
hormonal blood levels until calving occurs. In addition, dexamethasone activity 
depends on the route of administration i.e., intramuscular versus intravenous 
injection (Toutain et al., 1982) and the type of dexamethasone esters - 
dexamethasone-21 trimethyl acetate versus dexamethasone-21 sodium phosphate 
used (Fairclough et al., 1981a). Suffices to say that both short and long-acting 
dexamethasone preparations showed declining profiles and dexamethasone levels 
were not maintained within a desired range during the treatment. This is the short 
fall of the current treatment and hence, finding a controlled drug release system to 
achieve a sustained dexamethasone release during the treatment would be 
advantageous. 
1.2.6.3 Some conceptually developed dexamethasone delivery systems 
An injectable biodegradable sustained release formulation was developed when 
drug compounds were entrapped in cross-linked bovine serum albumin 
microbeads (Lee et al., 1981). The bovine serum albumin (BSA) is used to bind 
many drugs. This binding is reversible and retards drug release from an injection 
site until the albumin is degraded by enzyme proteolysis.  
Dilova et al. (1999) has developed a preparation of BSA microspheres associated 
with dexamethasone. BSA microspheres containing dexamethasone were 
manufactured by means of heat denaturation.  About 0.1 g of dexamethasone was 
suspended in 10 mL of a sodium phosphate buffer and 1 g of BSA was dissolved 
in the suspension. 100 mL of sunflower oil was then added to the suspension and 
the mixture was emulsified at 1000 rpm. The resulting emulsion was added to 400 
mL of preheated sunflower oil. Heating and stirring were maintained for 60 
minutes at 100°C. The suspension was then allowed to cool to 25°C. After 
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filtration and washing with ether, the microspheres were stored at 4°C until used. 
An evaluation of the potential use of albumin microspheres as a drug delivery 
system to provide sustained release of dexamethasone in vivo has been 
investigated (Dilova et al., 1999). In vivo dexamethasone release from albumin 
microspheres was achieved for a period of a week, but non-linear release over 
time and declining profiles were inevitable. Therefore, another route of 
dexamethasone delivery is essential as intramuscular and intravenous routes failed 
to produce a linear drug release over time. 
1.2.6.4 The vagina as a route for dexamethasone delivery 
The vagina as a route of drug delivery has been known since ancient times 
(Hussain & Ahsan, 2005). The vaginal route offers numerous advantages as a site 
for drug delivery, such as convenient access, prolonged retention of formulations, 
a great permeation area, high vascularization, relatively low enzymatic activity, 
and the avoidance of hepatic first-pass metabolism. The level of interest in both 
local and systemic vaginal drug delivery systems has increased considerably 
within recent years (Bernkop-Schnürch & Hornof, 2003). In addition, various 
auxiliary agents some of which are permeation enhancers, such as bile salts or 
solubility-enhancing agents including cyclodextrins, have been developed for 
vaginal use to improve drug solubility and bioavailability at the site of delivery.  
1.2.6.4.1 Intravaginal controlled drug delivery 
The vagina has been recognized as a potential route for progesterone 
administration since the mid-Seventies when it was used to control oestrous 
cycles in cattle (Rathbone & Macmillan, 2004). Progesterone was homogenously 
incorporated into a silicone based type-matrix to control drug release at a 
predefined and reproducible rate for prolonged periods. Drug release from the 
polymer matrix followed a diffusion controlled process based upon Fick’s Law 
(Rathbone et al., 2001). Initially the diffusion process starts with the elution of the 
solid drug near the surface of the polymer matrix. This leads to the formation of a 
drug depletion zone within the matrix over time. The depletion zone becomes 
larger and larger and the drug requires more time to diffuse to the interface 
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between the delivery system and the site of delivery. This increased diffusion path 
causes a non-linear dependence of drug release with extended time. In addition, 
dexamethasone compounds are ionisable unlike progesterone (a nonionisable 
compound), and might exhibit low solubility in a silicone matrix and a better 
solubility in a hydrophilic poly-ε-caprolactone polymer (Section  2.4.1.7.3). 
However, the passive diffusion controlled mechanism of polymeric matrix 
delivery systems may be replaced by active control, such as a battery driven pump 
as part of an intravaginal device. More recently, IBD (Intelligent Breeding Device) 
and EMID (Electronically Modulated Intravaginal Device) for delivering multiple 
drugs simultaneously have been conceptually developed (Rathbone & Macmillan, 
2004). Both the IBD and EMID use a gas controlled delivery system, which is 
capable of delivering multiple drugs at various times and in various patterns. A 
detailed comparison of the similarities and differences of the two delivery systems 
are elaborated on in Chapter Four (Sections  4.1.1 and  4.1.2). Most recently, drug 
delivery scientists have also developed an electronically controlled drug delivery 
system that is designed for use in the vagina of dairy cows (Cross et al., 2004). 
Unlike IBD and EMID, this device has electronic components which are built 
from off-the-shelf parts based on a 16-bit microcontroller and a 433.92 MHz radio 
transceiver placed inside a syringe. The microcontroller reads and logs sensor data 
and controls drug release, which is accomplished using electrolytic gas production 
from a gas cell the current of which is controlled by the microcontroller. Similarly, 
to the IBD and EMID devices, the produced gas pressure propels the syringe 
piston and releases the formulation. Delivery from the device could be remotely 
controlled from the animal or overridden via the wireless link to deliver an 
arbitrary and complex variable-rate profile of a drug. However, as the time the 
present research was carried out only IBD and EMID were available.  
1.2.6.5 Hypothesis for possible solutions for induced calving 
The electronically controlled drug delivery technologies could be programmed to 
deliver an increasing amount of drug over time, thus producing a slowly rising 
blood profile that would mimic closely that seen naturally. The new drug delivery 
system, which could deliver dexamethasone intravaginally to its desired site of 
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action in a controlled way to maintain effective levels for a desired period, would 
be an advantage. The technology may provide prolonged delivery of the drug 
while maintaining its blood concentration within therapeutic limits, thereby 
achieving a desired release profile of dexamethasone until parturition. The device 
could be loaded with formulated long- acting dexamethasone suspension and the 
rate of drug release that could be adjusted by controlling the rate of gas production 
by the battery driven pump.  
1.2.6.5.1 Sub-hypothesis for drug delivery 
As demonstrated, different dexamethasone formulations produced varied blood 
profiles using the same route (Toutain et al., 1982). The best dexamethasone 
candidate for induced calving must be identified and the goal is to identify a 
dexamethasone analogue with high absorption rates across the vaginal mucosa. 
This may be achieved by: 
• developing an in vitro permeation method to screen dexamethasone 
analogues to monitor their ability to permeate non-biological and 
biological membranes. 
• formulating dexamethasone analogues to enhance their aqueous solubility 
and permeation through these membranes.  
• developing UV and HPLC assays to characterise the formulated 
dexamethasone compounds. 
• assessing the intravaginal drug delivery system for suitability to deliver 
dexamethasone formulation and also to develop an appropriate release 
assessment method for the device. 
• conducting some preliminary experiments of in vivo animal work. 
• assessing the outcomes and recommend future work. 
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1.3 Oestrous synchronisation in cattle 
Oestrous synchronisation is the manipulation of the reproductive cycle such that 
all treated cows come into oestrus at a predefined period with normal fertility 
(Kesler et al., 1995). Oestrous synchronisation involves administration of 
hormones, which are delivered in a synchronous fashion and that are released in a 
similar manner to by the endogenous endocrine system thereby simulating the 
blood level changes of these hormones in a normal oestrous cycle in cows with 
the aim of controlling the oestrous cycle (De Rensis & Peters, 1999; Rathbone et 
al., 2001). More specifically, oestrous synchronisation involves the manipulation 
of ovarian activity so that the time of ovulation can be predicted without the need 
for oestrous detection. The blood level concentration changes of progesterone and 
oestradiol during oestrous cycle regulates reproduction and oestrus behaviour of 
cows.  
Reliable oestrus detection in cows requires several periods of intensive daily 
observation and is, therefore, time consuming and expensive for dairy farmers (De 
Rensis & Peters, 1999). The average rate of oestrus detection is about 50% with 
wide variation amongst dairy farmers. This may lead to a large proportion of 
animals being artificially inseminated while they are not in oestrus. In addition, 
different farmers have different objectives in what they wish to achieve among 
their dairy cows and some may want to have as many cows as possible becoming 
pregnant by artificial insemination (AI) within a particular time span or to have 
calving occur a short period of time. Some other reasons why farmers would 
consider controlling the oestrous cycle in their dairy cattle (Rathbone et al., 2000) 
include: 1) reducing the time and labour costs in detecting a reliable oestrous time, 
2) allowing for more cost effective implementation of timed AI programmes, 3) 
increasing the use of AI with fresh, transported or frozen semen in order to use 
desirable genes, 4) allowing seasonal breeding at optimum time in the season and 
5) maximising reproductive efficiency with ovulation control programmes to 
provide producers with substantial opportunities to reduce production cost and 
enhance profitability.  
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Ideally, farmers want to achieve a predetermined time for effective mating with 
normal fertility without having to carry out oestrous detection of their herds. In 
addition, for cows to become pregnant and to avoid any failures of insemination, 
oestrus must be accurately identified (Gordon, 1996). The identification of a 
precise method of inducing and synchronising oestrus and ovulation in cows 
would be an important advance in cattle management so that cattle may be 
artificially inseminated at predetermined times (De Rensis & Peters, 1999). The 
methods of controlling the oestrous cycle, recent advances of the physiology and 
endocrinology of bovine oestrous cycle are discussed in the following sections. 
1.3.1 Physiology and endocrinology of bovine post-partum 
Cows are normally pregnant for 285 out of 365 days of a year, leaving only 80 out 
of 365 days to conceive following calving to maintain an optimal calving pattern 
(Nation, 1997). In addition, cows require several weeks to recover from calving 
and begin a new cycle. During this period, cows undergo a change in 
physiological state from pregnancy to the initiation of lactation and resumption of 
a fertile oestrous cycle. The period after calving is known as post-partum, which 
is defined as the interval from parturition to complete uterine involution (Lewis, 
1997). During this period, the uterus shrinks to resume its pre-pregnancy size and 
ovaries regain their cyclical activity (Kindahl et al., 2004; Nation, 1997). Uterine 
involution may require 30 days post-partum followed by a return of the oestrous 
cycle (Nation, 1997). The post-partum period is divided into three sub-periods 
(Lewis, 1997):  
1. Puerperal, the interval from parturition until the pituitary gland becomes 
responsive to GnRH which lasts approximately 7 to 14 day, 
2. Intermediate, the interval from the time that the pituitary gland becomes 
responsive to GnRH to the first post-partum ovulation, 
3. Postovulatory, the interval from the first ovulation to complete uterine 
involution. 
The post-partum anoestrus duration or the interval of sexual inactivity between 
the parturition and the following oestrous period varies considerably among cows 
with many contributing factors (i.e., parity, breed, health, nutrition level, body 
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condition, etc.) and has been reviewed by Nation (1997). Furthermore, the first 
ovulation is often not accompanied by oestrus, in which case, the first expression 
of oestrus accompanies the second ovulation, post-partum. In addition, as Nation 
(1997) indicated, some cows may not show any oestrous cycle for at least 60 days 
because of the prevalence of post-partum anoestrus. This leaves only a small 
chance for cows to become pregnant again, during which time they must show 
oestrus so they can be efficiently mated.  
1.3.2 Endocrinology of the bovine oestrous cycle 
The oestrous cycle is controlled by hypothalamic-pituitary-ovarian axis, where the 
ovarian oestradiol acts on receptor cells in the hypothalamus to secrete GnRH, 
which in turn, causes the release of both luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) from the anterior pituitary gland. LH and FSH 
promote steroid synthesis, ovarian follicular growth and ovulation. GnRH plays a 
crucial role in regulating ovarian activity during the normal oestrous cycle of a 
cow, as well as in initiating ovarian activity prior to the onset of puberty and after 
periods of anoestrus. The bovine oestrous cycle is generally divided into four 
subsequent phases and are referred to as proestrus, oestrus, metoestrus, and 
dioestrus, on the basis of the hormonal changes that occur (Hafs et al., 1976). The 
oestrous cycle is also divided into two major phases generally known as the 
follicular and luteal phases, on the basis of the different structures present in the 
ovary (Evans, 2003; Rathbone et al., 2001). The follicular phase is comprised of 
proestrus and oestrus and lasts from 3 to 7 days. The proestrous and oestrous 
periods are primarily controlled by oestrogen levels and are associated with 
growth of the follicle and, therefore, are called the follicular phase of the cycle. 
The metoestrous and dioestrous periods are associated with growth of the corpus 
luteum (CL), are primarily under the influence of progesterone and called the 
luteal phase of the cycle.  
1.3.2.1 Proestrus 
Proestrus is the period of the menstrual cycle that begins from the time of 
regression of the CL to the onset of the new oestrous cycle. The proestrus period 
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lasts 2-6 days during which time a dominant ovulatory follicle matures. During 
this maturation period, the dominant follicle produces increasing amounts of -17β 
oestradiol. When the -17β oestradiol levels peak in the presence of undetectable 
levels of progesterone, the proestrous period ends and oestrus commences 
(Rathbone et al., 1998).  
1.3.2.2 Oestrus 
Oestrus is the period of sexual receptivity in the cow and is characterised by the 
animal being willing to be mounted by other herd mates, both male and female 
(Gordon, 1996). Other behavioural signs of oestrus include vulvar swelling, 
restlessness, clear vaginal mucus discharge, and bellowing. Oestrus is the period 
of receptivity of a cow to a male. The oestrous period lasts for 8-30 hrs (Rathbone 
et al., 1998) or 12-24 hrs (Downey, 1980). The high circulation concentrations of 
-17β oestradiol that coincides with a low concentration of progesterone and 
initiates a surge in LH concentrations that usually exceeds 30 ng/mL (Rathbone et 
al., 1998), which, in turn, ruptures the follicle destined for ovulation.  
1.3.2.3 Metoestrus 
Metoestrus is the period that begins from the cessation of oestrus to the early 
development of the CL. The metoestrous period ranges between 0-5 days starting 
from day 0, on which ovulation takes place and is characterised by the formation 
of the CL (Figure  1.3). Cells of the granulosa and theca internal layers of the 
ruptured ovarian follicle form the CL (Gordon, 1996). These granulosa and theca 
internal layers start to transform and differentiate by forming large and small 
luteal cells, respectively. The former cells secrete progesterone and oxytocin and 
are responsive to PGF whereas the latter cells secrete progesterone and are 
responsive to LH. During the metoestrous period progesterone levels start to 
increase beginning on day 3 or 4 from around 1 ng/mL to 4 ng/mL (Rathbone et 
al., 1998). 
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Figure  1.3 presents idealised changes in blood progesterone, oestradiol and LH 
during the bovine oestrous cycle (Hafs et al., 1976).  
 
Figure  1.3. Changes in hormone concentrations during the cow’s inter-oestrous cycles (Hafs 
et al., 1976). 
1.3.2.4 Dioestrus 
Dioestrus is the period of the oestrous cycle when the CL is fully functioning and 
lasts for 6-18 days. During this period, the progesterone concentration produced 
mainly by the large luteal cells, rapidly increases from 6 ng/mL and reaches 10 
ng/mL by days 8 or 9 and remain elevated for the duration of the CL life span 
(Gordon, 1996; Rathbone et al., 1998; Rathbone et al., 2001; Mann et al., 1998; 
Downey, 1980; Hafs et al., 1976) before starting to decline on day 18 (Figure  1.3).  
1.3.2.5 Follicular development during the oestrous cycle 
The selection of a single dominant follicle, which attains the ability for final 
maturation and ovulation during the oestrous cycle, culminates in ovarian follicle 
growth in the cattle (Mihm et al., 2002). Ovarian follicular development occurs in 
a wave-like pattern (Evans, 2003). Two or three waves of follicular development 
occur during the oestrous cycle (Soboleva et al., 2000). Each wave consists of a 
group of growing follicles, classified into larger dominant and smaller follicles. 
Over several days, one follicle grows larger than the others and is selected to 
Chapter One 
28 
become the dominant follicle while the smaller follicles regress (Fortune, 1993). 
The first follicular wave emerges on day 1 of the cycle and the selection of the 
dominant follicle takes between days 2 and 3 of the cycle and the follicle becomes 
dominant between days 4 and 5 (De Rensis & Peters, 1999). The dominant follicle 
reaches its maximum size between days 6 and 7 of the cycle. This is followed by a 
period of relative stability between days 6 and 10 and then it decreases in size and 
is no longer identifiable by day 15. This loss of the dominant follicle coincides 
with emergence of a new follicle wave, preceded by a transient increase in FSH. 
The second dominant follicle emerges on day 10 of the cycle and will ovulate 11 
days later.  
Animals with three follicular waves, the first, second and third follicular waves 
emerge on days 1, 9 and 16, respectively. The third dominant follicle ovulates 7 
days later (De Rensis & Peters, 1999). Therefore, oestrous cycles with cows with 
two follicular waves are 2 days shorter than the three wave cycles (21 versus 23 
days). However, it was found that cattle populations differ in the relative 
proportion of cows exhibiting two wave versus three wave cycles. Some 
publications have reported that 80% of cows have three wave cycles whereas 
others have also found that about 80% of cows have two wave cycles. It is clear 
that the first dominant follicle does not ovulate during the normal bovine oestrous 
cycle. Yet the dominant follicle that develops in the presence of functioning CL 
will undergo atresia due to the absence of a frequent LH pulse pattern inhibited 
because of high progesterone concentrations. Therefore, only the dominant 
nonatretic follicle that is present when the CL regresses has the opportunity to 
ovulate. 
1.3.2.6 Luteolysis 
The three hormones responsible for the initiation of luteolysis are progesterone, 
oestradiol and oxytocin (Goff, 2004). Together they regulate the uterine secretion 
of PGF that causes regression of the CL. Progesterone can regulate PGF secretion 
such that prolonged exposure of the endometrium to progesterone promotes the 
endometrial accumulation of arachidonic acid, a precursor of PGF and the 
cyclooxyginase enzyme which are necessary for the synthesis of PGF. On the 
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other hand, progesterone also exerts a suppressive effect on PGF secretion by 
blocking oxytocin receptor gene expression during the early and mid-luteal phases 
of the oestrous cycle (Ivell et al., 2000). The progesterone block to oxytocin 
receptors is lost after 12 days of continuous exposure, possibly due to the loss of 
progesterone receptors (Goff, 2004). At the end of the luteal phase, oxytocin 
triggers a positive feed back loop on the endometrial oxytocin receptor mediating 
the release of PGF, which feeds back to the CL to cause the secretion of more 
oxytocin and to induce luteolysis. During the luteal phase, there is an increase of 
oestradiol and oestradiol receptors, whereby the activated oestradiol receptors 
stimulates the up regulation of oxytocin receptors. The oestradiol effect is 
dependent on progesterone exposure to the endometrium because the effect is 
only observed after the endometrium has been primed by progesterone for a 
certain period of time. At the end of the luteal phase, the endometrium becomes 
responsive to oxytocin to initiate the excitability and the contraction of the 
myometrium. Therefore, progesterone controls the timing of luteolysis by 
mediation through the control of endometrial oxytocin receptors.  
1.3.3 Introduction to control of the oestrous cycle 
The main methods of controlling the oestrous cycle are through the manipulation 
of the life span of the CL by either prolonging the luteal phase or by use of 
progestagens or by inducing premature luteolysis by prostaglandins. Manipulation 
of the follicular phase by lengthening/shortening the luteal phase or inducing 
premature luteolysis using pharmacological hormone treatments can control the 
oestrous cycle (De Rensis & Peters, 1999). GnRH or human chorionic 
gonadotrophin (hCC) has recently been used for the manipulation of follicle 
development to achieve precise synchrony of ovulation. Oestrus has been 
synchronised in cattle with progestorone-oestradiol or progesterone-PGF 
combinations (Odde, 1990).  
1.3.3.1 Oestrous control with PGF 
Traditionally, single drug therapy for oestrous control was established once PGF 
was identified as the natural luteolytic hormone in cattle (Lauderdale, 1975). The 
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luteal phase can be terminated or shortened prematurely by intramuscular or 
vulvar subcutaneous injection of PGF. This compound causes regression of the 
CL and a decrease in circulating progesterone, thereby allowing the resumption of 
gonadotrophic stimulation to release GnRH which, in turn causes a surge of LH 
and FSH to initiate follicular development and maturation so that responding 
cows should show oestrous signs 2-4 days after treatment (Rathbone et al., 2001). 
The limitation of this method is that only 50-70% of the treated animals 
responded to a single administration as PGF injections can only be effective 
during the luteal phase of the cycle. Fertility of oestrus after PGF treatment did 
not differ from that of untreated animals (Odde, 1990). Assuming cows have a 21-
day oestrous cycle there might be two populations of cows, one which would be 
without CL while the other group might have a fully functioning CL (i.e., from 
day 5 onwards of the oestrous cycle) at the time of the treatment. All cows that 
have CL, are potentially responsive to PGF injection, which will cause regression 
of CL, reduction of blood levels of progesterone, and return to oestrus (Rensis and 
Peters, 1999). However, PGF treatment is ineffective during the follicular phase 
of the first 5 days of the oestrous cycle (Lucy, 2001). Moreover, cows injected 
between days 7 and 8 or 15 and 16 of the cycle showed oestrus earlier than those 
injected between days 12 and 14. It was suggested that the considerable variation 
in the interval from PGF treatment to oestrus and ovulation could be attributed to 
the status of the follicular wave at the time of treatment. Finally, oestrus is not 
synchronised precisely using PGF treatment since animals were detected in 
oestrus over periods of 5 days (De Rensis and Peters, 1999). Therefore, two PGF 
injections 11 days apart are necessary to improve synchrony of oestrus. Double 
PGF injections 11 days apart applied to heifers induced a high oestrous response 
(80-90% responding between 2-4 days), but it was less precise in the lactating 
cows (Gordon, 1996). 
1.3.3.2 Oestrous synchronisation with progesterone 
Progesterone or its analogues have been used in oestrous synchronisation 
programmes for cattle for many years (Whisnant & Burns, 2002). These include 1) 
feeding in meal, 2) injection in oil or other media, 3) subcutaneous implants, 4) by 
way of intravaginal devices such as PRID (Progesterone Releasing Intravaginal 
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Device, which consist of a stainless steel coil and looped nylon structure covered 
by a layer of progesterone impregnated silastic), CIDR™-B (Controlled Internal 
Drug Release Device, which is made of a T-shaped nylon structure covered by a 
layer of progesterone impregnated silastic) or sponges (polyurethane sponges 
containing progesterone) (Gordon, 1996).  
The main biological functions of progesterone include oestrous suppression and 
inhibition of a pre-ovulatory LH surge during the insertion of the progesterone 
releasing device in the animal (Odde, 1990). The oestrous cycle resumes for a 
cycling cow upon the removal of a device (Kesler & Favero, 1995). Rathbone et 
al. (2000) have reviewed several progesterone delivery methods and their 
administration routes (i.e., intramuscular injection, oral administration through the 
diet, ear implants, and intravaginal administration) for oestrous control of 
domesticated livestock. 
1.3.3.3 Commercial progesterone releasing intravaginal inserts for the 
oestrous control 
Commercially available progesterone releasing intravaginal drug delivery systems 
include PRID, CIDR™-B, Cuemate™, INVAS (Intravaginal Application System 
comprising a polypropylene spine, which is covered by progesterone matrix), 
Rajamehendran rubber tubing, containing progesterone and oestradiol-17β and 
sponges. These devices are inserted intravaginally and are usually left in place for 
between 7 and 12 days. Progesterone is released slowly from the device and 
absorbed into the system via the vaginal mucosa, the luteal phase condition will 
be maintained entirely by progesterone absorbed from the inserts. This will 
prevent oestrus and ovulation for the treatment period and all treated cows should 
commence a follicular phase immediately after removal of the device (Rathbone 
et al., 2001).  
It is essential that an intravaginal device is retained in an animal during the 
treatment. Retention rates of the PRID and CIDR™-B are reported to be 95 and 
99.2%, respectively (Rathbone et al., 2000). The CIDR™-B is further elaborated 
because of the particular interest of this thesis. The CIDR™-B has been 
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commercially available since 1987 (Rathbone et al., 2002). A product containing 
1.92 g of progesterone (the same drug load of PRID) was initially formulated to 
deliver progesterone for a 12-day period based on the knowledge that 
progesterone provides potent suppression of oestrus and ovulation following 
insertion. The removal of a device causes a rapid drop in progesterone 
concentration in the blood circulation and promotes oestrous synchronisation 
within a herd and allows for mass artificial insemination to take place. The 
amount of progesterone released during a 15-day treatment period was highly 
repeatable and is dependent on the initial progesterone content (Macmillan& 
Peterson, 1993). In this study, however, individual treated animals showed wide 
variations in plasma progesterone concentrations. The progesterone blood levels 
achieved using commercially approved progesterone releasing products, CIDR™-
B as an example, provided blood progesterone levels less than those observed (4-5 
ng/mL from Rathbone et al., 2002) during the natural mid-luteal phase (9-10 
ng/mL see Figure  1.3) (Rathbone et al., 2001). To date oestrous synchronisation 
programmes have been shortened to 7-8 days. In this period, a sustained 
progesterone delivery that provides a minimum plasma progesterone 
concentration of 2 ng/mL over the last four days of treatment is required 
(Rathbone et al., 1998). Since oestrous synchronisation programmes are shortened, 
a high residual drug load in the CIDR™-B after removal is inevitable. Therefore, 
reduction of the initial progesterone load in the CIDR™-B or reusing the CIDR™-
B more than once without compromising the effective plasma profile to induce 
oestrous synchrony may be an advantage. 
1.3.3.3.1 Re-engineering or reuse of CIDR™-B 
The residual amount of progesterone remaining in a used CIDR™-B after removal 
was investigated (Ogle, 1999). Ogle (1999) found that the residual amount of 
progesterone was dependent upon the length of insertion and the initial 
progesterone load in the CIDR™-B. Reducing the initial progesterone load would 
lead to a reduction in the cost of raw material (progesterone) and less 
environmental concerns for the disposing of waste into the environment.  
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The re-engineering of commercially available CIDR™-B inserts while reducing 
the drug load was investigated using a shorter treatment duration of 7 days 
(Rathbone et al., 2002). Both the initial drug load (from 1.92 to 1.34 g) and the 
residual drug remaining in the product after removal (from 1.31 to 0.72g) were 
reduced. In addition, the lower drug load CIDR™-B showed the same 
progesterone plasma levels as the commercially available CIDR™-B.  
The blood profiles of the two CIDR™-B products fluctuated between 3 and 3.5 
ng/mL for the last six days of treatment (Rathbone et al., 2002). However, there 
was a clear difference in the plasma progesterone profiles between the commercial 
and re-engineered (approx 5-6 ng/mL versus 4-4.5 ng/mL, respectively) CIDR™-
B products prior to day 2. This can be explained by the higher drug load product 
having a higher drug concentration gradient between the surface of the CIDR™-B 
and the surrounding vaginal lumen fluids of the cow at the time of insertion 
compared to the lower drug load product. In addition, a comparative study of 
pregnancy rates following fixed time AI in beef cattle was investigated (Colazo et 
al., 2004) using CIDR™-B inserts that have been used more than once. In this 
study heifers were given a new or once used CIDR™-B (CIDRs were sterilised by 
autoclaving before reuse). Overall pregnancy rate was not affected by either new 
or once-used CIDRs in heifers treated with a new or once used CIDR™-B (48.3% 
of 145/300 heifers versus 46.2% of 146/316 heifers). In the same study, cows 
were given once used and twice used CIDRs. Overall pregnancy rate of cows 
treated with once used CIDR™-B showed a higher pregnancy rate than those 
treated with a twice-used CIDR™-B (62.4% of 113/181 versus 48.4% of 88/182 
cows, respectively). Furthermore, cows treated with twice used CIDR’s in the 
same cow did not significantly improve the pregnancy rates compared to a single 
twice used CIDR™-B.  
1.3.3.3.2 Cuemate intravaginal inserts for the oestrous control 
Cuemate™ is a drug-releasing insert administered intravaginally to cattle. It 
contains 1.56 g of progesterone used for oestrous control purposes. It consists of a 
semi-rigid wishbone onto which are threaded two progesterone containing silastic 
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cylindrical pods which have an enclosed cap end that locks the pods in place on 
the wishbone (McDougall et al., 2004). An injection moulding process is used to 
manufacture the progesterone impregnated fluted pods of the Cuemate™. The 
wishbone shaped spine function facilitates the administration, retention and 
removal of the insert (Rathbone & Macmillan, 2004). There appears to be more 
than one type of commercially available Cuemate™ and two types of Cuemate™ 
with a drug load difference (1.56 g versus 1.4 g of progesterone) have been 
reported (McDougall et al., 2004; Hanlon et al., 2002, respectively). Cuemate™  
is reported to offer excellent animal comfort, efficacy and the ability to re-use the 
carrier "wishbone" thereby reducing costs to consumers (Hanlon et al., 2002). The 
Cuemate™ consists of two main components, the carrier body and two treatment 
pods. The carrier body called a "wishbone" is used to hold the pods inside the 
vagina and is re-usable, being made from a plastic that can be sterilised between 
treatments. The two "treatment pods" are attached to the arms of the wishbone. 
The pods contain progesterone (1.56 g or 1.4 g, 10 % w/w) that is formulated into 
a silicone matrix.  
In a study of the comparison of the efficacy of CuemateTM and CIDR™-B a large 
scale clinical trial (in 423 cows) for the treatment of anovolatory anoestrus was 
conducted (Hanlon et al., 2002). In this study, 51% and 49% cows were treated 
with CuemateTM and CIDR-B™, respectively. All inserts were removed within six 
days of insertion, and 24 hours later, each cow was given an intramuscular 
injection of 1 mg oestradiol benzoate. This trial resulted in no significant 
difference between the 3-day submission rate for cows treated with a CuemateTM 
or CIDR-B™ (92 % versus 94 %) or the conception rate to the induced oestrus (41 
% versus 43 %). This result clearly demonstrated that CuemateTM was as good as 
CIDR-B™ in this particular study. 
1.3.3.4 Conceptual drug releasing intravaginal inserts for oestrous 
control 
There are some developed intravaginal drug delivery technologies for 
progesterone and oestradiol such as IBD, PCL-CIDR (progesterone releasing 
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intravaginal device, which consists of progesterone homogenously dispersed in a 
poly-ε-caprolactone matrix) and EMID (Rathbone et al., 2000). These drug 
delivery systems have been viewed by Rathbone et al. (2000). The EMID is 
critically evaluated in this research (Chapter Four). 
1.3.3.5 Subcutaneous drug delivery systems for oestrous control 
Ear implants of progestagen are available on the market that can efficiently 
release norgestomet (17α-acetoxy-11β-methyl-19-norpreg-4-ene-20, dione), 
which is a modified 19-norprogesterone (Kesler & Favero, 1995). Norgestomet 
implantation in cows for oestrous synchronisation have been reported (Kesler et 
al., 1995; Kesler & Favero, 1995; Kesler & Favero 1996; Kesler et al., 1997). 
Lower doses of the active pharmaceutical ingredient are required because 
norgestomet is more potent than progesterone (Kesler et al., 1995). Examples of 
these implants are CRESTAR® (silicon implant) and SYNCRO-MATE-B® 
(hydron implant). Hydron implants are manufactured with norgestomet 
homogeneously distributed through the hydron, whereas silicon implants contain 
dispersed crystalline norgestomet in a micro reservoir of aqueous PEG 400 within 
a matrix of polymerised silicone (Rathbone et al., 2000). The norgestomet content 
of both the hydron and silicon implants is 6 mg (Kesler et al., 1995). Both the 
hydron and silicon implants are cylinders of approximately 2.6 mm in diameter 
and 2.0 cm in length. These implants are inserted under the loose skin at the base 
of the ear using a special implantation device. Hydron implants and silicon 
implants have shown different in vitro drug release profiles. Silicon implants 
release norgestomet in a more homogenous and linear manner, while hydron 
implants release high quantities in the first two days and the quantity released 
decreases during the following days (Kesler et al., 1995). The implant is removed 
after 9 days by making a small incision and forcing it out. An in vivo study 
comparing the efficacy of hydron and silicon implants demonstrated that 
synchronised pregnancy rates were greater for hydron than silicon implants (53% 
versus 44% respectively) (Kesler et al., 1995). However, the requirement of 
aseptic technique during administration and the need for minor surgery to remove 
the implant to produce a precipitous decline in progesterone levels have resulted 
in this product having limited practical application (Rathbone et al., 2000).  
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Compared with the single hormone treatment for oestrous control, the 
progesterone treatments achieved excellent precision with the onset of the oestrus 
but with lowered fertility rates, whereas PGF treatments achieved less precision in 
onset of oestrus as well as variation in the fertility of individual (Rathbone et al., 
1998). Other hormones such as oestradiol and GnRH have also been used alone to 
alter the length of the oestrous cycle, but none of these has yet been successfully 
adapted into single hormone oestrous control programmes like those involving 
progesterone or PGF, due to their variable effects.  
However, single hormone treatment using progesterone has only been used to a 
limited extent due to route specificity and poor fertility rates. Progesterone cannot 
prevent the development of persistent dominant follicles during treatment, but can 
prevent only oestrus and ovulation. Synchrony of oestrus following the use of 
progesterone alone was not sufficient for success with a fixed time of 
insemination, and therefore, other drugs are necessary to co-administer with 
progesterone (Whisnant et al., 1999). At the end of the treatment, any persistent 
dominant follicle must be induced to ovulate, otherwise, this would lead to poor 
fertility (Rathbone et al., 2002). Advances in endocrinology knowledge have 
demonstrated that the poor fertility associated with the commercial products could 
be overcome using shorter treatment durations with the addition of co-
administered multiple hormones. For instance, >90% versus 85% of cattle can be 
induced to enter oestrus between 36-60 hours versus 24 hours of the end of 
treatment when using intravaginal inserts or subcutaneous ear implant 
progesterone releasing systems, with or without administering oestradiol benzoate, 
at the end of the treatment period (Cavalieri et al., 2004). 
Therefore, to achieve adequate oestrous synchronisation without compromising 
fertility a combination of multiple drugs administered at different rates and times 
throughout the treatment period is needed. For instance, additional compounds are 
administered at insertion or removal of a progesterone releasing device. It is well 
established that inclusion of oestradiol with progesterone appears to intensify the 
negative feedback on LH secretion compared to progesterone administered alone 
(Kesler & Favero, 1995). Other reasons for combined treatment are that the CL 
does not lyse in response to PGF until the fifth day following oestrus onwards and 
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oestradiol therapy increases the sensitivity of the CL to luteolytic PGF. Delivering 
more than a single active in combined synchronised luteolysis and ovarian follicle 
wave patterns could be achieved (Macmillan & Peterson, 1993).  
1.3.3.6 Combination of progesterone and oestradiol for the oestrous 
control 
A slow release formulation that involves a single intramuscular injection (i.m.) of 
biodegradable progesterone microspheres (progesterone + oestradiol benzoate) for 
controlling bovine oestrus and inducing puberty in beef heifers has been studied 
(Whisnant & Burns, 2002). These microspheres contained 625 mg of progesterone 
and 50 mg of oestradiol benzoate in poly-(DL-Lactide-co-glycolide 75:25) 
microspheres prepared using an emulsion based process (Rathbone et al., 2000). 
Progesterone plasma concentration patterns showed a rapid increase and sharp 
decline that may allow for oestrous synchrony. This treatment produced 
progesterone plasma concentrations (4-5 ng/mL) similar to that in the naturally 
occurring luteal phase. The follicular development and turnover were not 
determined in this study. About 75% of the treated cows were observed in oestrus 
over a two-day period. In addition, some heifers treated with a microsphere 
formulation containing oestradiol benzoate alone were observed in oestrus on day 
1 and 2. Also, an induced earlier onset of luteal activity in perpubertal beef heifers 
with a consistent pattern of progesterone plasma concentrations was observed 
(Whisnant & Burns, 2002). Similarly, as reviewed by Rathbone et al., 2000, a 
biodegradable sucrose acetate isobutyrate delivery system (SABER Mate B 
(Bovine)) to control the release of deslorelin acetate was developed for the use of 
oestrous control.  
Combined therapies allowed treatment durations of 10 and 12 days using the 
subcutaneous and intra-vaginal routes, respectively (Odde, 1990; Gordon, 1996). 
Progesterone administered for 14 to 20 days was effective in synchronising 
oestrus, but this was associated with lower fertility rates (Odde, 1990). Duration 
of the treatment was reduced and oestrous synchronisation improved by 
combining progesterone with an oestradiol. SYNCHRO-MATE®-B is a typical 
example of progesterone-oestradiol combination. A combination of progesterone 
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with either oestradiol benzoate or potent progestogens with oestradiol valerate has 
been used for oestrous control (Rathbone et al., 1998). Synchronising the stage of 
the follicle wave using a combination of either oestradiol or GnRH at the start of 
treatment with progesterone (PRID or CIDR™-B for 10-12 days) or the 
subcutaneous norgestomet (ear implants for 9-10 days) is ideal. Attaching a small 
gelatin capsule containing oestradiol benzoate into the inner surface of the PRID 
or CIDR™-B has also been developed as a combination drug therapy for oestrous 
control. Cows show oestrus within a few days of removal of the implant or 
withdrawal of the devices. Effective treatments suppress GnRH secretion from the 
hypothalamus so long as progesterone administration is maintained, but the 
release of GnRH resumes immediately following removal of the implant or 
withdrawal of PRID/CIDR™-B because of the rapid decline of progesterone 
concentration. Therefore, all the treated animals begin a follicular phase at the 
same time. 
More recently, McDougall et al.(2004) studied the effect of Cuemate™ 
progesterone dose titration and oestradiol benzoate on plasma progesterone 
concentration and follicle dynamics in anovulatory anoestrus post-partum pasture-
fed dairy cattle. Cuemate™ containing a normal dose (1.56 g) of progesterone or a 
modified Cuemate™ containing double (3.12 g) or triple (4.68 g) the normal 
progesterone dose with (2 mg) or without oestradiol benzoate for 8 days was used. 
McDougall et al.(2004) found that increasing the progesterone dose was 
associated with an increase in plasma progesterone concentration during the time 
of device insertion. However, plasma progesterone concentration for each of the 
three doses showed similar shaped profiles with increasing levels from the lowest 
to the highest dose. The average values of plasma progesterone of from day 1 up 
to day 8 were 1.2 ± 0.2, 2.0 ± 0.2 and 2.9 ± 0.2 ng/mL for normal, double and 
triple Cuemate™ progesterone doses, respectively. McDougall et al. (2004) also 
determined that there was no effect of oestradiol benzoate at the time of 
Cuemate™ insertion on plasma concentration and concluded that a delay in the 
subsequent follicle wave and more rapid follicle growth were associated with the 
increasing progesterone dose and oestradiol benzoate treatment.  
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Combinations of progesterone releasing products and PGF improved 
synchronisation rates in cows to 84% as compared to 57% for PGF alone (Lucy, 
2001). Other researchers found similar results after cows were treated with 
progesterone for 7 days prior to PGF administration (Macmillan & Peterson, 
1993). This occurs as all cows have a CL that has developed for at least 7 days as 
progesterone treatment suppresses any naturally occurring luteolysis, but does not 
affect any follicular development. PGF treatment ensures regression of any CL 
and therefore a new cycle begins. Other attempts have been made using injections 
of PGF or oestradiol benzoate or both in conjunction with a progesterone delivery 
device, PRID (Whisnant et al., 1999). It was found that the combination of 
progesterone, oestradiol benzoate and cloprostenol treatments resulted in 
significantly higher synchrony of ovulation and pregnancy rates compared with all 
other treatments. Oestrus synchrony of inclusion of 1 mg of oestradiol benzoate or 
5 mg of -17β oestradiol with progesterone and cloprostenol was equally effective, 
and there were no differences between heifers and cows.  
Furthermore, a combination system of PGF and/or GnRH (Rathbone et al., 2001) 
has also been developed. The administration of GnRH induces ovulation and/or 
luteinization of the dominant follicle. Given that the time for a follicle to become 
dominant is around 8 days and dominance normally lasts about 4 days, injection 
of PGF 6-7 days after GnRH induces luteolysis allowing a new follicle to ovulate. 
A comparative study of oestrous synchronisation rates using double PGF 
injections, GnRH + PGF and human chorionic gonadotropin (hCG) +PGF was 
investigated (Coyan et al., 2003). Application of a GnRH or hCG prior to a PGF 
injection provided better oestrous synchronisation rates than two injections of 
PGF. This was explained by hCG (it exerts a primarily LH effect with very little 
of the FSH effect) and GnRH which cause ovulation or initiation of a new 
follicular wave. It is possible that a fully functioning CL, which is responsive to 
PGF treatment, is formed after 7 days of hCG and GnRH treatment. This type of 
treatment was effective because it controls both the follicular and luteal phases of 
the oestrous cycle. 
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1.3.3.7 Oestrous synchronisation with PGF and GnRH 
As effective oestrous synchronisation of the oestrous cycle requires the control of 
both luteal and follicular functions, a combination of three injections of GnRH, 
PGF and GnRH (on days 0, 7 and 9, respectively) was developed to synchronise 
the follicular wave and timing of ovulation followed by a fixed time for AI. Using 
this method known as Ovsynch, ovulation occurs between 24 to 32 hours after the 
second GnRH injection. The rate of oestrous synchronisation was between 87 to 
100% of lactating dairy cows. Two modifications of the Ovsynch protocol, which 
are referred to as Co-Synch and Select Synch have also used extensively in 
postpartum beef cows (Patterson et al., 2003). Co-Synch is similar to Ovsynch, 
and the sole difference is that cows are inseminated when the second GnRH 
injection is administered. Select Synch differs in that cows do not receive a 
second GnRH injection as in the Ovsynch protocol and they are inseminated 12 
hours after oestrus is detected. However, these treatments are very expensive 
because of the increased number of times the animal is handled and the associated 
veterinarian cost needed for herd administration.  
1.3.3.8 Current oestrous control programme and its deficiency 
A combination of multiple drugs has become necessary to achieve affective 
oestrous control. The current practice of oestrous control treatment is based on the 
control of both luteal and follicular functions and protocols as found in the recent 
literature are as follows (Patterson et al., 2003; Rathbone et al., 2001; Cross et 
al.,2004): On day 0 CIDR™-B is inserted to release progesterone to inhibit 
ovulation and oestradiol benzoate is injected intramuscularly to induce follicular 
atrasia. The device is removed at the end of the treatment, followed by an 
intramuscular injection of PGF to regress any CL. Oestradiol benzoate is injected 
intramuscularly on day 9 to initiate a new oestrous cycle.  
Therefore, there is a need for a drug delivery system that enables the delivery of 
multiple drugs at appropriate times. The delivery should perform a sustained 
release of progesterone for 7 or 8 days, as well as providing an immediate release 
dose of oestradiol followed by a delayed release dose of a PGF one day before 
removal of the device. The current drug delivery system for oestrous control is 
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based on a single drug delivery programme, and therefore, it cannot control the 
luteal and follicular functions using the same delivery system. Further research is 
needed to improve current oestrous control programmes.  
It is the aim of this research to assess an electronic drug delivery system for the 
delivery of progesterone, oestradiol and PGF, for the control of the bovine 
oestrous cycle. 
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2 Preformulation properties of selected steroids useful 
for administration via the intravaginal route 
2.1 Introduction 
Preformulation is the physicochemical characterisation of the solid and solution 
properties of compounds (Steele Gerry, 2004). Preformulation studies performed 
on a drug compound in order to produce information to enable the formulation of 
a stable and pharmaceutically sound drug dosage form. The physicochemical 
properties of a variety of steroidal compounds for the purpose of determining their 
suitability for incorporation into a novel intravaginal drug delivery system were 
determined. Although information could be found in the literature on the 
preformulation properties of numerous steroids, much information was lacking for 
the specific steroids investigated in this study. Therefore, an investigation into the 
physicochemical characteristics of the steroids investigated in this research was 
conducted. 
Preformulation typically involves establishing qualitative and quantitative 
techniques to determine the physicochemical properties of the steroids 
investigated in this research (Table  2.1). Some key physicochemical properties 
which are integral and need to be determined during drug preformulation stages 
are solubility, lipophilicity, ionisation constant (pKa) and permeability (Avdeef, 
2001; Kerns & Di, 2004). High solubility and lipophilicity are both crucial for 
drug permeability across biological membranes. A low solubility is detrimental to 
absorption after drug administration and can cause false low estimates of 
compound activity in bioassay (Kerns & Di, 2004). A high hydrophilic drug can 
have poor passive transcellular permeability. In addition, increasing lipophilicity 
of a drug reduces aqueous solubility and therefore the lipophilicity and solubility 
may tend to cancel one another in terms of increased permeability (Schoenwald & 
Ward, 1978).  
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Table  2.1 summarises the physicochemical properties that must be elucidated and 
why tests are performed. 
Table  2.1. Physicochemical tests carried out during preformulation studies. 
Test/activity Reason for test/activity Reference How determined 
HPLC analysis 
For quantitative analysis Experimental 
determination 
UV spectroscopy For quantitative analysis 
(Steele Gerry, 
2004) 
Experimental 
determination 
Infra Red (IR) 
spectroscopy 
For identification purposes 
(Steele Gerry, 
2004) (Cohen, 
1973) 
Experimental 
determination/ 
Literature 
Elemental analysis To define empirical formula 
(Steele Gerry, 
2004) 
Literature 
pKa 
Extent of ionisation is important 
for solubility, stability and drug 
absorption 
(Steele Gerry, 
2004) 
Literature 
Log10 of partition 
coefficient (Log P) 
Degree of lipophilicity is 
important for drug absorption 
Literature 
Apparent partition 
coefficient 
Apparent partition coefficient is 
important for drug absorption 
(Ritschel, 1988; 
Steele Gerry, 
2004) 
Experimental 
determination 
Solubility 
Solubility is important for drug 
absorption 
(Ritschel, 1988; 
Steele Gerry, 
2004) 
Experimental 
determination 
Molecular weight 
MW is important for drug 
transport through membranes 
(Ritschel, 1988; 
Steele Gerry, 
2004) 
Literature 
Retention times on 
HPLC (C18) 
Ranking the drugs in order of 
their lipophilicity  
(Veith et al., 1979; 
Kerns & Di, 2004) 
Experimental 
determination 
Differential 
Scanning 
Calorimetry 
To determine melting point of 
pure drugs or complexes 
(Clas et al., 1999) 
Experimental 
determination 
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The common steroid molecule consists of a four-fused ring structure, three with 
six carbons and one with five carbons in the ring (Figure  2.1). All steroids are 
derivatives of this common structure (Dawson et al., 1986). The four ring 
structures are conventionally lettered as indicated in Figure 2.1 (A, B, C & D). 
The carbon position of a steroid compound is conventionally numbered according 
to the system listed for cholestane (Figure  2.1). There are usually methyl groups 
on carbon positions 10 and 13, and often an alkyl group at position 17.  
 
Figure  2.1. Numbering of steroid carbon atoms of cholestane molecule. 
 
Different steroids contain different functional groups attached to different 
positions on the molecule. For instance, some steroids studied in this research 
have ester groups at different carbon positions of the steroid molecule. 
Dexamethasone acetate and dexamethasone isonicotinate have acetate and 
isonicotinate groups on carbon position 21, respectively. Likewise, 
dexamethasone valerate has a valerate group on carbon, position 17 and 
dexamethasone dipropionate has propionate group on both carbon positions 17 
and 21. Oestradiol benzoate has a phenolic group on carbon position 3.  
Steroids occur naturally in humans and animals (Osamu Nozaki, 2001) and 
analogues can be produced synthetically. As previously discussed in Chapter One, 
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steroids are extensively used throughout the veterinary pharmaceutical industry in 
farm animals for the control of reproduction (e.g., progesterone and oestradiol), 
parturition (e.g., dexamethasone) and growth promotion (e.g., oestradiol). 
Testosterone is used in dogs for the purpose of chemical castration. However, the 
use of steroids in farm animals will be the focus of this research. 
Steroids are relatively insoluble in water. To increase steroid solubility and 
bioavailability of steroids, cyclodextrin molecules can be used (Loftsson & 
Brewster, 1996). Cyclodextrins are cyclic (α-1,4)-linked oligosaccharides of α-D-
glucopyranose containing a relatively hydrophobic central cavity and hydrophilic 
outer surface. The most common pharmaceutical application of cyclodextrins is to 
enhance solubility in aqueous solution (Loftsson & Brewster, 1996). The most 
common cyclodextrins are α-cylodextrin, β-cyclodextrin and γ-cylodextrin, which 
consist of six, seven, and eight glucopyronose units, respectively.  
The physicochemical properties of the most commonly used cyclodextrins and 
some of their derivatives are summarised in Table  2.2.  
The size of the cyclodextrin cavity is crucial to increase steroid solubility and 
bioavailability (Loftsson, 1995). For example, α-cylodextrin has the smallest 
cavity which can only be used for small molecules, whereas β-cyclodextrin is the 
most useful for most drugs of average size range and γ-cylodextrin can be used for 
large molecules. However, a low aqueous solubility of β-cyclodextrin limits its 
use (Loftsson, 1995).  
The molecular structure of the parent cyclodextrins (α-cylodextrin, β-cyclodextrin 
and γ-cylodextrin) has been modified to form cyclodextrins derivatives which are 
more soluble than their parent cyclodextrins. 
This has involved alkylation (methyl and ethyl derivatives) or hydroxylation 
(hydroxypropyl and hydroxyethyl derivatives) of the parent cyclodextrin 
compounds listed inTable  2.2.  
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Table  2.2. Natural cyclodextrins and some of their derivatives that are currently used in 
pharmaceutical products (Loftsson & Brewster 1996; Loftsson & Stefansson 2002). 
Cyclodextrin type Substitution1 MW2 Solubility 
in water 
(mg/mL)3 
Central cavity 
diameter (Å)4 
α-Cyclodextrin  - 972145 - 4.7 - 5.3 
β-Cyclodextrin  - 1135 18.5 
2-Hydroxypropyl-β-cyclodextrin  0.65 >1400 600 
Randomly methylated β-
cyclodextrin  
1.8 >1312 500 
β-Cyclodextrin sulfobutyl ether 
sodium salt  
0.9 >2163 500 
6.0 - 6.5 
γ-Cyclodextrin  - 1297 232 
2-Hydroxypropyl-γ-cyclodextrin  0.6 >1576 500 
7.5 - 8.3 
1Average number of substituents per glucopyranose repeat unit. 2MW given by the supplier, or the 
calculated value based on the average degree of substitution, for the water-free substance. 
3Solubility in pure water at 25°C. 4Loftsson (1995). 
 
2-Hydroxypropyl-β-cyclodextrin (HPβCD) was selected for use due to its high 
solubility (Table  2.2) in aqueous solution and its potential use to improve the 
bioavailability of various steroids (Usayapant & Iyer, 1999; Loftsson et al., 2003; 
Loftsson et al., 1994), thereby favourably altering permeation through biological 
and non-biological membranes. 
2.2 Steroid permeation through non-biological and biological 
membranes using side-by-side cells 
Side-by-side cells are used to screen compounds for their ability to permeate 
membranes. It is well documented that both non-biological and biological 
membranes have been used in side-by-side cells (Friend, 1992; Haigh & Smith, 
1994; Zhang & Robinson, 1996). Membranes can also be classified according to 
their characteristics and barrier function resulting in four main groups (Loftsson et 
al., 2003). These four different types of membranes are: 1) lipophilic membrane 
barriers to drug delivery from aqueous vehicles through the membrane, 2) porous 
membranes that are permeable to free drug but impermeable to drug/cyclodextrin 
complexes, 3) porous membranes that are permeable to both free drug and 
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drug/cyclodextrin complexes and 4) membranes which possess both aqueous 
diffusion barrier and lipophilic membrane barriers towards drug permeation.  
Both resistance of the lipophilic membrane and that of the adjacent aqueous 
boundary layer have controlled passive drug penetration across biological and 
non-biological membranes (Loftsson et al., 2003). Cyclodextrins can enhance 
drug delivery through artificial and biological membranes (Loftsson et al., 2003). 
Composition of a drug formulation, and the physicochemical and physiological 
composition of a membrane, will determine what type of enhanced effect is 
obtained. For instance, cyclodextrins will enhance drug delivery through diffusion 
control or aqueous diffusion and lipophilic controlled barriers (e.g., fish skin or 
hairless mouse skin membranes). The effect of cyclodextrin on in vitro drug 
permeation through biological membranes has been investigated (Lopez et al., 
2000). It was found that cyclodextrin increased the amount of dexamethasone 
acetate transferred across hairless mouse skin with respect to free dexamethasone 
acetate in water alone. 
However, biological membranes suffer from a disadvantage in that they require 
external preparation prior to use and the viability decreases over time. Biological 
membranes also require sensitive analytical techniques such as HPLC to 
differentiate the drug from extraneous material that may leach out of the 
membranes. In contrast, artificial membranes offer the advantage of needing little 
or no preparation, are easier to use, do not require complex analytical techniques 
and do not deteriorate during use. However, to be of any value, they should be 
usable as an alternative to biological membrane and capable of predicting the 
permeability of compounds in vivo. Poly-ε-caprolactone (PCL) is a polymer that 
is readily available, easily fabricated into thin flat sheets and low in cost (Pitt, 
1990). Silicone polymer is also known to be useful for drug-loaded films that can 
be applied to the skin, implanted subcutaneously or inserted into several of body 
cavities (Juliano, 1980). In this research, permeation rates and permeability 
coefficients of the steroids with PCL, silicone, synthetic skin membrane and 
excised mucosa were investigated. An artificial model membrane was selected 
from the non-biological membranes for screening the steroids.  
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2.3 Methods 
2.3.1 Steroids 
The steroids investigated in this research are listed in Table  2.3. 
Table  2.3. Drugs, grade, suppliers, molecular formula and molecular weight of compounds 
used in the study. 
Drug Grade Supplier Company & 
Country 
Molecular 
formula 
Molecular 
weight 
CAS 
Dexamethasone C22H29FO5 392.47 50-02-2 
Dexamethasone 
acetate 
C24H31FO6 434.5 
1177-
87-3 
Dexamethasone 
isonicotinate 
C28H32FNO6 497.6 
2265-
64-7 
Dexamethasone 
dipropionate 
C28H37FO7 504.6 
55541-
30-5 
Dexamethasone 
valerate 
USP 
micronized  
Australian 
generic Pty ltd 
Crystal 
Pharma, Spain 
C27H37FO6 476.577 
33755-
46-3 
Progesterone USP Grade Pharmacia USA C21H30O2 314.47 57-83-0 
Oestradiol-17β C18H24O2 272.4 50-28-2 
Oestradiol-benzoate 
BP 2002 
Ph.Eur.4 
Gedeon Richter 
Ltd 
Budapest 
Hungary C25H18O3 376.5 50-50-0 
 
These compounds were selected based on what is currently used in the veterinary 
field and upon their availability from suppliers. 
The chemical structure of the steroids used in this study are shown in Figure  2.2. 
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a) Dexamethasone, CA Index Name: 
Pregna-1,4-diene-3,20-dione, 9-fluoro-
11,17,21-trihydroxy-16-methyl-, (11β,16α)- 
(9CI). 
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b) Dexamethasone acetate, CA Index Name: 
Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-
fluoro-11,17-dihydroxy-16-methyl-, (11β,16α)- 
(9CI). 
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c) Dexamethasone isonicotinate, CA Index 
Name: Pregna-1,4-diene-3,20-dione, 9-fluoro-
11,17-dihydroxy-16-methyl-21-[(4-
pyridinylcarbonyl)oxy]-, (11β,16α)- (9CI)   
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d) Dexamethasone valerate, CA Index 
Name: Pregna-1,4-diene-3,20-dione, 9-
fluoro-11,21-dihydroxy-16-methyl-17-[(1-
oxopentyl)oxy]-, (11β,16α)- (9CI)   
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e) Dexamethasone dipropionate, CA Index Name:  
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-
methyl-17,21-bis(1-oxopropoxy)-, (11β,16α)- (9CI)   
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f) Progesterone, CA Index Name: 
Pregn-4-ene-3,20-dione (9CI)   
Me
OH
HO
H
H H
S
S
S
R
S
 
g) Oestradiol 17-β, CA Index Name: 
Estra-1,3,5(10)-triene-3,17-diol (17β)- 
(9CI). 
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h) Oestradiol benzoate, CA Index Name: Estra-
1,3,5(10)-triene-3,17-diol (17β)-, 3-benzoate (9CI).  
Figure  2.2. Chemical structures of (a) Dexamethasone (b) Dexamethasone acetate (c) 
Dexamethasone isonicotinate (d) Dexamethasone valerate (e) Dexamethasone dipropionate (f) 
Progesterone (g) Oestradiol-17β and (h) Oestradiol benzoate. These figures were obtained 
via www.scifinder.com.  
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2.3.2 Analytical methods 
2.3.2.1 Infra Red (IR) spectrometry 
IR spectroscopy was performed to confirm the identity of all steroids used in this 
research. An infrared spectrometer (Bomen, MB104, A.I. Scientific, New Zealand) 
with an Attenuated Total Reflectance attachment and Flat Plate Crystal was used. 
Three scans were performed on each sample with the instrument resolution set at 
4 cm-1 and spectral range set at 3600-6000 cm-1. For each run, sufficient sample 
was used to completely cover the ATR crystal.  
2.3.2.2 Melting point determination by Differential Scanning 
Calorimetry (DSC) 
DSC analysis was carried out according to the method described by Vianna et al. 
(1998). DSC measurements were conducted using a differential thermal analysis 
instrument (TA Instruments, DSC 2920, USA) linked to a data analysis station 
(Thermal Solution 1.2J, TA Instrument). DSC thermal analysis was performed in 
order to define the melting point of pure and formulated steroidal compounds used 
in this research.  
All the DSC traces for the melting point of each sample were analysed by 
measuring heat flow differences between the sample and a reference. Samples of 
materials of weight 4-7 mg were accurately weighed in hermetic sealed 
aluminium pans and scanned over a temperature range of 25-270 °C at a heating 
rate of 10°C/minute and with an air flow rate of 50 mL/minute. An empty sealed 
hermetic aluminium pan was chosen as the reference sample. A graph of heat flow 
(mW) versus temperature (ºC) was plotted from the generated data. The 
intersection of the extrapolated baseline prior to the transition with the 
extrapolated leading edge of the transition of the heat flow versus temperature 
graph was taken as an extrapolated onset melting temperature (Clas et al., 1999). 
The peak temperature (Tm) was also obtained from the graphs for all the steroids.  
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2.3.2.2.1 Oestradiol-cyclodextrin complexation 
Complexes were prepared for DSC from freeze-dried drug/cyclodextrin mixtures 
(HPβCD or γCD [(Wacker-Chemie GMBH, Germany]), which were obtained 
from saturated drug solutions of steroids in 5% w/v cyclodextrin buffer (pH 5.0) 
at 39ºC. The mixtures were allowed to equilibrate in a water bath (Grant OLS200 
Shaking Water Bath, Grant Instruments Ltd, UK) at 39ºC at 50 strokes per minute 
for a week. The mixtures were centrifuged (Beckman, Avanti™ 30 Centrifuge, 
Beckman Instruments, Inc., USA) at 5700 rpm for 15 minutes. The supernatants 
were removed from the aqueous drug/cyclodextrin sediments and freeze-dried.  
Solid complexes of oestradiol benzoate or oestradiol-17β with γCD or HPβCD 
were obtained from saturated solutions of oestradiol benzoate or oestradiol-17β in 
the presence of the appropriate cyclodextrin (5% w/v cyclodextrin in PBS at pH 
5.0). The supernatant was removed and freeze-dried to obtain a dry powder for 
DSC analysis. Physical mixtures were obtained by direct mixing of either the 
oestradiol benzoate or oestradiol-17β and cyclodextrin and mixing at a ratio of 1:4 
drug to cyclodextrin. Approximately 0.200 and 0.210 grams of oestradiol-17β 
were weighed in separate glass bottles and mixed with 0.800 grams of γCD or 
0.840 grams of HPβCD, respectively. Similarly, 0.269 and 0.290 grams of 
oestradiol benzoate and 1.076 grams of γCD or 1.160 grams of HPβCD, were 
prepared in the same manner. 
2.3.2.3 Solubility of the steroids 
Solubility was determined at 39ºC by adding excess drug to the aqueous phase 
(5% w/v HPβCD in PBS, pH 5.0) and equilibrated in a water bath at 50 strokes 
per minute for 7 days. At periodic times samples were taken from the solution to 
provide evidence that equilibration had occurred. All samples were extracted from 
the supernatant using a syringe and passed through a 0.22 μm Millipore filter 
(preheated to 39ºC in an oven) with the first 2 mL being discarded. The sample 
was then appropriately diluted and analysed by UV spectroscopy at the peak of 
maximum absorbance (λmax) of the steroids. The blank was 5% w/v HPβCD in pH 
5.0 PBS. Determination of solubility values was performed in duplicate samples 
on three different days for each steroid. 
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2.3.2.3.1 Apparent association/dissociation constant (Kc) of drug-HPβCD 
complex  
In an aqueous cyclodextrin solution, when a drug forms a complex with 
cyclodextrin, the drug molecule, in part or in whole, is taken up into the somewhat 
lipophilic cylodextrin cavity (Loftsson et al., 2003). Then, the free drug molecule 
goes into equilibrium with the drug-cylodextrin complex. The equilibrium 
constant (association/dissociation constant) is Kc. The solubility of steroids was 
determined in various concentrations of HPβCD (0, 2.5, 5.0, 7.5, 10.0 and 12.5% 
w/v) in PBS (pH 5.0) at 39ºC as described in Section 2.3.2.3. All samples were 
extracted from the supernatant using a syringe and passed through a 0.22 μm 
Millipore filter (preheated to 39ºC in an oven) with the first 2 mL being discarded. 
The sample was then appropriately diluted and analysed by UV at the λmax of the 
relevant steroid. A blank was used that contained the same concentration of 
HPβCD in pH 5.0 PBS as the solution studied. The solubility of each drug versus 
the HPβCD concentration was plotted to determine the slope. A plot of drug 
solubility versus cyclodextrin is called a phase solubility diagram (Loftsson et al., 
2002; Loftsson et al., 2003). The phase solubility diagrams are used to calculate, 
the apparent association/dissociation constant (Kc). The linear phase solubility 
diagrams are thought to indicate that the drug-cylodextrin complexes are first 
order with respect to cyclodextrin and first or a higher order with respect to the 
drug  (Loftsson et al., 2002). If a water-insoluble drug molecule forms a complex 
with one cyclodextrin molecule, Kc (1:1), then Kc of the complex can be 
determined by the phase solubility method. When the aqueous solubility of the 
drug shows a linear increase when plotted as a function of the cyclodextrin 
concentration, Kc can be determined from the initial linear slope and the solubility 
of the drug in water (Co), according to Equation  2.1 (Babu & Pandit 2004). 
 
)1( SlopeC
SlopeK
o
c −=  Equation  2.1. 
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2.3.2.4 Partition coefficients 
A partition coefficient is a measure of the relative hydrophobicity of a compound 
(Kerns & Di, 2004). Generally, the partition coefficient is calculated from the 
relative distribution of a compound between a water immiscible organic solvent 
(e.g., octanol) and an aqueous buffer at varying pH. For instance, the octanol-
water partition coefficient of a compound is the ratio of the concentration of the 
compound in octanol and in aqueous buffer at equilibrium and at a specified 
temperature and pH (Kerns, 2001).  
2.3.2.4.1 Octanol: 5% w/v HPβCD buffer (pH 5.0) 
Partition coefficients were determined using the shake-flask method 
(Pharmaceutical Society of Great Britain Department of Pharmaceutical Sciences, 
1979; Kerns, 2001). Partition coefficients were determined between octanol and 
5% w/v HPβCD buffer (pH 5.0) at 39ºC in triplicate on two different days for 
each of the steroids investigated in the study. The absorbance of each steroid was 
measured using UV spectrophotometer.  
Pre-saturation of the two phases was carried out prior to the experiment. The two 
phases (n-octanol and the aqueous HPβCD-containing buffer) were pre-saturated 
in a separating funnel at 39ºC in an oven for six days. Pre-saturated aqueous phase 
was used to make a known concentration of drug solution and 25 mL of this was 
added to a 100 mL bottle. The appropriate volume of organic phase was then 
carefully added on top of the aqueous phase. The bottle contents were then gently 
shaken to equilibration in a water bath maintained at 39ºC for 24 hours (t = ∞). At 
equilibration, absorbance values (Abs∞) were determined. Apparent partition 
coefficients were calculated according to Equation  2.2.  
r
Abs
AbsAbsPc )(
0
∞
∞−=  Equation  2.2. 
 
Where Pc = partition coefficient, r = phase volume ratio (aqueous /organic phase).  
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2.3.2.4.2 PCL: 5% w/v HPβCD in PBS buffer (pH 5.0) partition 
coefficients 
Partition coefficients of the steroids were also determined by the shake-flask 
method between the PCL membrane and 5% w/v HPβCD in PBS buffer (pH 5.0) 
at 39ºC in triplicate on two different days for each of the compounds investigated 
in the study. The absorbance of the drug analogue was measured using a UV 
spectrophotometer. Very thin PCL sheets were prepared by placing PCL beads 
between two flat metal plates which were compressed between the jaws of a 
bench vice. The PCL sheets obtained were then cut into small pieces and used in 
the study.  
Partition coefficients were determined as described using Equation  2.2 except that 
r = phase weight (aqueous phase weight/PCL sheets weight) in this case.  
2.3.2.5 Ionisation constant and partition coefficient (octanol/water) 
values 
The charge state that a molecule exhibits at a particular pH is characterised by the 
ionization constant (pKa) of that molecule (Avdeef, 2001). Unless otherwise 
stated the pKa and partition coefficient in octanol/water values of the steroids 
studied in the thesis were found via www.scifinder.com. According to this web 
address, the pKa values were calculated using Advanced Chemistry Development 
(ACD) Software Solaris V4.67 (© 1994-2003 ACD). 
2.3.2.6 Side-by-side cell permeation 
2.3.2.6.1 Apparatus description 
The side-by-side diffusion cells used in this study were obtained from Crown 
Glass Co. Inc. (Somerville, New Jersey, USA). They are comprised of two half 
cells (donor and receptor) that were assembled in a purpose built rack which had a 
threaded screw on one side and when tightened, allowed a pressure seal to be 
made against the membrane and the half-cells. Each half-cell had a volume of 3.4 
mL and provided a surface area for permeation of 0.785 cm2. The donor cell was 
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loaded with excess steroid in 5% w/v HP-β-cyclodextrin [(2-Hydroxypropyl-β-
cyclodextrin (Wacker-Chemie GMBH, Germany)] in pH 5.0 phosphate buffer. 
The receptor cell was filled with 5% w/v HP-β-cyclodextrin in pH 5.0 phosphate 
buffer. The contents of each half-cell were stirred with small magnetic stirring 
bars (Spinbar, Stirring Bar, Teflon, Flea Micro, 7 x 2 mm., Pequannock, NJ, 
USA), which were rotated from the outside of the cell by a magnetic stirrer. 
Shallow round depressions in the interior of the cell held the stirrers close to but 
not touching, the membrane’s surface. The permeation experiments were 
conducted at 39ºC using a thermal instrument (Thermomix 1419 Pump, KMS Ltd., 
NZ) jacketing of the cells to supply recirculating water to maintain temperature 
control. The thermal jacket extended all the way to the membrane surface. A 
diagram of the side-by-side apparatus used in the study is shown in Figure  2.3. 
 
 b) 
 
Figure  2.3. Side view schematic (a) and actual used in the study (b) of side by-side cell. 
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Samples of the receptor phase were taken at defined time intervals, with a 
disposable plastic pipette (Total Lab System Ltd, Auckland, NZ) and accurately 
weighed (Sartorius Analytical Balance Type BP110S, Biolab Scientific Ltd, NZ) 
and then, if required, diluted with an appropriate volume of buffer before analysis 
by UV spectrophotometry (Beckman DU® 640, Beckman, USA). For each sample, 
an equal volume of buffer was added to the receptor phase and correct selection of 
the aqueous phase composition ensured that sink conditions prevailed in the 
receptor phase throughout the duration of the experiment. 
A single drug candidate and the selected model membrane were used to identify 
the factors that may affect drug permeation, such as, membrane thickness, 
temperature, pH and hydroxypropyl-β-cyclodextrin concentration in the donor 
phase.  
2.3.2.6.2.1. Selection of non-biological membrane 
Initial studies investigated several different types of membranes including silicone 
(150 μm thickness), synthetic skin (50 μm thickness) and PCL (140 μm thickness). 
2.3.2.6.2.2. Synthetic skin 
Synthetic skin membrane was obtained directly from the manufacturers 
(CoTranTM 9702 (2 mil, 9% vinyl acetate) 3M Pharmaceuticals, USA). 
2.3.2.6.2.3. Silicone  
Silicone membranes were obtained from DEC Manufacturing, (558 Te Rapa Road, 
Hamilton, NZ) and were manufactured using a purpose-built mould by injection 
moulding degassed 50:50 mixtures of Part A and Part B liquid silicone and curing 
at a temperature of 190ºC. Following manufacture, membranes were characterised 
by randomly sampling 10 membranes and their thickness determined using a 
micrometer screw gauge (Shardlow Micrometers Ltd, Sheffield, England). 
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2.3.2.6.2.4. Poly-ε-caprolactone 
PCL membranes were manufactured in-house using two highly polished 
aluminium plates of dimensions (165 x 100 x 11.5 mm), which were separated 
using feeler gauges to give a membrane thickness of 140 μm (Figure  2.4). There 
were some occasions where different membrane thicknesses were manufactured 
by using feeler gauges of different thicknesses. 
 
Figure  2.4. Photograph of plates, PCL bead and feeler gauges used to manufacture PCL 
membranes. 
PCL beads were placed on to the surface of one of the plates (Figure  2.4) and 
heated to 120ºC in a bench top oven (Sunbeam Bake and Grill, BT020A model, 
Sunbeam, New Zealand) for 30 minutes to ensure they were molten. The plate 
was removed and the second plate (also preheated to 120ºC) was placed on top of 
the first. The two plates were then squeezed between the jaws of a vice and the 
plates compressed together. A screw knob on one side of the vice was tightened 
against the plates to ensure that uniform pressure is applied on the membrane in 
each time. They were left under pressure until the plates equilibrated to ambient 
temperature (approximately 60 minutes). At this point, the plates were separated 
and the membrane removed. The thickness of the membrane was determined 
using a micrometer screw gauge by measuring five different points on the 
membrane and averaging the five values (Figure  2.5). 
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2 4 5 
3 
 
Figure  2.5. Diagram showing positions that thickness measurements were made on the PCL 
membrane. 
The average thickness measured from over five points of the PCL membrane 
segments is shown in Appendix-A and a typical PCL manufactured membrane is 
shown by Figure  2.6.  
 
Figure  2.6. Photograph showing some PCL membranes . 
2.3.2.6.2 Stability of membrane 
PCL membranes were subjected to scanning electron micrography (SEM) to 
determine if changes in the surface properties of the membrane (as an indication 
of the stability of the membrane) during the permeation experiment occurred. The 
surface of the membrane was compared to the surface properties of a freshly 
prepared membrane. 
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2.3.2.6.3 Effect of changing conditions 
The following conditions were changed to examine their effect upon 
dexamethasone permeation through PCL membranes of 140 μm thickness: 
1. Membrane thickness: 70 to 200 μm thickness. 
2. Temperature: 25, 30, 35 and 39ºC. 
3. Cyclodextrin concentration: 1.25, 2.5, 5, 7.5% w/v in PBS/pH 5.0. 
4. pH of the donor phase: 5, 7.4, 10 in 5% w/v in PBS. 
5. Sensitivity: 140, 141, 145, 146, 148 μm thickness. 
2.3.2.6.4 Screening of compounds through non-biological membranes 
Unless otherwise stated, the permeation rates of all compounds studied in this 
research were determined using PCL membranes (~140 µm) and the chosen 
conditions (39ºC and 5% HPβCD in PBS at pH 5.0) in side-by-side cells. The aim 
was to rank the studied steroids in order of their permeation rates.  
2.3.2.6.5 Excised cow vaginal mucosa (biological membranes) 
The permeation rates of dexamethasone, dexamethasone acetate, dexamethasone 
valerate, dexamethasone isonicotinate, dexamethasone dipropionate and 
progesterone were also determined using the side-by-side cell apparatus and 
excised vaginal mucosa. Excised vaginal mucosa was used as the membrane 
separating the two half-cells. The mucosa was obtained in a fresh state from 
Ruakura Abattoir (Hamilton, NZ), put in a clean plastic bag, transferred to the 
laboratory on ice. The membrane was used fresh or kept in a freezer (-18°C) and 
thawed to room temperature prior to use. The mucosa was dissected from the 
majority of the connective tissue without damaging it by cutting along the outside 
length of the fresh vaginal sample with a scalpel until it reached the inner section. 
This opened up and exposed the vaginal mucosal surface. The sample was then 
averted to expose an excised mucosa with relatively low degree of folding. The 
vaginal mucosa was then laid uppermost. Excess mucus was removed. The edge 
of the mucosa was grasped with fine forceps, stretched and cut between the 
lamina propria and the mucosa by allowing the tissue to hung while cutting 
submucosa using surgical blades (Swann Morton Ltd, Sheffield England). The 
blade was held in parallel position to the inner surface (submucosal side of the 
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mucosa) to cut the mucosa, which then could be peeled away easily in sheet form. 
A 6.0 cm diameter piece of the mucosal sheet was then taken and the thickness of 
the dissected piece measured at five positions (see Figure 2.5) using a micrometer 
screw gauge to determine thickness. This was then cut into two equal parts and 
mounted onto the side-by-side cells with the surface of the vaginal mucosa facing 
towards the donor phase. The average thickness of the tightly stretched dissected 
mucosa was found to be between 1.0 and 1.2 mm. 
The side-by-side cell study was performed under sink conditions over 10-12 hours. 
The donor cell was loaded with excess steroid in 5% w/v HP-β-cyclodextrin in pH 
5.0 phosphate buffer. The receptor cell was filled with 5% w/v HP-β-cyclodextrin 
in pH 5.0 phosphate buffer. The temperature was maintained at 39ºC.  
A 1.0 mL sample was taken at selected time intervals (0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 
6.0, 7.0, 8.0, 9.0 and 10.0 hours) and analysed for drug concentration by a 
validated HPLC assay for each steroid such that changes in the drug concentration 
in the receptor phase and rate of transfer through mucosa could be monitored. An 
equal volume (1.0 mL) of 5 % w/v HP-β-cyclodextrin in pH 5.0 phosphate buffer 
was added to replace the volume that had been removed. 
The peaks of the HPLC chromatogram generated from the analysed sample 
response were compared to those obtained the drug standards to see the effect of 
the mucosa on the drug. The concentration of a steroid transferred across the 
mucosal membrane at specific time in the receptor phase was calculated using the 
peak area and a standard calibration curve (peak area versus concentrations). The 
cumulative amount permeated drug appearing in the receptor phase (μg) versus 
time (hours) was plotted and analysed as described in Section 2.3.2.6.2 to 
determine the permeation rates of the studied drugs. 
2.3.2.6.6 Analysis of data obtained using side-by-side cells  
This study was carried out to investigate if there is any correlation between the 
physicochemical properties of the studied steroids (i.e., partition coefficient, 
solubility, HPLC retention time and/or molecular weight) and permeation 
Chapter Two 
61 
rates/permeability coefficients through the PCL model membrane and excised 
vaginal mucosa.  
Permeation rates and permeability coefficients across the PCL membrane were 
calculated for each steroid and their values were plotted against their respective 
log ocatanol-buffer partition coefficients.  
In addition, the permeation rate data generated using the selected model 
membrane will be evaluated to predict the permeation rate of selected steroids 
across excised vaginal mucosa in side-by-side cells. 
The permeation rate was determined from the slope of the cumulative amount of 
steroid appearing in the receptor phase as a function of time (t) when steady-state 
transfer was occurring as follows. Note the membrane flux (which is the amount 
of steroid that can be passed through a square unit of area) can be calculated from 
the permeation rate divided by the surface area (0.785 cm2). The slope is the 
cumulative amount of the tested steroid over time (ΔQ/Δt). Therefore from 
knowledge of the slope, the initial solubility of the steroid in the donor phase, C0, 
and the surface area available for transfer, A, the permeability coefficient, P can 
be calculated from (Artursson & Karlsson, 1991; Civiale et al., 2004) Equation 
 2.3.  
0PACt
Q =Δ
Δ  Equation  2.3. 
 
Therefore, the permeability coefficient can be calculated by rearranging Equation 
 2.3 to give: 
0AC
SlopeP =  Equation  2.4.
 
 
However, for a water-insoluble steroid (when C0 is practically impossible to 
experimentally determine) the permeability of some steroids across PCL 
membrane was alternatively determined using Equation  2.5 (Martin et al., 1983).  
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h
KDP =  Equation  2.5. 
 
K is the partition coefficient of a drug from aqueous solution to PCL membrane, h 
is the thickness of the membrane (cm) and D is the drug diffusion coefficient 
(cm2/sec) that was determined according to Equation  2.6. 
lagt
h
D
6
2
=  Equation  2.6. 
 
tlag is the lag time, which is the point of intersection when the steady state portion 
of the line of the cumulative amount penetrated (mg) through the membrane 
versus time (hours) extrapolated to the time axis (x axis). The latter equation can 
only be used when K, D and tlag are independently determined (Martin et al., 
1983). 
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2.4 Results 
2.4.1. Analytical methods 
2.4.1.1 Infra Red 
Table  2.4 shows the experimentally determined wave numbers for IR analysis of 
the steroids used in this study. 
Table  2.4. Wave numbers for IR analysis of the steroids used in this study. 
Drug  Wave number (cm-1) 
Dexamethasone 
620; 705; 852; 893; 913; 953; 981; 1033; 1054; 1092; 1135; 
1243; 1270; 1299; 1395; 1437; 1451; 1621; 1664; 1706 
Dexamethasone acetate 
608; 698; 739; 871; 968; 1022; 1055; 1079; 1118; 1186; 1255; 
1300; 1364; 1413; 1435; 1450; 1608; 1673; 1731; 2947 
Dexamethasone valerate 
626; 698; 813; 831; 892; 938; 980; 1031; 1066; 1256; 1306; 
1394; 1453; 1609; 1617; 1662; 1715; 1728 
Dexamethasone isonicotinate 
626; 705; 829; 848; 902; 983; 1044; 1063; 1117; 1288; 1411; 
1604; 1622; 1663; 1723; 1743 
Dexamethasone dipropionate 
686; 806; 881; 895; 926; 1040; 1062; 1082; 1114; 1242; 1257; 
1308; 1393; 1414; 1607; 1620; 1662; 171; 1750; 3301 
Progesterone 
638; 687; 778; 871; 893; 948; 1162; 1204; 1227; 1278; 1328; 
1356; 1385; 1614; 1661; 1698 
Oestradiol-17β 
619; 784; 818; 872; 916; 928; 1011; 1054; 1230; 1249; 
1281; 1355; 1497; 1585; 1608; 2862; 2934; 2959 
Oestradiol benzoate 
605; 620; 685; 704; 786; 815; 894; 1023; 1063; 1129; 
1174; 1213; 1262; 1378; 1450; 1495; 1723; 3552 
 
2.4.1.2 Melting point by DSC 
The extrapolated onset melting temperature was obtained by extrapolating the 
base line and the leading edge of the transition peak and finding their intersection. 
The resultant peak temperature (Tm) and literature values for the steroids used in 
the study are shown in Table  2.5. 
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Table  2.5. Extrapolated onset melting temperature, melting peaks and literature values (ºC). 
Drug Experimentally determined 
extrapolated onset melting 
temperature (ºC) 
Experimentally 
determined melting peak 
temperature (ºC) 
Literature 
melting point 
(0C) 
Dexamethasone 261.32 268.52 262-2641 
Dexamethasone 
acetate 
207.71 210.18 215 – 2211 
Dexamethasone 
isonicotinate 
267.28 269.54 250 – 2521 
Dexamethasone 
dipropionate 
205.22 206.99 Not found 
Dexamethasone 
valerate 
180.50 184.11 1802 
Progesterone 130.53 130.70 126-1313 
Oestradiol-17β 174.07 176.61 173-1793 
Oestradiol 
benzoate 
198.08 201.04 190-1984 
The Merck Index, 2001; 2Vianna et al., 1998); 2Product specification data sheet and 3(United 
States Pharmacopeial Convention.Committee of Revision., 1994).  4(Clarke et al., 1986). 
 
Table  2.5 demonstrates that the literature and experimentally determined DSC 
values for steroids tested are very similar. 
2.4.1.3 Oestradiol-cyclodextrin complexation 
DSC thermograms of oestradiol-17β and oestradiol benzoate complexes and 
physical mixtures with HPβCD or γCD are shown in the following thermograms 
together with comparison of the thermograms of the pure compounds.  
Disappearance of the original endothermic peaks of oestradiol benzoate and 
oestradiol-17β is clearly seen in the complex thermograms (Figure  2.7). This 
might be due to possible complex formations between oestradiol benzoate or 
oestradiol-17β and HPβCD or γCD. In addition, the shape change of the original 
endothermic peak of γCD is obvious in the oestradiol benzoate or oestradiol-17β-
γCD complex samples. 
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Figure  2.7. Thermograms of pure HPβCD, γCD, oestradiol-17β, oestradiol benzoate, their 
physical mixtures and complexes. 
The extrapolated onset melting peak temperatures (Tm) for the 
oestradiol/cyclodextrin complexes investigated in the study are shown in Table 
 2.6. Literature values of the melting peak temperatures of γCD and HPβCD were 
obtained as 151.0 and 105.1, respectively (Vianna et al., 1998). 
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Table  2.6. Experimentally determined melting peaks for the steroid-cyclodextrin complex or 
mixture. 
Sample name Experimentally determined melting peak values (˚C) 
γCD  141.34 
HPβCD  127.03 
Oestradiol benzoate γCD mixture 109.18 & 200.97  
Oestradiol benzoate HPβCD mixture 122.60 & 201.25 
Oestradiol 17β γCD mixture 127.19 & 159.14 
Oestradiol 17β HPβCD mixture 117.26 & 176.90 
Oestradiol benzoate γCD complex 122.02 
Oestradiol benzoate HPβCD complex 124.27 
Oestradiol 17β γCD complex 117.35 
Oestradiol 17β HPβCD complex 128.81 
Oestradiol 17β 176.61 
Oestradiol benzoate 201.04 
 
There are shifts of the original endothermic peaks of oestradiol benzoate and 
oestradiol-17β in the case of oestradiol benzoate or oestradiol-17β and HPβCD or 
γCD complexes. This might be due to potential complex formation of oestradiol 
benzoate or oestradiol-17β and HPβCD or γCD.  
2.4.1.4 Solubility of the steroids 
The solubility of the steroids investigated in the study in PBS buffer (pH 5.0) and 
with 5% HPβCD in PBS buffer are shown in Table  2.7. 
Table  2.7. The solubility of various steroids in PBS (pH 5.0) and 5% HPβCD/PBS buffer (pH 
5.0). (Mean ± SD; N=6). 
Steroid PBS (pH 5.0) Solubility 
(µg/mL) 
Solubility (µg/mL) 
5% HPβCD/PBS 
Dexamethasone  108.1 ± 4.8 4232 ± 44 
Dexamethasone acetate 23.9  ± 1.1 1372 ± 33 
Dexamethasone isonicotinate - 366 ± 2.8 
Dexamethasone valerate 12.4 ± 1.2 282 ± 11.1 
Dexamethasone dipropionate - 138 ± 2.2 
Progesterone 10.7 ± 1.0 3711 ± 63.2 
Oestradiol benzoate - 149.9 ± 3.8 
Oestradiol-17β - 2483 ± 27 
-Cannot be determined. 
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It was impossible to determine the solubility values of dexamethasone 
isonicotinate, dexamethasone dipropionate, oestradiol benzoate and oestradiol-17β 
in PBS (pH 5.0) alone due to insufficient solubility in the buffer and low UV 
sensitivity. 
2.4.1.4.1 Apparent association/dissociation constant (Kc) values of 
steroid-HPβCD complexes 
The solubility phase diagram of the steroids in PBS buffer (pH 5.0) with 0-12.5% 
HPβCD at 39ºC are shown in Figure  2.8. The solubility was expressed in moles to 
allow a comparison with literature values. 
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Figure  2.8. Solubility phase diagrams in 0 - 12.5% w/w HPβCD in PBS (pH 5.0) of steroids 
used in this study (DXM = dexamethasone).  
 
The apparent Kc values of the steroid-HPβCD complex calculated from the initial 
linear portion of the slope of the phase solubility diagram and the initial solubility 
in the buffer (PBS/pH 5.0) using Equation  2.1, are shown in Table  2.8. The Kc 
values of dexamethasone isonicotinate, dexamethasone dipropionate, oestradiol-
17β and oestradiol benzoate could not be calculated because the initial solubility 
(C0) value of these steroids could not be determined in the buffer alone. 
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Table  2.8. Apparent Kc (association/dissociation constant) values and slopes of solubility 
diagrams of the drug-HPβCD complexes of steroids used in this study (Mean + SD; N=6). 
Steroid Slope (M/M) Kc (M-1) 
Dexamethasone 0.200 ± 0.005 892 ± 26 
Dexamethasone acetate 0.059 ± 0.001 1121 ± 101 
Dexamethasone valerate 0.037 ± 0.001 1480 ± 148 
Progesterone 0.330 ± 0.019 16470 ± 1408 
 
The apparent Kc values increase from dexamethasone to progesterone (Table  2.8). 
The lipophilicity of these compounds increases with the same manner of the 
apparent Kc values (Table  2.10). 
2.4.1.4.2 Apparent partition coefficients (octanol: 5%HPβCD/PBS pH5.0) 
The apparent partition coefficients of the steroids investigated in the study are 
shown in Table  2.9. 
Table  2.9. Apparent partition coefficient (Papp) of steroids used in the study. 
Steroid 
 
Day 1 
Mean ± SD (N=3) 
Day 2 
Mean ± SD 
(N=3) 
Mean (N=6) SD Log 
Papp 
Dexamethasone 6.78 ± 0.31 7.3 ± 0.59 7.04 0.26 0.85 
Dexamethasone acetate 43.12 ± 0.36 40.97 ± 0.47 42.05 1.07 1.62 
Dexamethasone isonicotinate 115.5 ± 3.6 105.5 ± 13.7 110.50 5.00 2.04 
Dexamethasone valerate 206.88 ± 26.58 226.38 ± 28.27 216.63 9.75 2.34 
Dexamethasone dipropionate 363.37 ± 22.10 389.7 ± 34.19 376.535 13.17 2.58 
Progesterone 77.74 ± 3.36 80.22 ± 4.71 79.11 4.29 1.90 
Oestradiol benzoate 624.23 ± 10.49 599.73 ± 34.94 612.94 28.20 2.79 
Oestradiol-17β 41.88 ± 0.36 39.68 ± 2.13 40.80 1.86 1.61 
 
The retention times or lipophilicity ranking order using reversed phase HPLC for 
the steroids investigated are shown in Table  2.10.  
Table  2.10. Retention time/lipophilicity order of the steroids investigated in the study. 
Drug name Retention time (minutes) on HPLC (C18) 
Dexamethasone 6.01 
Dexamethasone acetate 8.13 
Oestradiol-17β 8.72 
Dexamethasone isonicotinate 9.94 
Dexamethasone valerate 14.50 
Dexamethasone dipropionate 14.70 
Progesterone 17.50 
Oestradiol benzoate 24.30 
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2.4.1.5 Apparent partition coefficients (PCL: 5% HPβCD/PBS pH 5.0) 
The apparent partition coefficient values (Mean ± SD, N=6) of steroids between 
PCL and pH 5.0 PBS buffer used in the study are shown in Table  2.11. 
Table  2.11. Apparent partition coefficient values of steroids between PCL and 
5%HPβCD/PBS at pH 5.0. 
Steroid Day 1 
Mean ± SD (N=3)
Day 2 
Mean ± SD (N=3)
Papp(Steroid/PCL) Log Papp 
Dexamethasone 
 isonicotinate 
9.27 ± 0.509 8.28 ± 0.509 8.78 ± 0.587 0.94 ± 0.03
Dexamethasone 
valerate 
23.24 ± 0.02 23.20± 0.40 23.29 ± 1.68 1.37 ± 0.03
Dexamethasone  
dipropionate 
67.17 ± 0.421 70.52 ± 0.421 68.86 ± 2.44 1.84 ± 0.02
Progesterone 1.46 ± 0.26 1.89 ± 0.09 1.67 ± 0.289 0.22 ± 0.08
Oestradiol benzoate 31.97 ± 0.33 23.75 ± 0.11 27.87 ± 4.14 1.44 ± 0.07
 
The apparent partition coefficient values of dexamethasone, dexamethasone 
acetate and oestradiol-17β could not be determined because these steroids were 
insufficiently soluble in to the PCL membrane. 
2.4.1.6 Ionisation constant (pKa) 
The pKa and partition coefficient (octanol/water) values of the steroids 
investigated in the study are shown in Table  2.12.  
Table  2.12. pKa and partition coefficient values of the steroids investigated in the study. 
Steroid pKa1 Partition coefficient (log P) 
Dexamethasone  12.14 ± 0.70 2.1± 0.58 
Dexamethasone acetate 12.05 ± 0.20 2.6 ± 0.58 
Dexamethasone isonicotinate 11.93 ± 0.70; 2.85 ± 0.10 3.3 ± 0.59 
Dexamethasone valerate 12.67 ± 0.20 4.0 ± 0.58 
Dexamethasone dipropionate 12.93 ± 0.20 4.2 ± 0.59 
Progesterone N/A 4.0  
Oestradiol-17β 10.37 ± 0.20 4.1 ± 0.25 
Oestradiol benzoate 18.02 6.2 ± 0.36 
1Obtained using Advanced Chemistry Development (ACD) Software Solaris V4.67 (© 1994-2003 
ACD). 2Spidey, Alchemist-Anabolic Mod (2003). 
Table  2.12 shows that progesterone is non-ionisable compound, but oestradiol and 
dexamethsone compounds are ionisable. Additionally, dexamethasone analogues 
have similar pKa values between 11.9 and 12.9.  
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2.4.1.7 Permeation studies 
2.4.1.7.1 Side-by-side cells (non biological membranes) 
2.4.1.7.2 Manufacture of membrane 
The silicone membranes manufactured by DEC Manufacturing are shown in 
Figure  2.9. 
 
 
Figure  2.9. Silicone membranes manufactured by DEC Manufacturing. 
 
The average thickness measured from over nine points of the silicone membrane 
segments is shown in Appendix-B. 
2.4.1.7.3 Effect of membrane type 
Individual values for dexamethasone permeation through PCL (~140 μm), 
silicone (~150 μm) and synthetic skin (50 μm) membranes are shown in 
Appendix-C1. Also individual values and rates of permeation for dexamethasone 
acetate through PCL (~140 μm), silicone (~150 μm) and synthetic skin (50 μm) 
membranes are shown in Appendix-C2. 
The summarised results for the initial studies assessing permeation of 
dexamethasone and dexamethasone acetate across several different types of 
membranes including silicone (150 μm thickness), synthetic skin membrane (50 
μm thickness) and PCL (140 μm) are shown in Table  2.13. 
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Table  2.13. Effect of membrane composition upon the rate of permeation of dexamethasone 
and dexamethasone acetate. 
Drug candidate Membrane 
type 
Membrane 
thickness (μm) 
Permeation rate 
(μg/h) 
Average 
permeation rate 
(μg/h) 
Silicone 150 0.089; 0.103; 0.094; 0.082 0.092 ± 0.008 
Synthetic 
skin 50 
0.057; 0.069; 
0.058; 0.044 0.057 ± 0.009 Dexamethasone base 
PCL 140 2.00; 2.35; 1.90; 2.42 2.17 ± 0.222 
Silicone 150 0.348; 0.374; 0.372 0.365 ± 0.012 
Synthetic 
skin 50 
0.064; 0.083 
0.069 0.072 ± 0.008 
Dexamethasone 
acetate 
PCL 140 2.78; 3.09 2.61 2.83 ± 0.199 
 
The permeation rates of dexamethasone and dexamethasone acetate were higher 
in PCL compare to silicone and synthetic skin membranes (Table  2.13). 
2.4.1.7.4 Stability of membrane 
Figure  2.10 shows the SEM photographs of the surface properties of the PCL 
membrane at the end of a 7-day run compared to the surface of a freshly 
manufactured membrane. There is no any obvious surface property difference 
between the used and the fresh PCL membrane.  
a b
 
Figure  2.10. SEM of the surface of the membrane at the end of the long run (a) compared to 
the surface properties of a freshly prepared membrane (b). 
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2.4.1.7.5 Effect of changing conditions 
The effect of changing conditions on dexamethasone permeation through PCL 
membranes of 140 μm thickness is shown in Table  2.14. 
Table  2.14. Effect of the PCL membrane thickness with single or duplicate runs on the 
cumulative amount permeated per unit area and permeation rates of dexamethasone. 
Parameter Variable *Flux (μg/h/cm2) Permeation rate 
(μg/h) 
Average 
permeation 
rate (μg/h)+SD 
70 5.29; 4.23 4.15; 3.32 3.74 ± 0.42 
83 3.92; 3.46 3.08; 2.72 2.90 ± 0.18 
86 3.69 2.90 2.90 
98 4.28 3.36 3.36 
102 3.44 2.70 2.70 
104 3.90 3.06 3.06 
114 3.44 2.70 2.70 
121 2.98 2.34 2.34 
130 3.03 2.38 2.38 
138 2.87;3.24 2.25; 2.54 2.40 ± 0.15 
139 3.24, 2.87 2.54; 2.25 2.40 ± 0.15 
140 2.39; 3.08 2.41; 2.73 
1.88; 2.42; 
1.89; 2.14 2.08 ± 0.22 
141 2.55; 2.99 2.00; 2.35 2.18 ± 0.18 
145 2.42; 3.08 1.90; 2.42 2.16 ± 0.26 
148 2.39 1.88 1.88 
170 1.76 1.38 1.39 
Membrane 
thickness(µm) 
180 1.40 1.10 1.10 
25°C 0.64; 0.66 0.50; 0.52 0.51 ± 0.01 
30°C 0.99; 1.11 0.78; 0.87 0.82 ± 0.05 
35°C 1.58; 1.34 1.24; 1.05 1.15 ± 0.10 Temperature 
39°C 2.96; 2.36 2.32; 1.86 2.09 ± 0.23 
1.25 w/v 2.04; 1.84 1.60; 1.44 1.52 ± 0.08 
2.5 w/v 2.33; 2.37 1.83; 1.86 1.85 ± 0.02 
5 w/v 2.97; 2.47 2.33; 1.94 2.14 ± 0.20 
Cyclodextrin 
concentration 
7.5% w/v 3.04; 3.16 2.39; 2.48 2.44 ± 0.05 
5.0 3.08; 2.42 2.42; 1.90 2.16 ± 0.26 
7.4 2.36; 2.11 1.85; 1.66 1.76 ± 0.10 pH of the donor phase 10.0 3.15; 2.29 2.47; 1.80 2.14 ± 0.34 
pH of the 
receptor phase 10 3.11; 2.66 2.44; 2.09 2.27 ± 0.18 
*NB: the flux was calculated using the permeation rate value divided by area of 0.785 cm2. 
From Table  2.14 it can be seen that the much thicker PCL membranes (≥150 µm) 
showed lower permeation rates, and therefore diffusion of dexamethasone across 
the thicker membrane would take longer. The thinner membranes (≤120 µm) 
showed higher permeation rates with some considerable variation. Improving 
permeation rates with less variation and need of reasonable time of diffusion 
across the membrane, 140 µm thick PCL was considered for further study. The 
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permeation rate showed dependence on temperature and cyclodextrin 
concentration but there was little or no effect due to variation in pH. 
2.4.1.7.6 Screening of steroids across PCL membrane 
The flux and permeation rate of various dexamethasone analogues through 140 
μm thick PCL membranes is shown in Table  2.15. 
Table  2.15. Flux and permeation rates of the different steroids across PCL membrane. 
Drug Flux 
(μg/h/cm2) 
Permeation 
rate 
(μg/h) 
Average  
permeation 
rate 
(μg/h) ±SD 
Permeation rate 
ratio relative to 
dexamethasone 
Dexamethasone 2.55; 2.99 2.42; 3.08 
2.00; 2.35; 
1.90; 2.42 2.17 ± 0.22 1 
Dexamethasone 
isonicotinate 0.71; 0.66 0.56; 0.52 0.543 ± 0.02 
Dexamethasone 
isonicotinate 
(pH 7.4) 
0.80; 0.87 
0.83; 0.82 0.63; 0.68; 0.65; 0.64 0.649 ± 0.02 
0.3 
Dexamethasone valerate 2.01; 2.46 1.58; 1.93 1.76 ± 0.18 0.8 
Dexamethasone 
dipropionate 
2.79; 2.70 2.19; 2.12 2.16 ± 0.04 1.0 
Dexamethasone acetate 3.55; 3.94 3.32 
2.79; 3.09; 
2.61 2.83 ± 0.20 1.3 
Oestradiol benzoate 5.20; 5.52; 4.55; 5.04 
4.08; 4.33; 
3.57; 3.96 3.99 ± 0.27 1.8 
Oestradiol-17β 7.12; 6.20 7.66; 7.46 
5.59; 4.87; 
6.01; 5.86 
5.58 ± 0.44 2.6 
Progesterone  34.87; 34.32; 26.42; 30.28 
27.37; 26.94; 
20.74; 23.77 24.71 ± 2.68 11.4 
 
The permeation rate ratio relative to dexamethasone of the tested steroids across 
the PCL membranes is shown in Table  2.15. Progesterone and dexamethasone 
isonicotinate showed the highest and the lowest values across the PCL membrane, 
respectively.  
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The diffusion coefficient and permeability coefficient values using Equation  2.4, 
Equation  2.5 and Equation  2.6 of various steroids through 140 μm thick PCL 
membrane are shown in Table  2.16.  
Table  2.16. Diffusion coefficient and permeability coefficient values of various steroids 
through 140 mm thick PCL membrane (Mean ± SD). 
Drug name D† (cm2/sec) X 10-7 Permeability coefficient
(Papp)‡ X 10-4 
cm/sec 
Permeability coefficient
(Paap)‡‡x 10-4 
(cm/sec) 
Dexamethasone 
4.8 ± 1.1 0.1 ± 0.01 
Dexamethasone acetate
2.6 ± 0.3 0.42 ± 0.04 
N/A 
Dexamethasone 
valerate 1.2 ± 0.2 0.51 ± 0.1 1.7 ± 0.2 
Progesterone 
6.5 ± 1.0 8.2 ± 1.0 0.55 ± 0.08 
Dexamethasone 
dipropionate 2.4 ± 0.1 11.2 ± 2.8 
Dexamethasone 
isonicotinate 3.3 ± 1.4 1.5 ± 0.5 
Oestradiol benzoate 
8.2 ± 0.1 
N/A 
19.3 ± 7.5 
†Equation  2.6; ‡Equation  2.4; ‡‡Equation  2.5.  
Permeability coefficients of the steroids studied across PCL membrane varied 
among different steroid analogues. There is a tendency of the permeability 
coefficient to increase with higher lipophilicity compounds such as progesterone, 
dexamethasone dipropionate and oestradiol benzoate (Table  2.16). 
2.4.2 Side-by-side cells (biological membrane) 
2.4.2.1 Screening of steroids across excised mucosa 
Table  2.17 shows the flux and permeation rates of the different steroids across 
excised vaginal mucosa. It was found that some steroids, which have an ester 
group on carbon position 21 such as dexamethasone acetate, dexamethasone 
isonicotinate and dexamethasone dipropionat, were found to hydrolyse. 
Dexamethasone was identified as a secondary compound of ester hydrolysis 
product of dexamethasone acetate and dexamethasone isonicotinate. 
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Table  2.17. Flux and permeation rates of the different steroids across excised vaginal mucosa. 
Drug name Flux [ester] 
(μg/h/cm2) 
Permeation rate 
[ester] (μg/h) 
Average 
permeation rate 
[ester] (μg/h) ±SD 
Dexamethasone* 16.92; 15.40 
21.26; 15.34 
13.28; 12.09;  
16.69; 12.04 13.53 ± 1.89 
Dexamethasone acetate 14.31; 16.42 
8.39; 18.01 
11.23; 12.89; 
 6.59; 14.14 11.21 ± 2.86 
Dexamethasone isonicotinate 0.84; 0.68 
0.54; 0.41 
0.66; 0.53; 
 0.42; 0.32 0.48 ± 0.12 
Dexamethasone valerate* 7.12; 6.28 
8.37; 7.99 
5.59; 4.93 
6.57; 6.27 5.84 ± 0.63 
Dexamethasone dipropionate 0.60; 0.82 
0.43; 0.55 
0.47; 0.64 
0.34; 0.43 0.47 ± 0.11 
Progesterone*  14.27; 11.11 
21.03; 11.55 
11.20; 8.72 
16.51; 9.07; 11.38 ± 3.11 
*Compounds not hydrolysing. 
Table  2.18 shows the permeation rates of the ester hydrolysis product of 
dexamethasone acetate and dexamethasone isonicotinate across excised vaginal 
mucosa. The ester hydrolysis of dexamethasone dipropionate were observed on 
the chromatogram but not quantified due to not having a reference compound (e.g., 
dexamethasone-17-propionate). The peak due to the ester hydrolysis product was 
well separated from the principal peak due to dexamethasone dipropionate. 
Table  2.18. Permeation rates of the ester hydrolysis product (dexamethasone) obtained by 
dexamethasone acetate and dexamethasone isonicotinate across excised vaginal mucosa. 
Drug name Permeation rate 
[dexamethasone] (μg/h) 
Average permeation rate 
[dexamethasone] (μg/h) ±SD 
Dexamethasone acetate 1.91; 1.36; 1.85; 1.33 1.61 ± 0.27 
Dexamethasone isonicotinate 0.66; 0.53; 0.64; 0.62 0.61 ± 0.05 
 
Table  2.19 shows permeability coefficient values of the different steroids across 
excised vaginal mucosa. These values were calculated using Equation  2.4. 
Table  2.19. Permeability coefficients of the studied steroids across excised mucosa. 
Drug name Permeability coefficient 
(Papp)1 (cm/sec x 10-5) 
Average permeability coefficient
[ester] (cm/sec x 10-5) ±SD 
Dexamethasone 4.3; 4.0; 5.5; 3.9 4.4 ± 0.72 
Dexamethasone acetate 16.6; 19.1; 9.8; 20.9 16.6 ± 4.9 
Dexamethasone valerate 16.0; 14.1; 18.7; 18.0 16.7 ± 2.1 
Progesterone 37.0; 28.8; 54.6; 30.0 37.6 ± 12.0 
 
Chapter Two 
76 
Progesterone and dexamethasone showed the highest and the lowest permeability 
values across the excised mucosa, respectively. This is possibly due to the relative 
molecular size and degree of lipophilicity of progesterone compared to 
dexamethasone, dexamethasone acetate and dexamethasone valerate which may 
all contribute to the ranks of permeability values.  
2.5 Discussion 
2.5.1 Confirmation of identity of the active ingredients 
In order to confirm the identity of the steroids used in the study, experiments were 
conducted using IR and DSC analysis. The IR spectrum was analysed and the 
principle peaks were compared to those found in the literature for the same 
compounds or their chemical structures. The comparison is shown in Table  2.20.  
Table  2.20. Literature values and experimentally determine IR values for the steroids used in 
this study. 
Drug name  Experimentally observed 
principle Wave numbers (cm-1) 
Literature wave numbers (cm-1) 
Dexamethasone 852; 893; 1033; 1054; 1135; 1621; 1664; 1706 
852; 893; 1040; 1150; 1620 1670; 
1660; 1700 1,2 
Dexamethasone 
acetate* 
871; 968; 1055; 1608; 1673; 
1731; 2947 
852; 893; 1040; 1610; 1670; 1700; 
2960-2850 
Dexamethasone 
valerate* 
831; 892; 1031; 1394; 1609; 
1617; 1662; 1715 
852; 893; 1040; 1395; 1610; 1660; 
1670; 1700 
Dexamethasone 
isonicotinate* 
848; 983; 1044; 1604; 1622; 
1663; 1723;  
852; 893; 1040; 1610; 1660; 1670; 
1700 
Dexamethasone 
dipropionate* 
881; 895; 926; 1040; 1257; 
1662; 1701; 1750; 3301 
852; 893; 1040; 1260; 1610; 1660; 
1670; 1700; 1755-1725 3200-3600 
Progesterone 871; 1204; 1227; 1278; 1614; 1661; 1698 
872; 1209; 1232; 1614; 1662; 1700 
2,3 
Oestradiol-17β 818; 872; 1011; 1054; 1355; 1497; 1585; 1608; 2862  
818; 872; 1011; 1054; 1355; 1497; 
1585; 1608; 28624 
Oestradiol benzoate 704; 1063; 1129; 1262; 1723 704; 1075; 1220; 1250; 1724 2,3 
1(Cohen, 1973) and 2(Pharmaceutical Society of Great Britain.Department of Pharmaceutical 
Sciences, 1979); 3(Clarke et al., 1986) and 4(Salole, 1986). *Dexamethasone ester chains wave 
numbers from literature were obtained using infrared correlation charts by Weast (1988). 
The close agreement between the literature values and the experimentally 
determined IR values seen in Table  2.20 indicates that each of the steroids used in 
the study were as described by the supplier. The DSC traces were analysed and 
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endothermic melting peaks shown by the thermographs were compared to the 
reported melting point peak values for the steroids used in the study. Literatures 
values and experimentally determined DSC values for the steroids used in the 
study are shown in Table  2.5.  
Melting is an endothermic process in which the sample takes in a net quantity of 
heat (Clas et al., 1999). A 100% pure crystalline compound shows a sharp melting 
endothermic change. The presence of impurities or crystalline defects lead to a 
broadening of the melting endotherm and to a lowering of the melting temperature. 
According to the literature, the onset temperature where the transition temperature 
starts to deviate from the baseline can describe a melting endotherm. The 
extrapolated onset melting temperature is reported as the temperature at the 
intersection of the extrapolated baseline prior to the transition with the 
extrapolated leading edge of the transition. The endothermic melting peak is 
defined as the peak temperature (Tm). Extrapolated onset temperature and 
literature values shown in Table  2.5. The close agreement between the literature 
values and the experimentally DSC values seen in Table  2.5 again indicates that 
each of the steroids used in the study were pure as described by the supplier. 
2.5.2 Oestradiol-cyclodextrin Complexation 
Complexation leads to changes in the physicochemical properties of the steroids 
used in this study. The extrapolated onset melting peak temperatures for the 
oestradiol/cyclodextrin complexes investigated in the study are shown in Table 
 2.6. 
DSC thermograms showed endothermic peaks corresponding to the melting points 
of oestradiol benzoate, oestradiol-17β, γCD and HPβCD in physically mixed 
samples (Table  2.6), as shown in Figure  2.7. This indicates that there was no 
potential interaction between γCD or HPβCD and the oestradiols.  
The endothermic peaks for oestradiol benzoate or oestradiol-17β were absent in 
the thermograms from samples prepared from saturated solution. However, γCD 
and HPβCD melting peaks were always present with slight shifts. Broadening and 
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lowering of the melting temperatures seen for oestradiol and cyclodextrin are due 
to complex formation. The broadening is much more pronounced in the case of 
γCD than HPβCD. Presumably this is due to a different central cavity diameter 
(7.5-8.3 for γCD, 6.0-6.5 Å for HPβCD) (Loftsson et al., 1996; Loftsson et al., 
2003). It is possible that the drug has more central cavity space to interact with 
when γCD is used compare to HPβCD. 
The disappearance of the oestradiol benzoate or oestradiol-17β melting peaks in 
the complex samples showed that there was a possible interaction between the 
drug and cylodextrin. This might be due to γCD or HPβCD oestradiol complexes 
being in an amorphous state. A similar explanation was given (Babu & Pandit, 
2004) when inclusion of complexes of bupranolol with cyclodextrin were 
characterised by DSC and the melting point of bupranolol was found to 
completely disappear.  
However, further analysis of the pure samples and their complexes using X-ray 
diffractometry might explain the presence of the amorphous state further.  
2.5.3 Solubility and association/dissociation constants (Kc) 
The use of the drug carrier cyclodextrin is to improve the solubility and 
bioavailability of the steroids across artificial or/and biological membranes 
(Lopez et al., 2000). The phase-solubility diagram of dexamethasone in aqueous 
HPβCD solution was investigated (Loftsson et al., 1994). The solubility increased 
linearly as a function of HPβCD concentration with a slope of less than unity and, 
thus, formation of a 1:1 complex could be assumed. The Kc value of the 
dexamethasone-HPβCD inclusion complex was determined to be 1230 M-1.  
The phase-solubility diagram in aqueous HPβCD (0-12.5%w/w in PBS/pH 5.0) 
solution of steroids used in this study has been p shown in Figure  2.8 (see Section 
2.4.1.4.1). The solubility of all studied steroids was found to increase with an 
increase in HPβCD concentration. This is in agreement with data reported in the 
literature (Usayapant & Iyer 1999). The increase in aqueous solubility of the 
steroids is evidence of formation of a water-soluble drug HPβCD (1:1) inclusion 
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complex (Loftsson et al., 1994). In addition, a slope of less than unity (Kc) 
suggests the formation of a drug-cyclodextrin (1:1) complex. Moreover, the 
disappearance of the oestradiol benzoate or oestradiol-17β melting peaks in DSC 
scans of HPβCD complexes samples showed that there was interaction between 
the steroids and cyclodextrin (see Section 2.5.2). 
The ranking order of solubility profile dependency on HPβCD content increase 
was progesterone, oestradiol-17β, dexamethasone, dexamethasone acetate, 
dexamethasone valerate, oestradiol benzoate, and dexamethasone isonicotinate 
and dexamethasone dipropionate (Figure  2.8). It seems that structural complexity 
(perhaps presence of attached groups on steroid compound such as ester chains), 
size and the initial solubility of these steroids all contribute to give different 
solubility diagram profiles. 
It was found that the total amount of drug in solution is a function of both the 
intrinsic solubility of the drug in the absence of cyclodextrins and of the 
complexation constant, Kc, and sometimes the two effects can cancel out (Stella et 
al., 1999). In addition, the solubility of most drugs increases with increasing 
temperature. West (2003) reported that the body temperature of a cow might vary 
between 38.9 and 39.4ºC. In addition, any product resulting from this research 
would be intravaginally administered into cows. It was therefore decided to 
conduct the preformulation experiments at a temperature of 39ºC. According to 
the literature, the formation rate constant of the drug/cyclodextrin complex was 
found to be close to that of a diffusion controlled process and weakly dependent 
on structure of the drug and Kc, while the dissociation rate constant was very 
structure sensitive and inversely proportional to Kc (Stella et al., 1999).  
The linear phase solubility diagrams of dexamethasone and dexamethasone 
acetate Kc values (Table  2.8) are in agreement with data reported in the literature. 
In this study, the Kc values for complex formation were 892 and 1121 M-1 versus 
literature values of 1230 (Loftsson et al., 1994) and 2240 M-1 (Usayapant et al., 
1991) for dexamethasone and dexamethasone acetate, respectively.  
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In principle, drug/cyclodextrin complexes may dissociate due to a decrease in Kc 
as the complex is exposed to a pH, which changes the charge status of either the 
drug or the cyclodextrin (Stella et al., 1999). Additionally, binding of drugs to 
cyclodextrins has been shown to be an exothermic process (ΔH is negative). 
Hence, any increase in temperature results in a weakening of the complex, and 
thus an increase in the free fraction of drug. This can explain lower values of Kc of 
the studied steroids compared with values of 39°C versus 23-25°C, respectively.  
2.5.4 Side-by-side-cells and using non-biological membranes 
Various non-biological membranes were investigated in side-by-side cell 
experiments. Synthetic skin of known thickness (50 µm) was used as received. 
However, the membranes that were manufactured by DEC Manufacturing or in-
house were characterised in terms of their thickness and uniformity of thickness. 
The silicone membranes manufactured by DEC Manufacturing (Figure  2.9) were 
shown to exhibit a uniform thickness with an average thickness of 150 ± 8 µm 
ranging from 140.0 to 166 µm. PCL membranes manufactured in-house for use in 
the study (Figure  2.6) were also shown to exhibit a uniform thickness with an 
average of 143.1 ± 5.0 µm ranging from 138.0 to 148 μm. 
Initially, the effect of membrane composition on the permeation of two 
compounds (dexamethasone and dexamethasone acetate) was studied in order to 
identify a membrane for use in future experiments. Three membranes were 
investigated: silicone, synthetic skin and PCL. Several criteria were identified that 
the membrane should meet for use in these studies. These included: (i) ready 
availability or ease of manufacture; (ii) sufficiently cheap to purchase or 
manufacture; (iii) exhibition of a reproducible thickness; (iv) stability for the 
duration of the side-by-side cell studies (up to 7 days); (v) permeability to the 
steroids used in the study. Each of the membranes investigated fulfilled criteria (i) 
to (iv), however, the membranes were observed to vary in their permeability 
toward steroids. Permeation rates for dexamethasone and dexamethasone acetate 
across the membranes were ordered from the slowest to the fastest as follows 
synthetic skin followed by silicone followed by PCL (Figure  2.11). 
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Figure  2.11. Rate of permeation (Mean ±SD, N = 4) for dexamethasone ( ) and 
dexamethasone acetate (￭ ) through silicone, synthetic skin and PCL membranes. 
The high permeability of PCL led to it ultimately being chosen as a membrane for 
use in this reseasrch, since it resulted in high steroid concentrations appearing in 
the receptor phase thus allowing for easy and accurate detection of the steroids by 
a simple UV analytical method. The high permeability of PCL also meant that the 
duration of an experiment could be reduced (compared to the other membrane 
types) and yet still provides an accurate estimate of the permeation rate.  
However, in contrast to silicone membrane or synthetic skin, the PCL membrane 
is a degradable polymer. Therefore, it was important to show that the membrane 
was not degrading over the time course of an experiment. An experiment was 
initiated using dexamethasone and dexamethasone acetate that studied the effect 
of 7 days exposure of the membrane to the aqueous phase used in the side-by-side 
cell studies on the stability of the PCL membrane. SEM photomicrographs 
revealed that freshly manufactured and exposed membranes had the same surface 
characteristics suggesting that no degradation had taken place. 
In addition, the linearity (R2 ≥0.9996) of the appearance of the steroids in the 
receptor phase suggests that no degradation of the membrane is occurring during 
the course of the experiment (Figure  2.12). 
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Figure  2.12. Rate of permeation (Mean ±SD, N = 4) for dexamethasone acetate (¡) and 
dexamethasone () through PCL membranes. 
The effect of changing conditions in the donor and receptor phases upon 
dexamethasone permeation through PCL membranes of 140 μm thickness was 
studied. As the thickness of the membrane increased, the rate of permeation 
decreased (Figure  2.13). 
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Figure  2.13. Effect of PCL thickness on dexamethasone permeation rate through PCL 
membranes. 
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The temperature of the donor and receptor phase also affected the rate of 
permeation with increasing temperature increasing permeation rate (Figure  2.14). 
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Figure  2.14. Effect of temperature on dexamethasone permeation rates. 
 
Cyclodextrin concentration was also seen to affect the rate of permeation of 
dexamethasone. As the concentration of cyclodextrin was increased in the donor 
phase, the rate of permeation increased (Figure  2.15). Since passive diffusion is 
driven by high drug concentration in the aqueous vehicle, the increase of 
dexamethasone in solution can explain the increase of dexamethasone permeation 
through the PCL membrane. This was in agreement with what is reported in the 
literature (Loftsson et al., 1994). 
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Figure  2.15. Effect of cyclodextrins (HPβCD) concentration on dexamethasone permeation 
rates. 
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Changing the pH of the donor phase (while keeping the receptor phase pH at 5) 
had no effect on the rate of permeation of dexamethasone (Figure  2.16).  
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Figure  2.16. Effect of donor and receptor phases’ pH (5 vs. 5; 7.4 vs. 5; and 10 vs. 5 for the 
donor and receptor phases respectively) on dexamethasone permeation rates. 
 
In addition, changing the pH of the receptor phase to pH 10 (from pH 5) had no 
effect upon permeation rate. It is expected that ionised species penetrate poorly 
through the membranes compared with non-ionised species (Mashru et al., 2005). 
The effect of pH on the rate of permeation would be expected to be negligible due 
to the fact that dexamethasone has a pKa value greater than 12.0 which is at least 
two or more pH units away from the range of the tested pHs.  
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Figure  2.17 shows the rate of permeation of different steroids through PCL 
membranes. 
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Figure  2.17. Effect of steroids on rate of permeation profiles through PCL membranes 
(Mean ± SD, N=2). 
 
The permeation rate profiles of the various steroids significantly varied. 
Progesterone showed the highest permeation rate of all tested steroids. There is a 
trend of decreasing permeation rate from oestradiol-17β, oestradiol benzoate to 
dexamethasone analogues (Figure  2.17). Haigh & Smith (1994) have reported that 
the steroid partition coefficient between donor or receptor phase and the 
membrane is the most important variable that can affect the permeation process. 
The different permeation rate profiles could be explained by different solubility, 
lipophilicity, relative molecular size and molecular shape among the steroids. The 
permeation rate is function of the steroid concentration in the donor phase as well 
as the partition coefficient (Schoenwald & Ward, 1978) between the steroid and 
the membrane.  
Figure  2.18 shows the relationship between permeation rates versus partition 
coefficient expressed in LogP at octanol: pH 5/5%HPβCD, retention time on 
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HPLC (C18), solubility at pH 5/5%HPβCD and partition coefficient at pH 
5/5%HPβCD/PCL membrane of some steroids. It can be seen from Figure  2.18 
that the permeation rates of these compounds did not show any obvious trend with 
their physicochemical properties. 
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Figure  2.18. Permeation rates through PCL membranes versus partition coefficient (a), 
retention time on HPLC (C18) (b), solubility (c), and partition coefficient (pH 
5/5%HPbCD)/PCL membrane (d) of some steroids. 
 
Figure  2.19 shows the relationship between permeability coefficients versus 
partition coefficient (LogP of octanol: pH 5/5%HPβCD), retention time on HPLC 
(C18), solubility at (pH 5/5%HPβCD) and partition coefficient (pH 
5/5%HPβCD)/PCL membrane of some steroids. 
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Figure  2.19. Effect of partition coefficient (LogP)(pH 5/5%HPbCD) (a), retention time on 
HPLC (C18) (b) solubility at (pH 5/5%HPbCD) (d), and partition coefficient (pH 
5/5%HPbCD)/PCL (d) upon the permeation rates through PCL of some steroids. 
 
It can be seen from Figure  2.19(a-b) that as the LogP and retention time of the 
compound increase, so does its permeability coefficient. However, other 
physicochemical properties did not show any obvious correlation with the 
permeability coefficients of the steroids. Both the partition coefficient and 
retention time indicate the lipophilicity of the steroids. Since the partition 
coefficients and retention time showed a correlation with the permeation rates, the 
PCL appears to be non-porous and lipophilic membrane. The PCL membrane 
appears to offer some rate-limiting step to steroids permeation. This type of 
barrier function is inherited to the membrane for which only dissolved free drug 
molecules will have to partition from the aqueous donor to the membrane 
(Loftsson et al., 2003). Therefore, the lipophilicity between the membrane and 
drug reflects the ability of the drugs to leave the donor phase and partition into the 
membrane (Figure  2.19a). The use of PCL as a model membrane in side-by-side 
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cell experiments results in the advantage that compounds rapidly permeate 
through it, resulting in the need for less sensitive analytical techniques to be 
developed and potentially only short experimental times can be used to generate 
sufficient data to provide a reliable estimate of the permeation rate. In addition, 
the PCL membrane can be used for showing a sufficient discriminatory power 
between steroidal dosage forms. 
2.5.5 Side-by-side-cells using excised mucosal membranes 
All of the steroids studied permeate across excised mucosal membranes with 
varying permeation rates. A typical curve of the cumulative amount of steroid 
permeated through excised mucosa over time (i.e., dexamethasone valerate) is 
shown in Figure  2.20a. Some other examples are shown in Appendix-D. A linear 
(R2 ≥0.9986) relationship was obtained when the total amount of each steroid 
analogue in the receptor phase was plotted against time. Therefore, the 
dexamethasone analogues and progesterone permeation through excised mucosa 
transport can be described by zero order kinetics. Figure  2.20a exhibits a lag time 
(the time before establishing steady state concentration across membrane) which 
was not used in the calculation of the linear portion of the curve to determine the 
slope of the line. An example of a typical curve that is used for permeation rate 
calculations of the steroids studies is shown in Figure  2.20b. 
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Figure  2.20. A typical cumulative amount of dexamethasone valerate across excised mucosa 
membrane (Mean ±SD, N=4) including (a) and excluding the lag phase (b). 
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Some steroids showed higher permeation rates than others, as previously shown in 
Table  2.17. This could be a possible combination of the steroid lipophilicity and 
the concentration gradient between the two sides (donor and receptor phase) of the 
membrane. Dexamethasone acetate, dexamethasone isonicotinate and 
dexamethasone dipropionate showed ester bond hydrolysis when the excised 
mucosal membrane was used. In addition, no secondary product was found when 
dexamethasone acetate and non-biological membranes (i.e. silicone or PCL 
membrane) were used in side-by-side cells. Therefore, it is possible that some 
esterase enzymes are present in the vaginal mucosa membrane which are specific 
enough to cleave the ester bond at the carbon 21 position of dexamethasone 
acetate, dexamethasone isonicotinate and dexamethasone dipropionate. This 
possibility is supported by other researchers who found that dexamethasone ester 
hydrolysis was occurring in biological tissues due to esterase enzymes (Lopez et 
al.,2000 & Civiale et al., 2004). In addition, other researchers found that 
dexamethasone was released from dexamethasone isonicotinate or dexamethasone 
sodium phosphate due to ester hydrolysis and was available in the systemic 
circulation immediately following intravenous or intramuscular administration 
(Toutain et al., 1982; Welch et al., 1973; Fairclough et al., 1981a).  
Interestingly, the dexamethasone ester on the carbon 17 position (i.e. 
dexamethasone valerate) did not show any secondary metabolic products. This 
suggests the presence (in the excised mucosa) of a stereo-specific enzyme, which 
only cleaves at a specific ester bond. From the chemical structure of 
dexamethasone esters on the carbon 21 position, which is more exposed to 
enzymatic hydrolysis reactions, seems to be more susceptible to the hydrolysis 
unlike position 17 esters, which is perhaps due to possible steric hindrance and 
stereospecifity of the enzymes causing the hydrolysis. Further evidence is that one 
secondary product was found from dexamethasone dipropionate, which has two 
ester bonds on carbon position, 17 and 21. The carbon position 21 ester bond was 
likely to be cleaved perhaps due to its lack of steric hindrance and thereby 
susceptibility to the hydrolysis as shown by the ester hydrolysis on carbon 
position 21 of dexamethasone acetate or dexamethasone isonicotinate.  
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Figure  2.21 shows the correlation of permeation rates between PCL and excised 
mucosa. It can be seen from Figure  2.21 the permeation rate values using PCL 
cannot predict the rate of permeation through excised mucosa for the same steroid, 
and therefore, the PCL was not an ideal model membrane to choose for predicting 
the rate of permeation through excised mucosa.  
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Figure  2.21. Correlation of permeation rates between PCL and excised mucosa. 
 
Figure  2.22 shows the relationship between permeation rates and log solubility in 
a pH 5/5% HPβCD solution through the excised mucosa of some steroids. It can 
be seen that as the solubility of the compound increases so does its permeation 
rate. The steroid compound can be sheltered inside the HPβCD cavity, become 
more soluble and creating a large concentration gradient between the donor and 
receptor phases and thereby improving the rate of permeation. 
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Figure  2.22. Effect of solubility upon the permeation rate of some steroids. 
 
Table  2.21 presents the permeability coefficients and their permeability relative to 
that for dexamethasone using Equation  2.4. 
Due to the poor solubility of dexamethasone isonicotinate and dipropionate in the 
PBS buffer, the permeability coefficient values were impossible to determine 
using Equation  2.4. 
Table  2.21. Permeability coefficients and their ranking order of some steroids through 
excised mucosa. 
Drug name Average permeability coefficient
[ester]  (cm/sec x 10-5) ±SD 
Permeability coefficient ratio 
relative to dexamethasone 
Dexamethasone 4.4 ± 0.72 1 
Dexamethasone acetate 16.6 ± 4.9 4 
Dexamethasone valerate 16.7 ± 2.1 4 
Progesterone 37.6 ± 12.0 9 
Dexamethasone 
isonicotinate 
Dexamethasone 
dipropionate 
Impossible to be determined 
 
The permeability coefficients of the tested steroids through excised mucosa are 
ranked from the highest to the lowest as follows: progesterone followed by 
dexamethasone valerate/dexamethasone acetate followed by dexamethasone as 
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shown in Table  2.21. The rank order of the permeability coefficients seems to 
follow increasing order of lipophilicity.  
Figure  2.23 shows the effect of molecular weight on the permeation and 
permeability rates through the excised mucosa of some steroids. A trend shows 
the permeation and permeability values decreased with increasing of the steroid 
molecular weight. For instance, the steroids with lower molecular weights, such as 
progesterone and dexamethasone (DXM), showed high permeation rates compare 
to those with higher molecular weights such as DXM dipropionate and DXM 
isonicotinate (Figure  2.23a). This finding was in agreement with reported 
information that demonstrated the transport of a drug molecule through living 
membranes is a size dependent (Ritschel, 1988).  
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Figure  2.23. Effect of molecular weights on permeation (a) and permeability values (b). 
A close agreement of the progesterone permeability coefficient through excised 
vaginal mucosa obtained in this study and the literature value (37.6 versus 69 x 
10-5 cm/sec, respectively) was obtained (Chien, 1992). Similarly, dexamethasone 
and dexamethasone acetate permeability coefficient values obtained in this study 
showed the same order of magnitude with the literature values across a Caco-2 
cells monolayers (4.4 versus 1.3 x 10-5 cm/sec for dexamethasone) (Artursson & 
Karlsson, 1991) or/and bovine conjunctival epithelial cells (4.4, 16.6 versus 0.1, 
1.8 x 10-5 cm/sec for dexamethasone and dexamethasone acetate, respectively) 
(Civiale et al., 2004). 
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Ester bond hydrolysis of dexamethasone acetate, dexamethasone isonicotinate and 
dexamethasone dipropionate has been observed. Dexamethasone valerate was not 
hydrolysed and showed a relatively good permeability coefficient through vaginal 
mucosa. Dexamethasone acetate existed in two forms, which are dexamethasone 
and dexamethasone acetate. The latter dexamethasone ester permeability was 
good as per dexamethasone valerate. However, both the two forms of 
dexamethasone acetate are active drugs. 
2.6 Conclusion 
The IR spectrum and DSC results were found to be in close agreement with those 
found in the literature for the same compounds. The solubility phase diagrams for 
the different steroids showed different profiles due to their different 
physicochemical properties. 
An in-vitro steroid permeation technique was developed and validated using side-
by-side cells with non-biological membranes. 
A simple method using tools made in-house was developed to manufacture PCL 
membranes with defined thicknesses. The PCL membrane used for the extended 
study appeared very similar under the SEM to a similar unused membrane, 
indicating that it had retained its integrity. The permeation rate remained constant 
over the 7 days for which permeation was monitored, supporting visual findings 
of membrane integrity. The effect of temperature on the permeation rate showed a 
positive relationship between increased temperature and the permeation rate. 
Changing the pH resulted in no significant change to the permeation rate, whereas 
increasing cyclodextrin concentration resulted in a small increase in the rate of 
dexamethasone permeation. Solubility and apparent partition coefficient values of 
the dexamethasone analogues, progesterone, and oestradiols (in 0-12.5%HPβCD 
at 39°C inPBS/pH5.0) were determined and found to be comparable to the 
available literature values.  
Dexamethasone analogues and progesterone could be easily permeated through 
PCL and excised vaginal mucosal membranes. In addition, oestradiol-17β and 
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oestradiol benzoate could be also easily absorbed and permeated through PCL. 
Reproducible and linear permeation rates of the steroid studied were obtained 
from side-by side cell experiments using the PCL and excised mucosa membranes.  
The potential advantage of PCL as a model membrane in side-by-side cell 
experiments arises from the rapidity with which compounds permeate through it, 
resulting in the need for only short experimental times to generate sufficient data 
to provide a reliable estimate of the permeation rate. It is also cheap to purchase 
and easily fabricated in the laboratory into thin flat sheets. However, experiments 
conducted using dexamethasone and its analogues, oestradiol-17β, oestradiol 
benzoate, and progesterone, suggest that PCL is not a useful model membrane 
since it is a poor predictor of permeation rate across (excised) vaginal mucosa.  
The excised mucosa was permeable to the tested steroids with some differences in 
degree of permeation. Bothe molecular weight and solubility of the steroid 
affected the rate of permeation. The rate of permeation increased with increasing 
the solubility of the steroid. Conversely, both rate of permeation and permeability 
values decreased with increasing the molecular weight of the steroid. 
The ester group on the carbon 21 position for dexamethasone acetate, 
dexamethasone isonicotinate and dexamethasone dipropionate were hydrolysed. 
The ester group of dexamethasone valerate did not show any hydrolysis. 
Dexamethasone acetate and dexamethasone valerate showed higher permeability 
values across vaginal mucosa compare to other tested dexamethasone analogues 
and therefore, they could be used for induced calving pervaginum administration.  
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3 Analytical methods 
3.1 Introduction 
Initially an analytical UV spectrophotometric (Spectrophotometer DU® 640, 
Beckman, USA) method was developed and validated for all steroids studied in 
this research. This analytical method was used for in vitro permeation experiments 
to measure steroid permeation across non-biological (140 μm thick poly-ε-
caprolactone, 150 μm thick silicone and 50 μm thick synthetic skin) membranes 
as described in Chapter Two (Section  2.3.2.6). The use of the UV method was 
considered because it is fast, easy and inexpensive compare to HPLC. 
The same analytical UV method was used for the determination of dexamethasone 
concentration from the EMID (electronically modulated intravaginal device) using 
an in vitro Drug Dissolution Method as described in Chapter Four (Section 
 4.2.6.2) .  
However, it was found that using biological tissues such as excised vaginal 
mucosa requires sensitive analytical techniques such as HPLC to differentiate the 
analyte from extraneous material that may come off the membrane. Therefore, the 
development and validation of an HPLC method was essential. 
In addition, HPLC assays for progesterone, oestradiol-17β and cloprostenol 
stability were developed. All dosage forms of these three compounds were 
evaluated by assessing their chemical and physical stability and the results of this 
stability study are presented in Chapter Five (Section  5.3.5). 
3.2 Materials and methods 
3.2.1 List of reagents 
The following reagents which were used: Sodium dihydrogen orthophosphate 1-
hydrate, di-Sodium hydrogen orthophosphate anhydrous, ammonium acetate, HCl 
(36%) and NaOH (BDH laboratory supplies Poole, BH15 1TD, England), 
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hydrogen peroxide (H2O2 100 volume 27%, Andrew Industrial Ltd, New Zealand), 
2-Hydroxy-propyl-β-cyclodextrin, HPβCD, (Wacker-Chemie GMBH, Germany), 
Hydroxy-propylmethylcellulose (Shin-Estsu Chemical Co., Ltd, Japan), HPLC 
grade methanol (Scharlau, Chemie, S.A), alcohol [specially denatured alcohol, 
SDA] Mobil, NZ) and deionised water. The following steroids were used: 
dexamethasone, dexamethasone acetate, dexamethasone isonicotinate, 
dexamethasone dipropionate, dexamethasone valerate, progesterone, oestradiol-
17β and oestradiol benzoate (all of which were described in Chapter Two) and 
cloprostenol sodium (Everlight Chemical Industrial Corporation, Taiwan). The 
reagents used were analytical grades. 
3.2.2 List of equipment 
Ultrasonic bath (Soniclean Pty. Ltd, Australia), UV (Spectrophotometer DU® 640, 
Beckman, USA), four-place analytical balance (Sartorius Analytical Balance Type 
BP110S, Biolab Scientific Ltd, NZ), HPLC system comprised of a Waters® 1525 
Binary HPLC Pump, Waters® 2996 Photodiode Array Detector, Waters® 717 Plus 
Autosampler fitted with a Column heater (Waters, Milford, MA, USA). 
Empower® software (Waters®, Milford, MA, USA), 0.20 µm membrane filter 
(Minisart®-plus, Sartorius Corporation, Germany). Hanson Dissolution Testing 
Apparatus (Hanson SRII8 Dissolution Test Station equipped with water bath, 
dissoette and autosampling apparatus, Hanson Instruments, USA). 
3.2.3 Analytical methods 
3.2.3.1 UV spectroscopy 
3.2.3.1.1 Preparation of 5% HPβCD in PBS (pH 5.0) 
Phosphate buffer of pH 5.0 was prepared in deionised water following the 
procedure given by Lentner (984) from a combination of sodium dihydrogen 
orthophosphate 1-hydrate (66 mM NH2PO4·H2O, 9.2 g/L) and di-Sodium 
hydrogen orthophosphate anhydrous (66 mM N2HPO4, 9.5 g/L) 99:1 buffer ratio. 
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Following manufacture of the buffer, 5% w/v (50 g/L) HPβCD was added and 
dissolved using ultrasound for 30 minutes. 
3.2.4 Determination of the wavelength of maximum absorbance 
(λmax) 
The λmax of the steroids were determined by scanning (UV Spectrophotometer) a 
20 μg/mL solution of each steroid in 5% HPβCD in PBS (pH 5.0) or deionised 
water/ethanol over the wavelength range 200–400 nm. From this scan, the peak of 
maximum absorbance was identified.  
In addition, the effect of buffer composition on the λmax for dexamethasone was 
also determined using various buffers to investigate the ruggedness of the UV 
method. The buffers with different pH were prepared using the procedure given 
by Lentner (984). These buffers were phosphate buffer (pH 5.0), phosphate buffer 
(pH 7.4), 1-5% HPβCD in PBS (pH 5.0), 5% HPβCD in PBS (pH 7.4), 10% 
ethanol in PBS (pH 5.0), 25% ethanol in PBS (pH 5.4), 50% ethanol in PBS (pH 
5.8), 10% ethanol/0.1% gel (HPMC) in PBS (pH 5.0). Another reason why this 
experiment was carried out was to investigate the effect of the different buffers (in 
the release media) on the delivery rate of the EMID (Section  4.2.6.2) using the in 
vitro drug dissolution method. 
3.2.5 Preparation of calibration standards 
Calibration standards of the steroids were prepared from a stock solution that was 
prepared by accurately weighing 0.0500 g of the specific steroid in a 50 mL 
volumetric flask using a four decimal place analytical balance and filling up to the 
mark with alcohol. The mixture was subjected to ultrasound for 20 minutes until 
all drugs were completely dissolved.  
Standards were prepared by serial dilution of the stock solutions with buffer (5% 
HPβCD PBS at pH 5.0) to make working standards between 0 and 50 μg/mL. 
Working standards differed between different steroid analogues due to their 
different solubilities. 
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3.2.6 Validation of UV spectrophotometer assay 
The UV assay was validated according to linearity and range, accuracy, precision 
and limits of quantitation using methods described by the United States 
Pharmacopoeia (USP, 1994). 
3.2.6.1 Linearity and range 
Calibrations curves of absorbance values verus concentrations were produced for 
each of the steroids investigated. This process was repeated to assess the accuracy 
and precision of the linearity and range. Linear regression of the slopes of the 
calibration curves was compared to determine the linearity of the working 
standards for each steroid. The linearity and the ranges of all steroid analogues 
were also determined in conjunction with accuracy and precision. A relative 
standard deviation (%RSD) from the true values was calculated for both lower 
and upper range concentrations. In order to have a suitable level of precision and 
accuracy, the percentage RSD for lower and upper range concentrations were 
chosen to be ≤10 and 5%, respectively. The results are reported in Table  3.6. 
3.2.6.2 Accuracy  
For each steroid, validation standards with three different concentrations (i.e., 4.0, 
30.0 and 40.0 μg/mL) were prepared and analysed in triplicate on three different 
days and their concentrations were calculated from the linear regression line of a 
standard calibration curve made on the same day. The deviation of the calculated 
results from their true concentrations was determined to assess the accuracy of 
each method. These results are reported in Table  3.6. 
3.2.6.3 Precision  
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple 
sampling of the same homogeneous sample under the prescribed conditions (USP, 
1994). Precision may be considered at three levels: repeatability (intra-assay 
precision), intermediate precision (within different days) and reproducibility 
(between laboratories). Executing repeat absorbance readings of a single standard 
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solution and determining the relative standard deviation of the results about the 
mean value assessed repeatability. Intermediate precision of all steroid analogues 
were determined in conjunction with the accuracy, linearity and ruggedness 
experiments from relative standard deviations data of intra-day and inter-day 
reproducibility of calibration standards for these parameters. These results are 
reported in Table  3.6. 
3.2.6.4 Limit of quantitation 
To determine the limit of quantification of the UV assay 1, 2 and 3 μg/mL 
solutions of dexamethasone, its analogues and progesterone were accurately 
prepared in duplicate and their absorbance values determined against the blank 
(5% HPβCD PBS at pH 5.0). The concentrations of the standards were calculated 
against the linear regression line of a standard calibration curve made on the same 
day. This procedure was performed in duplicate on three different days. In order 
to have a suitable level of precision and accuracy, the %bias from true values for 
lowest standard concentration was set to be ≤15% for quantitation limit of the 
tested steroids. These results are presented in tables of Appendix-F. 
3.3 HPLC  
The HPLC assay was validated by assessment of its linearity and range, accuracy, 
precision, limit of quantitation and limit of detection by the methods described by 
Ogle (Ogle, 1999). 
3.3.1 HPLC System 
Chromatography was performed on an HPLC system comprised as listed in 
Section 3.2.2. All data were assessed using Empower® software. Before any 
analyses were carried out, the column was equilibrated with the mobile phase 
until a constant temperature of 30ºC was reached. A column oven was used to 
control the temperature. The HPLC running conditions are as shown in Table  3.1. 
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Table  3.1. HPLC running conditions. 
Parameter   Value 
Blank volume  20 μL 
Sample injection volume 20 μL 
Temperature 30ºC 
Mobile phase (methanol and deionised water)  70:30 
Detection wavelength was monitored at  242 nm dexamethasone, its analogues and 
progesterone 
Column type and Guard column Phenomenex® (Phenomenex (NZ) Ltd) 
Column description Luna 5 μm C18 
Column dimensions 250 x 4.6 mm 
Guard column description C18 (ODS, Octadecyl), SecurityGuard™ 
Guard column dimensions 4.0 x 3.0 mm 
Flow rate  1 mL/min 
Pressure  2200-2500 p.s.i 
Analytical run time 10-30 minutes (varied with the drug analogues) 
 
3.3.2 Preparation of standard solutions for the HPLC standard 
curve 
Initially a stock solution of a specific steroid was prepared by accurately weighing 
0.0100 g of crystalline drug analogue using a four decimal place analytical 
balance. To the drug, 100 mL of alcohol was carefully added and made up to 100 
mL volume. The mixture was subjected to ultrasound until the crystals had 
completely dissolved. The concentration of the resultant standard solution was 
100 μg/mL. Working standards of between 0.1 and 5.0 μg/mL were then prepared 
from the stock solution by diluting with alcohol using precision pipettes. The 
working standard solutions were filtered using a 0.20 μm membrane filter prior to 
HPLC analysis. 
3.3.3 Calibration curves 
For each steroid, the peak area of the chromatograms versus the concentrations of 
the standards was plotted to obtain the calibration curves. Equations of the 
computed regression lines and correlation coefficients were also calculated. Once 
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standard curves with very good linearity and reproducibility (inter-day and intra-
day reproducibility) were obtained, they were used to calculate any unknown 
sample concentrations. A fresh standard calibration curve was made on the same 
day as the unknown samples were analysed. 
3.3.4 HPLC validation 
3.3.4.1 Linearity and range 
The linearity of dexamethasone and progesterone responses were determined by 
analysing two sets of calibration standards (0.0, 0.2, 0.5, 1.0, 2.0, 3.0, 4.0 μg/mL) 
prepared and analysed on two different days and performing linear regression on 
the results. Analysis of standards at 0.2, 2.0 and 4.0 μg/mL and comparison of 
their concentrations against the standard curve determined the range of 
workability for the method for these steroids. The linearity of dexamethasone 
acetate, dexamethasone valerate, dexamethasone dipropionate and dexamethasone 
isonicotinate was determined by analysing three sets of calibration standards (0.0, 
0.4, 0.5, 1.0, 2.0, 3.0, 4.0 and 5.0 μg/mL) and performing linear regression on the 
results. Analysis of standards at 0.2, 2.0 and 5.0 μg/mL and comparison of their 
concentrations against the standard curve determined the range of workability for 
the method for these steroids. 
3.3.4.2 Accuracy  
Accuracy was determined by analysing standards at 0.2, 2.0 and 4.0 μg/mL for 
dexamethasone and progesterone and at 0.4, 2.0 and 5.0 μg/mL for the other 
steroids. Accuracy was established by calculating the concentrations against the 
standard calibration curve made on the same day and assessing the %bias of the 
calculated results from their true concentrations.  
3.3.4.3 Precision  
Precision was established by comparing the experimentally determined 
concentrations of replicate 0.2, 2.0 and 4.0 μg/mL dexamethasone and 
progesterone standards against the standard curve and the relative standard 
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deviations of the results about their means were determined. For the remaining 
steroids, standards of 0.4, 2.0 and 5.0 μg/mL were used.  
3.3.4.4 Limit of quantitation 
The limit of quantitation was established by determining the background response 
of the method from multiple blank determinations, followed by analysis of 
standards near the detection limit. The limit of quantitation was determined using 
0.1 and 0.2 μg/mL for dexamethasone and progesterone and 0.1, 0.2, 0.4 μg/mL 
for the remainder of the steroidal compounds. 
3.4 HPLC stability indicating assays for progesterone, 
oestradiol-17β and cloprostenol 
3.4.1 HPLC stability assay parameters 
The progesterone HPLC stability assay was provided by DEC Manufacturing, 
along with recommendations for its verification (Personal communication). The 
chromatographic conditions for the HPLC stability assay are listed in Table  3.2. 
Table  3.2. Chromatographic conditions for the analysis of progesterone 
Parameter Value 
Blank volume  10 μL 
Sample injection volume 10 μL 
Column temperature 30ºC 
Mobile phase (methanol: deionised water 60:40 
Detection wavelength  254 nm 
Column type  Waters SymmetryShieldTM RP18 
(Symmetry® Column) 
Guard column  Waters SymmetryShieldTM RP18 (SynteryTM 
Guard) 
Column dimensions 250 x 4.6 mm, 5 μm 
Guard column dimensions 20 x 3.9 mm, 5 μm 
Flow rate  1.2 mL/min 
Pressure  2200–4000 p.s.i. 
Analytical run time 70 minutes 
 
The same HPLC system and method as described in Table  3.2 for the analysis of 
progesterone was used for the analysis of oestradiol-17β with the exception that 
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the detection wavelength was 280 nm. In addition, the same HPLC method for 
progesterone described in Table  3.2 was used for cloprostenol with the following 
changes. The flow rate was 1.0 mL/minute. The detection wavelength was 
monitored at 280 nm. The mobile phase remained as 60% methanol, 40% aqueous 
but the aqueous phase comprised 15 mM ammonium acetate in deionised water. 
In addition, the run time was shortened to 10 minutes.  
3.4.1.1 Verification of progesterone assay 
Verification of the progesterone HPLC stability indicating assay was achieved by 
assessment of linearity, accuracy and precision. Data were generated from 
working standard solutions, prepared as described in  3.4.1.1.1., on three different 
days.  
Criteria for acceptance of the method revalidation are shown in Table  3.3.  
Table  3.3. Criteria to be met for acceptance of method verification 
Parameter  Specification 
Linearity  R2 ≥0.999 
Range  Low standard %bias <20% and High standard %bias <2%  
Intercept  -80000 >intercept <80000  
Intercept  <2% of the target peak area 
Accuracy  %bias <2% 
Precision Injection repeatability <1.5%RSD 
 
3.4.1.1.1 Preparation of progesterone working standards for calibration 
curves 
The working standards were manufactured by accurately weighing 0.1700, 0.1380, 
0.1100, 0.0500 and 0.0030 g of progesterone crystalline powder. Each sample was 
transferred into a volumetric flask using a glass funnel. The sample was dissolved 
in an aliquot of alcohol with the aid of ultrasonification for 30 minutes. The 
solution was made up to 200 mL volume with ethanol. The resultant 
concentrations were 850, 690, 550, 250 and 15 µg/mL, respectively. The working 
standards were filtered using a 0.20 μm membrane filter and an approx 0.40 mL 
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of the filtrate was collected and transferred into 1.0 mL polyethylene snap cap 
vials (Waters, MA, USA) prior to analysis by HPLC. The corner of each vial cap 
was pierced with a small needle (Monoject®, polypropylene hub hypodermic 
needles, Fabrique Par, Sherwood medical, USA) prior to loading into the 
autosampler carousel, to prevent injection sample pressure causing irreproducible 
results. Calibration standards were analysed in triplicate, from the lowest to the 
highest concentration for all analytical runs.  
3.4.1.2 Verification procedure  
Mean peak areas of the analysed standards were plotted against concentration. 
The linearity, intercept and correlation coefficient values were determined by 
linear regression analysis performed on each set of calibration standards on each 
separate day. The accuracy of each calibration standard was determined by 
interpolation of the mean peak area (N=3) from the calibration curve generated for 
that day to determine the concentration of that standard. The percent bias was then 
determined using Equation 3.1.  
The %RSD of peak areas of triplicate injections was used to determine injection 
repeatability precision. A portion of the 690 µg/mL standard prepared in Section 
 3.4.1.1.1 was stored separately labelled as a QC standard. This solution was 
filtered independently and injected in triplicate to provide a further estimate of the 
accuracy and precision of the assay. Percent bias and injection repeatability were 
calculated for the QC standard following interpolation of the data from the 
calibration curve generated on the same day.  
Inter-day precision was determined by calculating the %RSD of three independent 
sets of working standards analysed on different days.  
3.4.2 Development and validation for oestradiol-17β  
This method was intended to be applied to the assay of 2.5 mg oestradiol-17β 
tablets. The proposed sample preparation for the assay involved crushing 10 
tablets and then dissolving the resulting powder in 100 mL alcohol. This would 
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provide a target oestradiol-17β concentration of 250 μg/mL. Experiments were 
conducted to define linearity, range and limit of quantitation based around the 
selected target concentration. In order to develop a stability indicating assay for 
oestradiol-17β, specificity was considered essential in order to confirm the 
suitability of the chromatographic conditions in the presence of degradation 
products and/ or other interferences. 
3.4.2.1 Forced degradation stress reactions in acidic, basic conditions 
and H2O2  
Acidic, basic and peroxide alcoholic solutions were prepared. To make 2 M HCl 
solution, 11.25 mL of the concentrated HCL solution (Section  3.2.1) was 
transferred in a 1000.0 mL flask and the volume was made with alcohol. Similarly, 
2% v/v H2O2 in alcohol was prepared in the same manner using 74 mL of the 
concentrated H2O2 in alcohol. To make 2 M alcoholic NaOH, 80 grams of NaOH 
granules were dissolved in 200 mL of water. Then, 20.0 mL of this solution was 
transferred in a 100.0 mL flask and the volume was made with alcohol. In 
addition, dilute stress solutions were made using their respective 2 M HCl, 2 M 
NaOH and 2% v/v H2O2 solutions. 
Forced degradation studies were performed on oestradiol-17β in the presence of 
acid, base and oxidative conditions. 0.5 g of oestradiol-17β crystalline powder 
was dissolved in either 100 mL of 0.1 or 2 M alcoholic HCl, 100 mL of 0.1 or 2 
M alcoholic NaOH, or in 100 mL of 1% or 2% v/v H2O2 in alcohol in 200 mL 
Schott bottles at 40ºC for two hours. Samples were withdrawn at the following 
predetermined time points: 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes. Prior to 
HPLC analysis, each sample was diluted with alcohol (1:9 dilution) and passed 
through a 0.2 μm nylon filter. 
3.4.2.2 Linearity, range, limit of quantitation and limit of detection  
Working standard solutions were prepared as described in Section  3.4.2.2.1 and 
injected in duplicate from lowest to highest concentration. Mean peak areas were 
plotted against concentration.  
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Linearity, intercept and correlation coefficient values were determined from the 
linear regression analysis performed on the calibration standards. Regression 
analysis was performed leaving out successive low level and high standards to 
determine an acceptable linear range. 
The accuracy of each calibration standard was then determined by taking the 
mean peak area of the duplicate injections and applying the calibration curve 
equation generated with the chosen linear range standards to give a theoretical 
concentration of the standard. Percent bias was determined by Equation  3.1. 
%bias = 100×−
a
at
C
CC
 Equation  3.1. 
 
where Ct and Ca are the theoretical and actual concentrations, respectively. 
The percentage assay recovery of analysed samples was calculated using Equation 
 3.2 as follows. 
% calculated = 100×
t
a
C
C
 Equation  3.2. 
 
The %RSD of peak areas of duplicate injections was used to determine injection 
repeatability precision. The quantitation limit was determined by the lowest 
concentration of oestradiol-17β that showed a quantifiable peak response on the 
chromatogram within ≤20% bias. The detection limit was determined by the 
lowest concentration of oestradiol-17β, which produced a peak response on the 
chromatogram but was impossible to quantify with an acceptable precision and 
accuracy.  
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3.4.2.2.1 Preparation of oestradiol-17β working standards for calibration 
curves 
The working standards were manufactured by accurately weighing 0.0100, 0.0200, 
0.0250, 0.0300, 0.0400, 0.0500 and 0.0600g of oestradiol-17β crystalline powder 
using a four decimal place analytical balance. Each weighed sample was 
transferred carefully through a glass funnel into a 100 mL volumetric flask and 
dissolved in alcohol with the aid of ultrasound for 30 minutes. The solution was 
then made up to 100 mL with ethanol. The resultant standard concentrations were 
100, 200, 250, 300, 400, 500 and 600 µg/mL, respectively. Low level standards at 
1, 2, 5 and 10 µg/mL were prepared by appropriate dilution from the 500 µg/mL 
standard. Prior to injection onto the HPLC column, the working standards were 
filtered through a 0.20 μm membrane filter and approximately 0.40 mL of the 
filtered sample was poured into 1.0 mL vials. 
Before each vial was loaded into the carousel from the lowest to the highest 
concentration standards, each corner of the snap cap was pierced with a small 
needle as previously described in Section  3.4.1.1.1, to prevent injection sampler 
pressure causing irreproducibility.  
3.4.2.3 Method validation 
The specifications determined for method validation are defined in Table  3.4.  
Table  3.4. Method parameters and specifications to be met for method validation. 
Parameter  Specification 
Linearity  R2 ≥0.999 
Range Low standard %bias <20% and high standard %bias <2% 
Intercept  <2% of the target peak area 
Accuracy  %bias <2% 
Precision Injection repeatability <1.5%RSD 
Limit of quantitation %bias <20% (5 ppm) 
Limit of detection  Concentration where peak observed but %bias >20% 
 
Chapter Three 
108 
3.4.2.3.1 Validation of linear range of assay 
Oestradiol-17β working standards of 5, 10, 100, 200, 300, 400 and 500 μg/mL and 
a separate 250 μg/mL QC standard were prepared as described in Section 
 3.4.2.2.1 on each of three separate occasions. Standards were injected in duplicate. 
Mean peak area was plotted against concentration and linear regression was 
performed to determine slope, intercept and correlation coefficient of the 
calibration curves. The accuracy of each calibration standard on each day was 
then determined by taking the mean peak area of the duplicate injections and 
applying the calibration curve equation generated on that day to give a theoretical 
concentration of the standard. Bias and injection repeatability were calculated as 
described in Section  3.4.2.2. Bias and injection repeatability were also calculated 
for a QC standard according to the calibration curve generated on each day. 
3.4.3 Development and validation for cloprostenol  
This method was intended to assay 100 mg amounts of a 0.75% w/w cloprostenol 
sodium formulation dissolved in 10 mL deionised water. From this, a target 
concentration of 75 μg/mL was established. Experiments were conducted to 
define linearity, range, limit of quantitation and limit of detection based around 
the selected target concentration. In order to develop a stability indicating method 
for cloprostenol sodium, specificity was considered in order to confirm suitability 
of the chromatographic conditions in the presence of degradation products. 
3.4.3.1 Forced degradation stress reactions in acidic, basic conditions 
and H2O2  
Cloprostenol powder of 0.01 g was weighed and dissolved in equal volume of 100 
mL of 1M HCL, 1M NaOH or 0.1%, 1% and 10% v/v H2O2 in deionised water in 
separate small Schott bottles. The samples were put in a dry oven at 40ºC for two 
hours. From each treatment, 9 samples were taken at specified time intervals for 
sample analysis (i.e., 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes) to 
qualitatively investigate drug degradation. These samples were passed through a 
0.20 μm filter prior to analysis by HPLC.  
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3.4.3.2 Linearity, range, limit of quantitation and limit of detection  
Working standard solutions were prepared as described in Section  3.4.3.2.1 and 
injected in duplicate from lowest to highest concentration. Mean peak areas were 
plotted against concentration. Linearity, intercept and correlation coefficient 
values were determined from the linear regression performed on the calibration 
standards. Regression was performed leaving out successive low and high level 
standards to determine an acceptable linear range. The accuracy of each 
calibration standard was then determined by taking the mean peak area of the 
duplicate injections and applying the calibration curve equation generated with the 
chosen linear range standards to give a theoretical concentration of the standard. 
The %RSD of peak areas of duplicate injections were used to determine injection 
repeatability precision as described in Section  3.3.4.3. Percent bias and calculated 
rates were then determined by the Equation  3.1 and Equation  3.2. The lowest 
concentration of cloprostenol produced a peak response on the chromatogram, but 
was impossible to quantify with acceptable precision and accuracy determined the 
detection limit. The quantitation limit was determined by the lowest concentration 
of cloprostenol sodium that showed a quantifiable peak response on the 
chromatogram within ≤20% bias. 
3.4.3.2.1 Preparation of cloprostenol standard solutions for the HPLC 
standard curve 
Stock solutions of cloprostenol were prepared by accurately weighing 0.0100, 
0.0150, 0.0250, 0.0300, 0.0350 and 0.0450 g of crystalline powder in separate 
small weighing boats using a four decimal place analytical balance. The weighed 
drug was transferred through a funnel into 50 mL volumetric flasks while rinsing 
with deionised water carefully and made up to 50 mL. The mixture was subjected 
to ultrasound until the crystalline powder was completely dissolved. The 
theoretical concentrations of resultant standards solution were 200, 300, 500, 600, 
750 and 900 μg/mL, respectively. Also 5, 10 and 100 μg/mL standards were 
manufactured from the 500 μg/mL standard solution with appropriate dilutions. 
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3.5 Results  
3.5.1 UV spectrophotometric profile 
The experimentally determined λmax in 5% HPβCD in PBS/pH 5.0 of the 
compounds used in the study are shown in Table  3.5. 
Table  3.5. λmax of the steroids used in the study of the UV assay. 
Drug λmax 
Dexamethasone 
Dexamethasone acetate 
Dexamethasone isonicotinate 
Dexamethasone dipropionate 
Dexamethasone valerate 
242 
Progesterone 246 
Oestradiol benzoate 233 
Oestradiol-17β 217 
 
In addition, the different buffer compositions or pH had no effect on λmax of 
dexamethasone. Regardless of any of the buffer systems used, the experimentally 
determined λmax of dexamethasone was remaining unchanged (242 nm). Therefore, 
this indicated the robustness of the wavelength used.  
3.5.1.1 Linearity and range 
Concentration versus absorbance values were plotted from data for the two sets of 
calibration standards to make two standard curves for all steroids studied (Figure 
 3.1). This data for the calibration working standards was generated to enable 
determination of slope, linearity and range of the UV method. 
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Figure  3.1. Standard calibration curves for the steroid studied to enable determination of 
inter-day reproducibility of slope, linearity and range of the UV assay. 
 
All data fitted very well to the linear regression lines (R2 ≥0.999) with 
reproducible slope values for each steroid studied (Figure  3.1).  
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3.5.1.2 Accuracy and precision 
The assessment of accuracy of the UV method for all steroids studied was 
conducted in conjunction with assessment of the precision of the method. The 
inter-day reproducibility of accuracy (% bias) and precision (%RSD) of the lower 
(4 μg/mL), middle (30 μg/mL) and high (40 μg/mL) range is shown in Table  3.6. 
The accuracy (%bias) and precision (%RSD) values presented in here were 
calculated from an average of two replicates of the standard with the lowest 
accuracy and precision of the sated range.  
Table  3.6. The inter-day reproducibility of accuracy (% bias) and precision (%RSD) of the 
lower (4 µg/mL), middle (30 µg/mL) and high (40 µg/mL) range standards. 
Drug Precision(%RSD) Accuracy(%bias) 
Dexamethasone ≤2.4 ≤1.3 
Dexamethasone acetate ≤0.7 ≤3.7 
Dexamethasone isonicotinate ≤2.4 ≤3.1 
Dexamethasone valerate ≤1.4 ≤10.0 
Dexamethasone dipropionate ≤2.9 ≤3.0 
Progesterone  ≤6.2 ≤5.0 
Oestradiol benzoate ≤2.6 ≤6.0 
Oestradiol-17β* ≤3.2 ≤1.0 
* The lower standard was10 μg/mL. 
In addition, the inter-day reproducibility of accuracy (≤3%bias) and precision 
(≤2.1%) of the middle and high standards were found to be very accurate and 
more precise than the lower range standard for the steroids studied (Appendix-E). 
This is because the lower standard is closer to quantitation limit than the middle 
and high standards. The raw data of inter-day reproducibility of accuracy and 
precision of the lower, middle and high ranges for each steroid is shown in tables 
of Appendix-E. 
3.5.1.3 Quantitation limit of the UV assay 
The data for quantitation limit of each steroid was determined to define the lowest 
concentration of the drug with acceptable accuracy and precision for the true 
value against the standard calibration curves. The quantitation limit of the UV 
assay of the steroids studied was 1, 1, 2, 2, 2 and 3μg/mL for dexamethasone, 
dexamethasone acetate, dexamethasone isonicotinate, dexamethasone valerate, 
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dexamethasone dipropionate and progesterone, respectively. The inter-day 
reproducibility for lowest standard concentration proved to have the %bias of 
≤15% from true values for quantitation limit of the tested steroids. The raw data of 
quantitation limit of the UV assay is shown in tables of Appendix-F. 
3.5.2 HPLC assay 
A typical chromatogram for the various steroids investigated in the thesis is 
shown in Figure  3.2. Some peaks reflecting the solvent front (mobile phase or 
junk materials) were eluted out of the column before 4 minutes of HPLC 
analytical run time. The retention time of dexamethasone peak appeared at 6.0 
minutes. All other steroids were eluting out of the column between 8 and 24 
minutes due to their different lipophilicity. The steroids were analysed on the 
HPLC system one at time. All steroids studied showed very good peak shape and 
a stable baseline as shown below. 
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Figure  3.2. A typical chromatogram for the steroids used in the study. 
The retention times of the steroids used in this study applied on the HPLC running 
conditions was previously presented in Chapter Two.  
3.5.2.1 Linearity and range 
Two calibration curves obtained on two different days of the validation procedure 
for steroids studied are presented in Figure  3.3. These were used to enable 
determination of slope, linearity and range of the HPLC method. 
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Figure  3.3. Standard calibration curves for the steroids studied to enable determination of 
inter-day reproducibility of slope, linearity and range of the HPLC assay. 
 
All data fitted very well to the linear regression lines (R2 ≥0.9991) with 
reproducible slope values for each steroid studied (Figure  3.3). 
3.5.2.2 Accuracy and precision 
The inter-day reproducibility of average three replicates used to determine the 
accuracy and precision of the lower, middle and high range (0.2 - 5 μg/mL) of the 
HPLC methods for the various steroids studied were ≥94.7% and ≤4.8%, 
respectively. The raw data is presented in tables of Appendix-G. 
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3.5.2.3 Limit of quantitation 
The limit of quantitation standards for steroids studied were 0.2, 0.2, 0.4, 0.4, 0.4, 
and 0.2 μg/mL for dexamethasone, dexamethasone acetate, dexamethasone 
isonicotinate, dexamethasone valerate, dexamethasone dipropionate and 
progesterone, respectively. Data acquired for determination of limit of 
quantitation are presented in tables of Appendix-H. 
3.5.3 HPLC stability indicating assays for progesterone, oestradiol-
17β and cloprostenol 
3.5.3.1 Progesterone HPLC stability indicating assay parameters 
The method was successfully verified to meet the recommended validated 
parameters as shown in Table  3.3. 
All progesterone working standards were carefully and accurately manufactured. 
Figure  3.4 shows the inter-day reproducibility of the regression equation for 
progesterone standard curves for working standards of three different days. The 
regression equations showed very linear (R2 ≥0.9998) and reproducible slopes 
(21444-21682) in the three different days (Figure  3.4). 
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Figure  3.4. Standard calibration curves for progesterone to enable determination of inter-
day reproducibility of intercept, linearity and range of the HPLC stability assay. 
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Table  3.7 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards of day 1. The results show the HPLC method was accurate 
and precise. 
Table  3.7. Mean peak area, %RSD, actual concentration and %bias of calibration standards 
of day 1. 
Standard  
concentration 
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %RSD Actual 
Concentration2
(μg/mL) 
%Bias3 
0 0 0 0 3.4 0 
15 281553 2789 1.0 16 -9.6 
250 5252212 13092 0.2 247 1.1 
550 11600288 27446 0.2 542 1.4 
690 14774707 26441 0.2 690 0.1 
850 18365260 79436 0.4 856 -0.7 
QC standard  15037038 27517 0.2 702 -1.7 
1N=3. 2Calculated from Y=21533x-72587. 3Equation  3.1. 
Table  3.8 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards of day 2. 
Table  3.8. Mean peak area, %RSD, actual concentration and %bias of calibration standards 
of day 2. 
Standard 
concentration 
(μg/mL) 
Mean peak area1 
(μV*Sec) 
SD %RSD Actual 
Concentration2 
(μg/mL) 
%Bias3 
0 0 0 0 0.09 0 
15 291355 2821 1.0 14 3.6 
250 5330818 9565 0.2 249 0.2 
550 11777318 48665 0.4 550 0.0 
690 14777453 31408 0.2 690 0.0 
850 18211639 55668 0.3 850 0.0 
QC standard 14787781 258376 1.7 690 -0.1 
1N=3. 2Calculated from Y= 21444-18824. 3Equation  3.1. 
The above results show the HPLC method was accurate and precise (Table  3.7 - 
Table  3.8). 
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Table  3.9 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards of day 3. 
Table  3.9. Mean peak area, %RSD, actual concentration and %bias of calibration standards 
of day 3. 
Standard 
concentration 
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %RSD Actual 
Concentration2 
(μg/mL) 
 
% Bias3 
0 0 0 0 3.1 0 
15 283814 1311 0.5 16 -7.8 
250 5317585.3 7849 0.1 248 0.7 
550 11690731 45941 0.4 542 1.4 
690 14858758 45151 0.3 688 0.2 
850 18510291 41375 0.2 857 -0.8 
QC standard 15074696 72960 0.5 698 -1.2 
1N=3. 2 Calculated from Y= 21682-66634. 3Equation  3.1. 
Table  3.10 shows the inter-day reproducibility of the mean peak areas of working 
standards from three independent calibration curves on three different days. 
Table  3.10. Inter-day reproducibility of the mean peak areas of working standards from 
three independent calibration curves1 on three different days. 
Day 1 Day 2 Day 3 Mean of the 
three days 
Concentration
(μg/mL) 
Mean peak area2
(μV*Sec) 
Mean peak area2
(μV*Sec) 
Mean peak area2
(μV*Sec) 
Mean peak area2 
(μV*Sec) 
SD %RSD
0 0 0 0 0 0 0 
15 281553 291355 283814 285574 4191 1.5 
250 5252212 5330818 5317585 5300205 34364 0.6 
550 11600288 11777318 11690731 11689446 72278 0.6 
690 14774707 14777453 14858758 14803639 38991 0.3 
850 18365260 18211639 18510291 18362397 121941 0.7 
1Tables 3.7, 3.8 and 3.9. 2N=3. 
The inter-day reproducibility of progesterone working standards from the three 
independent calibration curves made on the three different days is very precise 
(RSD ≤1.5%) over the stated range of standards between 15 and 850 µg/mL. 
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3.5.3.2 Oestradiol-17β HPLC stability indicating assays  
3.5.3.2.1 Forced degradation studies in acid, alkali and H2O2  
Oestradiol-17β was stable at 40ºC for two hours in 0.1 M alcoholic HCl, 0.1 M 
alcoholic NaOH and 1% v/v H2O2. In addition, the compound was stable in 2M 
alcoholic NaOH and there was no evidence of any degradation of the product on 
the chromatograms. In contrast 2M alcoholic HCl and 2% v/v H2O2 induced 
degradation of the oestradiol-17β. Degradation products were observed on the 
chromatograms (Figure  3.5). However, none of these degradant peak products 
interfered with the peak of interest. Oestradiol-17β was found to be completely 
unstable in 2% v/v H2O2 and the peak representing oestradiol-17β completely 
disappeared from the chromatogram. 
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Figure  3.5. Typical chromatogram showing the degradation peak (10.177 minutes) arising 
after exposure of oestradiol-17β to 2M HCl.  
3.5.3.2.2 Linearity, range, limit of quantitation and limit of detection  
The data for linearity range, precision and accuracy of oestradiol-17β using 
working standards from 0 to 600 μg/mL is shown in Table  3.11. In addition, this 
table shows the quantitation and detection limit of the tested working standards 
for the method. The %RSD values of working standards between 10 and 600 
μg/mL were ≤0.7% and 6.5% including 5 μg/mL (Table  3.11). The lower working 
standards of 1 and 2 μg/mL of oestradiol-17β have shown high %RSD (low 
precision) values of 55.8 and 15.8, respectively. In order to achieve the acceptable 
linear range of the assay the two lowest standards were left out.  
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Table  3.11. Linearity range, precision and accuracy of oestradiol-17β working standards 
from 0-600 μg/mL of working standards in conjunction with quantitation and detection limit 
of the tested standards for oestradiol-17β. 
Theoretical  
concentration (μg/mL) 
Mean peak area 
(μV*Sec) 
SD %RSD 
0 0 0 0 
1 4311 2406 55.8 
2 7668 1211 15.8 
5 17194 1112 6.5 
10 36413 93 0.3 
100 330660 602 0.2 
200 674252 449 0.1 
300 1003351 3330 0.3 
400 1350768 7200 0.5 
500 1639807 8303 0.5 
600 1840727 12891 0.7 
 
The results of regression analysis performed by leaving out successive low level 
and high standards determined the acceptable linear range is shown in Figure  3.6b. 
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Figure  3.6. Standard calibration curve for oestradiol-17β 0 and 600 μg/mL(a) and  0 and 500 
μg/mL (b) to enable determination the acceptable linear range of the HPLC stability assay. 
 
Furthermore, the linearity (R2) of regression analysis increased from 0.9972 to 
0.9996 by leaving out the higher (600 μg/mL) standard as shown in determined 
the acceptable linear range of the assay (Figure  3.6b). 
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Table  3.12 shows the accuracy and precision of calibration standards 
concentrations calculated the regression line equation (Y = 3312x + 4923 and R2 
= 0.9996) for oestradiol-17β. 
Table  3.12. Accuracy and precision of calibration standards concentrations calculated 
against their regression line equation (Y = 3312x + 4923 and R2 = 0.9999) for oestradiol-17β. 
Theoretical 
concentration (μg/mL) 
Mean peak area 
(μV*Sec) 
Actual concentration
(μg/mL) 
% Bias 
 
0 0 -1 0 
5 17194 4 -20 
10 36413 10 -4.9 
100 330660 98 -1.6 
200 674252 202 1.0 
300 1003351 301 0.5 
400 1350768 406 1.6 
500 1639807 494 -1.3 
 
The %bias values of all working standards between 10 and 500 μg/mL were 
≤4.9% and for the lowest standard (5g/mL) is not more than 20%. Therefore, the 
calibration standard concentrations were accurate and precise. All oestradiol-17β 
working standards were carefully and accurately manufactured. 
3.5.3.2.3 Validation of linear range of assay 
Figure  3.7 shows the inter-day reproducibility of the regression equation for 
oestradiol-17β standard curves for working standards of three different days. The 
regression equations showed very linear (R2 ≥0.999) and reproducible slopes 
(3323-3386) for the three different days (Figure  3.7). 
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Figure  3.7. Standard calibration curves for oestradiol-17β to enable determination of intra-
day reproducibility of slopes, linearity and range of the HPLC stability assay. 
 
Table  3.13 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards of day 1. The %bias values of all working standards between 
5 and 500 μg/mL were ≤5% except in one occasion.  
Table  3.13. Mean peak area, %RSD, actual concentration and %bias of calibration 
standards of day 1. 
Theoretical  
concentration  
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %  
RSD 
Actual 
Concentration2 
(μg/mL) 
% Bias3
 
0 0 0 0 1 0 
5 14242 1863 13.1 5 5.0 
10 34360 544 1.6 11 11.9 
100 330728 600 0.2 99 -1.3 
200 674709 339 0.1 200 0.2 
300 1012315 4211 0.4 300 0.0 
400 1340423 3582 0.3 397 -0.8 
500 1697791 1721 0.1 502 0.5 
QC standard  804870 1794 0.2 239 -0.05 
1N=2. 2Calculated from Y = 3386x - 3529 and R2= 0.9999. 3Equation  3.1. 
Table  3.14 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards of day 2. The %bias values of all working standards between 
5 and 500 μg/mL were ≤0.01%.  
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Table  3.14. Mean peak area, %RSD, actual concentration and %bias of calibration 
standards of day 2. 
Theoretical  
concentration 
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %  RSD Actual 
Concentration2
(μg/mL) 
% Bias3 
 
0 0 0 0 0.2 0 
5 17595 214 1.2 5 0.01 
10 34443 465 1.3 10 0.01 
100 330738 754 0.2 99 -0.01 
200 674429 331 0.0 202 0.01 
250 839851 239 -0.0 251 0.00 
300 1009691 2039 0.2 302 0.01 
400 1312730 4649 0.4 393 -0.02 
500 1684520 1075 0.1 504 0.01 
QC standard  839851 3293 0.4 251 0.4 
1N=2. 2Calculated from Y= 3342x+634 and R2 = 0.9996. 3Equation  3.1.  
 
Table  3.15 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards of day 3. The %bias values of all working standards between 
5 and 500 μg/mL were ≤0.3%. The above results show the HPLC method was 
accurate and precise. 
Table  3.15. Mean peak area, %RSD, actual concentration and %bias of calibration 
standards of day 3. 
Theoretical  
concentration  
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %  RSD Actual 
Concentration2 
(μg/mL) 
% Bias3
 
0 0 0 0 -2.5 0 
5 19449 779 4.0 3 -0.33 
10 35054 1346 3.8 8 -0.20 
100 338506 7715 2.3 99 -0.01 
250 831552 3204 0.4 248 -0.01 
300 1038400 16611 1.6 310 0.03 
400 1357373 1097 0.1 406 0.01 
500 1638280 3366 0.2 491 -0.02 
QC standard  831551 11956 1.4 248 -0.9 
1N=2. 2Calculated from Y = 3323x+8334 and R2 = 0.999. 3Equation  3.1. 
Table  3.16 shows the inter-day reproducibility of the mean peak areas of working 
standards from three independent calibration curves on three different days. The 
%RSD values of all working standards between 10 and 500 μg/mL were ≤1.1%. 
The lowest standard of 5μg/mL showed 15% of RSD value which is still within 
the acceptable range as previously described in Table  3.4 . 
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Table  3.16. Inter-day reproducibility of the mean peak areas of working standards from 
three independent calibration curves1 on three different days. 
Day1 Day2 Day3 Mean of the three daysTheoretical 
concentration
(μg/mL) 
Mean 
peak area2 
(μV*Sec) 
Mean  
peak area2
(μV*Sec) 
Mean  
peak area2
(μV*Sec) 
Mean  
peak area2 
(μV*Sec) 
SD %RSD
0 0 0 0 0 0 0 
5 14242 17595 19449 17095 2639 15.4 
10 34360 34443 35054 34619 379 1.1 
100 330728 330738 338506 333324 4488 1.3 
200 674709 674429 -3 674569 198 0.0 
250 -3 839851 831552 835701 5868 0.7 
300 1012315 1009691 1038400 1020135 15872 1.6 
400 1340423 1312730 1357373 1336842 22536 1.7 
500 1697791 1684520 1638280 1673530 31241 1.9 
1Tables 3.13, 3.14 and 3.15. 2N=3.  3Standards not prepared on that day. 
The inter-day reproducibility of oestradiol-17β working standards from the three 
independent calibration curves made on the three different days is very precise 
(RSD ≤1.7% except 5 µg/mL quantitation limit standard) over the stated range of 
standards between 5 and 500 µg/mL (Table  3.16). 
3.5.3.3 Cloprostenol HPLC stability indicating assay 
3.5.3.3.1 Forced degradation stress reactions in acidic, basic conditions 
and H2O2  
Neither the 1 M aqueous HCl nor the 1 M aqueous NaOH induced any 
degradation to occur in the cloprostenol when subjected to 40ºC for two hours. 
Very rapid cloprostenol degradation was observed in the case of exposure of 
cloprostenol to 10% v/v H2O2. No degradation of cloprostenol was observed when 
cloprostenol was exposed to 0.1 % v/v H2O2. When 1% v/v H2O2 was used the 
peak of interest was observed to get smaller, however, no degradation peaks were 
observed and no interference of the peak representing cloprostenol was detected. 
3.5.3.3.2 Linearity, range, limit of quantitation and limit of detection  
The data for linearity range, precision and accuracy of cloprostenol using working 
standards from 0 to 900 μg/mL is shown in (Table  3.17). In addition this table 
shows the quantitation and detection limit of the tested working standards for the 
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method. The precision of injection reproducibility is ≤3.4% of RSD between 5 
and 900 μg/mL standards. 
Table  3.17. Linearity range, precision and accuracy of cloprostenol working standards from 
0-900 μg/mL of working standards in conjunction with quantitation and detection limit of 
the tested standards for cloprostenol. 
Concentration 
(μg/mL) 
Mean peak area 
(μV*Sec) 
SD %RSD 
0 0 0 0 
5 7656 261 3.4 
10 17037 401 2.4 
100 162634 2685 1.7 
200 331061 2234 0.7 
300 516057 2595 0.5 
500 856564 2008 0.2 
600 1040790 6101 0.6 
750 1231565 9265 0.8 
900 1442398 859 0.1 
 
The results of regression analysis performed by leaving out successive low level 
as well as high standards shown in Figure  3.8b determined the acceptable linear 
range in Table  3.18. 
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Figure  3.8. Standard calibration curves for cloprostenol 0-900 μg/mL (a) and 10-900 μg/mL 
(b) to enable determination linearity and range of the HPLC stability assay. 
 
The results of regression analysis performed by leaving out successive low and 
high level standards to determined the acceptable linear (R2 ≥0.9998) range for 
cloprostenol was between 10 and 600 μg/mL standards Figure  3.8b. All 
cloprostenol working standards were carefully and accurately manufactured. 
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3.5.3.3.3 Validation of linear range of assay 
Table  3.18 shows the accuracy and precision of calibration standards 
concentrations calculated against their regression line equation (Y= 1730-4437 
and R2 = 0.9998) for cloprostenol. Table  3.18 shows the mean peak area, %RSD, 
actual concentration and %bias of calibration standards of day 1.  
Table  3.18. Accuracy and precision of calibration standards concentrations calculated 
against their regression line equation (Y= 1730-4437 and R2 = 0.9998) for cloprostenol. 
Theoretical concentration 
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %  RSD Actual 
Concentration 
(μg/mL) 
% Bias2
 
10 17037 401 2.35 12 20.0 
100 162634 2685 1.65 97 -3.4 
200 331061 2234 0.67 194 -3.0 
300 516057 2595 0.50 301 0.3 
500 856564 2008 0.23 498 -0.5 
600 1040790 6101 0.59 604 0.7 
1N=2. 2Equation  3.1. 
The %bias values of all cloprostenol working standards between 10 and 600 
μg/mL were ≤20% and therefore the calibration standard concentrations were 
accurate and precise (Table  3.18). Figure  3.9 shows the inter-day reproducibility 
of the regression equation for cloprostenol standard curves for working standards 
of three different days. The regression equations showed very linear (R2 ≥0.9998) 
and reproducible slopes (1713 - 1733) in the three different days (Figure  3.9). 
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Figure  3.9. Standard calibration curves for cloprostenol to enable determination of inter-day 
reproducibility of intercept, linearity and range of the HPLC stability assay on three 
different days. 
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Table  3.19 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards for cloprostenol on day 2. 
Table  3.19. Mean peak area, %RSD, actual concentration and %bias of calibration 
standards for cloprostenol on day 2. 
Theoretical concentration  
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %  RSD Actual 
concentration2 
(μg/mL) 
% Bias3
 
10 16003 718 3.3 11 10.0 
100 166135 843 0.5 95 4.7 
200 333349 1237 0.4 194 3.0 
300 511702 1620 0.3 299 0.3 
500 849790 0 0.0 499 0.3 
600 1028925 3120 0.3 604 -0.7 
QC standard 601159 9544 1.6 352 0.03 
1N=2. 2Calculated from Y= 1713x-3318 and R2 = 0.9999. 3Equation  3.1. 
Table  3.20 shows the mean peak area, %RSD, actual concentration and %bias of 
calibration standards for cloprostenol on day 3. 
Table  3.20. Mean peak area, %RSD, actual concentration and %bias of calibration 
standards for cloprostenol on day 3. 
Theoretical concentration  
(μg/mL) 
Mean peak area1
(μV*Sec) 
SD %  RSD Actual  
concentration2 
(μg/mL) 
% Bias3
 
10 20201 700 3.4 14 13.2 
100 162772 962 0.6 96 -4.2 
200 336830 799 0.2 197 -1.6 
300 518832 3289 0.6 302 0.7 
500 857401 431 0.1 499 -0.3 
600 1036228 1051 0.1 602 0.4 
QC standard 588340 6990 1.2 343 2.7 
1N=2. 2Calculated from Y= 1725-2516 and R2 = 0.9998. 3Equation  3.1.  
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Table  3.21 shows the inter-day reproducibility of the mean peak areas of working 
standards from three independent calibration curves on three different days for 
cloprostenol. 
Table  3.21. Inter-day reproducibility of the mean peak areas of working standards from 
three independent calibration curves1 on three different days for cloprostenol. 
Theoretical  
concentration 
Day 1 Day 2 Day 3 Mean  
of the three days 
(μg/mL) Mean  
peak area2 
Mean  
peak area2 
Mean  
peak area2 
Mean  
peak area2 
  (μV*Sec) (μV*Sec) (μV*Sec) (μV*Sec) 
SD 
  
%RSD 
  
0 0 0 0 0 0 0.0 
10 16003 17037 20201 17747 2187 12.3 
100 166135 162634 162772 163847 1983 1.2 
200 333349 331061 336830 333746.67 2905 0.9 
300 511702 516057 518832 515530.33 3594 0.7 
500 849790 856564 857400.5 854584.83 4173 0.5 
600 1028925 1040790 1036228 1035314.3 5985 0.6 
1Tables 3.18, 3.19 and 3.20. 2N=3. 
The inter-day reproducibility of cloprostenol working standards from three 
independent calibration curves on three different days is very precise (RSD ≤1.2% 
except 10 µg/mL standard which is 12.3% for which was selected to be a 
quantitation limit standard) over the stated range of standards between 10 and 600 
µg/mL (Table  3.21). 
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3.6 Discussion  
3.6.1 Developed and validated analytical methods 
The UV assays and their parameters developed in this thesis are compiled in 
Table  3.22. 
Table  3.22. Combined parameters developed and validated for the steroids studied in this 
thesis for the UV assay. 
Range (μg/mL) Quantification 
limit (µg/mL) 
Drug λmax1 Slope 
(≥) 
linearity 
(R2 ≥) 
Lower 
limit 
Upper 
limit 
 
Dexamethasone 0.031 0.9997 4 50 1 
Dexamethasone 
acetate 
0.029 0.9999 4 50 1 
Dexamethasone  
isonicotinate 
0.032 0.9999 4 40 2 
Dexamethasone  
valerate 
0.028 0.9997 4 50 2 
Dexamethasone  
dipropionate 
242 
0.027 0.9998 4 50 2 
Progesterone 246 0.050 0.9996 4 30 3 
Oestradiol benzoate 233 0.055 0.999 4 30 
Oestradiol-17β 217 0.025 0.9996 10 50 
Not determined 
15% HPβCD in pH 5.0/PBS. 
All UV assays were shown to be linear within the stated range, precise and 
accurate. In addition, experiments performed using dexamethasone suggested that 
these assays are robust with respect to buffer composition as shown in section 
3.4.1.  
In addition, the inter-day reproducibility of accuracy and precision of the lower (4 
μg/mL), middle (30 μg/mL) and high (40 μg/mL) range were also accurate and 
precise for the stated range of each steroid as previously explained in section 
3.4.1.2.  
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Though the UV method is not specific, it is fast, easy and inexpensive compare to 
the HPLC method.  
The HPLC assays and their parameters developed in this thesis are compiled in 
Table  3.23. 
Table  3.23. Combined parameters developed and validated for the steroids studied in this 
thesis for the HPLC assay. 
Range (μg/mL) Drug Peak 
time 
(minutes) 
Slope 
(≥) 
linearity 
(R2 ≥) 
Lower 
limit 
Upper 
limit 
Detection 
limit 
(μg/mL) 
Quantification 
limit (μg/mL) 
Dexamethasone 6.01 44244 0.9994 0.2 4 0.1 0.2 
Dexamethasone 
acetate 
8.13 36890 0.9997 0.5 5 0.1 0.2 
Dexamethasone  
isonicotinate 
9.94 38637 0.9995 0.4 5 0.2 0.4 
Dexamethasone  
valerate 
14.50 33913 0.9997 0.4 5 0.2 0.4 
Dexamethasone  
dipropionate 
14.70 35729 0.9991 0.4 5 0.2 0.4 
Progesterone 17.50 62088 0.9995 0.2 4 0.1 0.2 
 
All HPLC assays were shown to be linear within the stated range, precise and 
accurate (Table  3.23). The HPLC method is specific and selective. However, the 
HPLC is time consuming (longer analytical run time), complex (programme set-
ups) and expensive (cost of consumables) compare to UV method. 
3.6.2 HPLC stability indicating assays for progesterone, oestradiol-
17β and cloprostenol 
Verification of the existing stability indicating HPLC assay for progesterone 
supplied by DEC Manufacturing QC Laboratory was successfully achieved (Table 
 3.24 ). All specification limits were met and therefore the method is revalidated. 
The generation of the three independent standard curves plotted using the data 
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from Figure  3.4, respectively, provided data that met the predefined verification 
specifications.  
Progesterone retention time was the same between laboratories at approximately 
27 minutes and the method linearity, slopes, intercepts, accuracy and precision of 
the 15 to 850 μg/mL range were very reproducible between the DEC and InterAg 
laboratories. The inter-day reproducibility data of the verified method (Table  3.10) 
and the method precision of target concentration were excellent (≤1.5 %RSD, for 
an average of 0.2, 1.7 and 0.50%, RSD = 0.8%).  
Table  3.24. Method parameters, specifications and experimentally determined values for 
progesterone method verification. 
Parameter  Specification limits Experimentally determined values 
in this research 
Linearity1  R2 >0.999 R2 ≥0.9998 
Range2 
Low range %bias <20% 
 
High range %bias <2% 
Low = 15 μg/mL (%bias = 9.6, 3.6 and 7.8%) 
 
High = 850 μg/mL (%bias = 0.74, 0.0 and 0.8) 
Intercept1  
Minimum:-80000, 
Maximum:80000 
-72587, –18824 and -66634 
Accuracy2  %bias <2% 1.7, 0.1 and 1.2 %bias at QC standard 
Precision2 
Injection repeatability 
<1.5%RSD 
0.2, 1.7 and 0.50 %RSD at QC standard 
1Figure  3.4. 2Tables 3.7, 3.8 and 3.9. 
Development and validation of a stability indicating assay for oestradiol-17β was 
successfully achieved by adopting a slight modification to the method supplied by 
DEC QC Laboratory for progesterone (change of analytical wavelength). This is 
because oestradiol-17β absorbs at different wavelength from progesterone. A 
similar wavelength was used by previous researchers using HPLC stability assay 
methods for either oestradiol-17β  or one of its analogues. Kotiyan & Vavia (2000) 
and Segall et al. (1999) used the analytical wavelength of 280 and 286 nm for 
oestradiol-17β and oestradiol valerate, respectively.   
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The peak representing oestradiol-17β appeared at 28 minutes and was shown 
through forced stability studies to remain independent of the degradation peak. 
The additional peak appeared on the chromatogram of oestradiol-17β exposed to 
2M HCl due to formation of degradation product as shown in Figure  3.5. This was 
explained by the fact that oestradiol-17β molecule is prone to dehydration in 
acidic conditions. For instance, in 1M HCl at 70ºC for 2 hours caused oestradiol-
17β degradation as it was investigated by Kotiyan & Vavia (2000). This occurs 
due to loss of a molecule of water on 17-β-hydroxyl group of oestradiol-17β to 
form degradation product. In the same study, oestradiol-17β was stable in basic 
conditions. This also is in accord with absence of any additional peak indicating 
decomposition of oestradiol-17β samples which were exposed in basic conditions 
in our study. The generation of three independent standard curves of Figure  3.7, 
respectively provided data that validated the method shown in Table  3.25. The 
specification limits were met and therefore this validates the method. 
Table  3.25. Validated parameters for oestradiol-17β HPLC stability indicating assay. 
Parameter  Specification limits Experimentally determined values 
in this research 
Linearity1 R2 ≥0.999 R2 ≥0.999 
Range2  
Low range %bias <20% 
 
High range %bias <2% 
Low range = 5 μg/mL (%bias = 5.0, 0.01 
and -0.33%) 
High range = 500 μg/mL (%bias = 0.5, 
0.01 and -0.02 %) 
Intercept1  
Minimum:-80000 
Maximum: 80000 
-3530, 634 and 8334 
Accuracy2 %bias <2% 
-0.05, 0.4 and -0.09% (%bias at QC 
standard) 
Precision2 Injection repeatability <1.5%RSD 
0.2, 0.4 and 1.4 % (%RSD at QC 
standard) 
1Figure  3.7, 2Tables 3.13, 3.14 and 3.15. 
The method linearity, slopes, intercepts, accuracy and precision of the 5 to 500 
μg/mL range was very reproducible. The inter-day reproducibility data of the 
verified method (Table  3.16) and the method accuracy and precision of target 
concentration were excellent (≤1.4 %RSD) and (≤0.4%bias) as seen in Table  3.25.  
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Development and validation of a stability indicating assay for cloprostenol was 
successfully achieved by adopting several modifications to the method supplied 
by DEC QC Laboratory for progesterone (change of analytical wavelength, flow 
rate and pH of mobile phase). Cloprostenol has different physicochemical 
properties from progesterone or oestradiol-17β and therefore different 
chromatographic conditions were required.  
The peak representing cloprostenol appeared at 6 minutes and was shown through 
forced stability studies to remain independent of degradation peaks. No additional 
peak, indicating degradation, appeared on the chromatograms. The generation of 
three independent standard curves (Figure  3.9, respectively) provided data that 
validated the method shown in Table  3.26. The specification limits were met and 
therefore this shows that the method is validated. 
Table  3.26. Validated parameters for cloprostenol HPLC stability indicating assay. 
Parameter  Specification limits Experimentally determined values 
in this research 
Linearity1 R2 ≥0.999 R2 ≥0.9998 
Range2 
Low range %bias <20% 
 
 
High range %bias <2% 
Low range of 10 μg/mL (%bias = 20, 10 and 
13% ) 
High range of 600 μg/mL (%bias = 0.7, - 0.7 
and 0.4%) 
Intercept1  Minmum: -80000 
Maximumn:80000 
-4437, -3318 and -2516 
Accuracy2  %bias <3% (%bias = 0.03 and 2.7% ) 
Precision2 Injection repeatability <1.5%RSD 1.6 and 1.2 %RSD at target concentration 
1 Figure  3.8b and Figure  3.9, 2 Tables 3.18, 3.19 and 3.20. 
The method linearity, slopes, intercepts, accuracy and precision of the 10 to 600 
μg/mL range was very reproducible. The inter-day reproducibility data of the 
validated method (Table  3.21) and the method precision of target concentration 
were excellent (≤1.5%RSD). 
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3.7 Conclusions 
UV and HPLC analytical methods were developed and validated for in vitro 
permeation and Drug Dissolution Testing (UV only) experiments on the steroids 
studied in this research. In both methods, assays were shown to be linear within 
the stated range, precise and accurate. 
In addition, the HPLC stability assays for progesterone were revalidated and for 
oestradiol-17β and cloprostenol were developed and validated. All the HPLC 
stability assays were also shown to be linear within the stated range, precise and 
accurate. In addition, there were no additional peaks, which were not originally 
apparent, indicating no degradation interfering in the stability assays of the tested 
drugs. 
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4 Assessment of an electronically controlled drug 
delivery technology for veterinary applications 
4.1 Introduction 
A veterinary controlled drug delivery technology provides for dosing animals with 
a drug or drugs at predefined and reproducible rates, often for prolonged periods 
of time. These systems can provide significant benefits compared to single 
injection dosage forms including (Rathbone et al., 2000): 
• the ability to tailor or to integrate the administration of health and 
production oriented pharmaceuticals around the constraints of farm 
management systems, 
• a reduction of stress to the animal by decreasing the number of times the 
animal is handled, 
• financial benefits to the animal’s owner resulting from reduced 
veterinarian cost, optimisation of employees time by reducing the time 
needed for herding administration, 
• improved therapeutic outcomes, 
• the maintenance of drug levels within a desired range, 
• increased patient compliance, 
• increased cost benefits to the end user. 
 
A common means of controlling the delivery of a drug is through the use of a 
polymer. The drug is incorporated into either a natural or synthetic polymer 
matrix and is slowly released at a rate that is dependant on the physicochemical 
properties of both the drug and the polymer. These systems offer several 
advantages: 
• they are cheap to manufacture, 
• a variety of polymers are available and the release profile can therefore be 
tailored to meet a particular need. 
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However, they also have certain disadvantages, which include: 
• once manufactured the release rate cannot usually be adjusted, 
• once manufactured it is difficult to modify the duration of release, 
• the technology is usually route specific and cannot be transferred, 
• each technology is often developed for a specific active drug, and the 
polymeric system technology is often not applicable to other drugs, 
• the release profile from simple polymeric systems declines with time, 
resulting in non-linear release of drug over time and declining blood 
profiles. 
 
Amongst the ways scientists have attempted to overcome these problems is the 
development of systems that use electronic devices to control the rate and duration 
of drug delivery. In such cases, drug delivery control resides in the electronic 
circuitry, and is not dependant upon the properties of the drug. Such systems offer 
versatility in: 
• adjustable release rates, 
• adjustable durations of release, 
•  the capability of being designed for several different routes, 
• applicability to a wide range of drugs, 
• sustaining high blood profiles as a result of uniform and linear release of 
drug over time. 
 
Examples of electronically controlled devices used for farm animals include the 
SMARTT1® Intelligent Breeding Device (IBD) and the Electronically Modulated 
Intravaginal Device (EMID). Most of this thesis is concerned with the EMID. A 
description of SMARTT1® is provided for comparative purposes. 
 
 
 
Chapter Four 
136 
4.1.1 The SMARTT1® IBD 
The SMARTT1® IBD is shown in Figure  4.1. 
 
Head (three small reservoirs) 
 
Figure  4.1.SMARTT1® Intelligent Breeding Device (Cross, 2002). 
 
The IBD was developed in New Zealand for the purpose of controlling the 
oestrous cycle in cattle (Rathbone et al., 1998; Cross, 2002). This device 
comprises three main sections, an outer plastic sheath is designed to protect the 
inner compartment, which comprises an electronic chip and board, four drug 
reservoirs, a retention mechanism and a tail (Figure  4.1). The retention 
mechanism has an umbrella configuration shape and is located at the head of the 
device. 
The main drug reservoir is located at the bottom of the device, and contains 5 mL 
of a progesterone formulation. This reservoir opens directly to a small orifice at 
the top of the device (Cross, 2002) via a small bore stainless steel tube that opens 
to the exterior at the flat face. The other three reservoirs, each of which has a 
maximum capacity of 0.45 mL, are located near the head of the device and 
contain either oestradiol or prostaglandin. Tight fitting santoprene rubber seals are 
used to prevent drug solutions from leaking from their reservoirs during storage 
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and while in the animal. There is a movable piston and spring between the main 
rubber seal and the bottom of the device.  
The remainder of the device comprises a circuit board and batteries. The circuit 
board contains a controlling chip, a power-on indication LED and a quartz timer 
(Rathbone et al., 1998; Cross, 2002). Drug release from the reservoirs is 
controlled electronically according to a pre-programmed electronic chip. The 
small orifice of the inner compartment reservoir is opened and closed by a switch 
mechanism that is operated by a solenoid, and drug can only leave the reservoir 
when the switch is in the open position. The batteries and an electronic timing 
system of the device control a solenoid that operates a valve, which in turn, 
controls the drug release slowly and continuously over a 10 day period under the 
influence of the spring pressurized piston.  
Unlike other conventional drug delivery systems that are currently on the market 
such as the PRID and CIDR™-B, the IDB technology offers the advantage of 
incorporating multiple drugs required for oestrous control of cattle within a single 
device. 
However, because the batteries and electronics take up so much room and there is 
limited room available for the main reservoir, there are restrictions on the capacity 
of the drug reservoirs of the device. Also the nature of the spring loaded 
controlled orifice release mechanism is such that any small blockage could 
adversely affect dosage after that point and could undermine practical application 
of the IDB technology (Cross, 2002). Finally, the IBD has a limited volume 
capacity and a very complex design. Unlike the IBD technology, the EMID offers 
the advantage of having a large volume reservoir and a less complex design.  
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4.1.2 EMID description 
4.1.2.1 Development prior to this study 
The EMID is shown in Figure  4.2. The EMID is assembled from injection 
moulded plastic components. 
 
Figure  4.2. EMID for the delivery of progesterone, oestradiol benzoate and prostaglandin. 
 
It is noteworthy that the final EMID arrangement has tinfoil adhered onto the 
outside of the body (not shown). The main reservoir of the EMID inner 
compartment has a 30 mL capacity and an outlet area of 0.22 cm2 whereas the 
secondary chambers have a total volume of 100 mL each and an individual outlet 
area of 1.1 cm2. Tight fitting santoprene rubber bungs seal the small chambers at 
the top and bottom (Figure  4.2).  
The progesterone formulation is dispensed from the device by a gas-producing 
battery located in the back of the EMID. A resistor in contact with the battery 
controls gas release and as the gas is produced, it accumulates and creates a 
pressure on the piston. The piston then moves forward and dispenses known 
volumes of the formulation from the main reservoir of the EMID. Part way 
through the process, pistons in the secondary chambers are activated by the 
primary piston and cause the secondary chambers to open, thereby releasing 
oestradiol benzoate and/ or prostaglandin.  
Secondary chamber
Wings 
Main reservoir
Main piston 
Secondary piston
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Similar to the IBD technology, the EMID offers the advantage of incorporating 
the multiple drugs that are required for oestrous control of cattle within a single 
device. 
However, in contrast to the IBD the main reservoir has a large volume enabling 
more scope for formulation strategy. In addition, the large outlet orifices 
associated with the large reservoir and secondary chambers are less susceptible to 
blockage as compared to the IDB technology.  
The EMID appears to offer the advantages that are required for the complex and 
demanding requirements of delivering the drugs associated with either oestrous 
control or induced calving. Therefore, the objective of this chapter was to 
critically evaluate the EMID for its application for either oestrous control or for 
the induction of calving. 
4.1.2.2 Evaluations made during this study programme 
Early in the in vivo animal work, it became apparent that there were a number of 
parameters of the EMID which did not maintain consistency. In particular, it 
appeared that many of the physical components of the EMID were prone to act 
differently or even to fail when placed in the vagina compared to simple in vitro 
air or aqueous environments. The piston was sticking in the barrel and the tinfoil 
was separating from the plastic resulting in a non-linear release profile. In 
addition, the EMID was not being retained for the full duration of the treatment 
and caused a high incident of vaginal damage among treated animals. These 
observed and unexpected failures of the technology led to the need to 
reinvestigate independently and in multi-factorial combinations, each component 
of the device (e.g. piston material, body composition, gas-cell function, and 
retention wings), and the properties of the payload which was to be released. Also 
development of an in vitro release test to correlate EMID release rates from in 
vitro with in vivo rates was investigated. 
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4.2 Description of the assembled EMID and its components 
A list and general description of the main components of the EMID are shown in 
Figure  4.3.  
Component material Description Photograph 
Main body (typically 
made from 
polypropylene (PP), 
high density 
polyethylene (HDPE) 
or like materials) 
Retention wings (a) 
Body and main 
reservoir (b) Secondary 
reservoirs (c) Outlet 
orifice (d) 
 
Primary piston 
comprising o rings 
(made from a variety of 
silicone or other plastic 
materials) and carrier 
(polyvinyl chloride 
(PVC) 
The silicone piston 
comprising silicone O-
rings (f) positioned 
over the carrier (g) 
 
Secondary piston 
carrier (made from PP 
or HDPE) and piston 
(santoprene) 
Secondary piston (h) is 
located over the piston 
carrier (i)  
Plug (made from PP or 
HDPE) and O-ring 
(silicone). 
Comprises an O-ring 
seal over a plastic plug 
 
Cap (made from PP or 
HDPE) 
Plastic end cap that 
locates over the plug 
 
Gas cell unit 
Battery (gas cell) and 
the resistor (the wire) 
 
Figure  4.3. EMID components. 
a 
c
d 
f 
g 
i 
h 
b 
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The rate of release from the EMID is controlled by the rate of gas production, 
which was proportional to, and controlled by, the applied current (Bunt et al., 
1998). The resistor is placed in series with the battery (Varta 4690 Simatec, 
Switzerland), thereby influencing the current (Equation  4.1.). Gas produced from 
the reaction 6H2O → 2H2(g) + O2 (g) + 4H+ + 4OH- is a function of the amount of 
current and time as follows: 
electronsmol
product mol x 
96500
1Farad x (s)  x time(A)current  = (moles) produced Gas  Equation  4.1. 
 
All EMID components were manufactured and supplied by a technical injection 
moulding company (Millennium Plastics, Te Rapa, Hamilton). 
4.2.1 Assembly of the EMID 
All EMIDs were easy to assemble (Section  4.2.1.1), although care had to be taken 
to follow the defined procedure. In addition, friction welding required the need to 
remove a very fine film of silicone lubricant that was deposited from the piston as 
it was pushed up to the top of the EMID to ensure a successful welding process. 
This was easily removed by use of a tissue and 10% toluene in ethanol. Toluene 
dissolves and removes the silicone lubricant. 
4.2.1.1 Assembly of the EMID 
To assemble the EMID the following steps were followed. 
1. A thin layer of silicone lubricant (Dow Corning 360 medical fluid, 350 
CST Dow Corning Corporation, Midland, USA) was applied onto the 
surface of each of the silicone o-rings that make up the primary piston. 
2. The lubricated primary piston was inserted into the body by pushing it 
through the open back of the EMID and positioned at the head of the 
device. 
3. The plug was friction welded onto the back of the body.  
4. Fix the O-ring onto the plug and apply a surface coating of lubricant. 
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5. Where appropriate apply tinfoil (Sellotape, New Zealand) around the 
outside of the body. The tinfoil is used to reduce gas diffusion through the 
polymer. 
6. Fill the EMID with the formulation. 
7. Seal the two small chambers with the secondary pistons. 
8. Attach the resistor to the gas cell (Varta 4690 Simatec, Switzerland) and 
load into the back of the EMID. 
9. Push the cap onto the plug and fix it in place by screwing it into position. 
 
The final assembled EMID is shown in Figure  4.4. 
 
Figure  4.4. Assembled EMID with or without tinfoil. 
 
4.2.1.2 Measurement of the EMID function 
For most biological applications, a test procedure is required, which monitors the 
release of the particular bioactive material from the device. This issue is addressed 
near the end of this chapter (Section 4.4), but for evaluation of the EMID, a 
simple mechanical means of monitoring the device performance involved the 
measurement of either the piston movement relative to a fixed point over time, or, 
the measurement of weight loss over time. 
“Due to the greatly differing types of technology involved, the methodology and 
results of each part are presented as sub-sections in this chapter.” 
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4.2.2 In vitro characterisation the component parts of the EMID 
4.2.2.1 Determination of the effect of piston material on the in vitro 
release rate 
4.2.2.1.1 Methods 
The effect of piston material type and piston design on the in vitro release rate 
was determined using the weight loss method. Polypropylene EMIDs covered in 
tinfoil containing 2% hydroxypropyl methylcellulose (HPMC) gel (Grade 60SH-
10000 USP [Shin_Etsu Chemical Co., Ltd, Chiyoda-ku, Japan]) were fitted with a 
resistor of 750 Ohms. Experiments were conducted at 40ºC/75%RH and the 
release rate was monitored for 12 days.  
The different piston designs are shown in Figure  4.5. Piston designs were 
classified into three major types which were: type A (original type, double O-ring 
piston), type B (solid silicone) and type C (various pistons over a polypropylene 
carrier).  
Description Piston design Photograph 
A) Original design 
(Double silicone O-ring type) 
Silicone O rings (a) positioned 
over the carrier (b) 
 
B) Solid type Solid piston 
 
C) Piston over polypropylene 
carrier 
Piston (various materials) (c) 
polypropylene carrier to 
provide support (d)  
Figure  4.5. Different piston designs investigated in this study. 
 
a 
b
d c 
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The different piston materials used in this study are shown in Table  4.1. 
Table  4.1. Different piston materials used in the study. 
Piston type Piston material (Trade
name) 
Material composition (polymer) 
A) Original type 
Double O-rings silicone
piston 
Silicone (Q74840 Dow coning) 
B) Solid type Solid silicone Silicone 
Santoprene (8211-35) + 10%
polypropylene 
Santoprene (90% and 10%polypropylene) 
Santoprene (201-73) Santoprene (100%) 
Santoprene (8211-75) + 1%
lube 
Santoprene 99%+1%lubricant 
Santoprene (8211-87A) Santoprene (100%) 
Santoprene (8211-87A) +
10% polypropylene 
Santoprene (90% and 10% polypropylene)
Reflex 123E Polyurethane 
Polypropylene Polypropylene (100%) 
Thermoflex 65A 1-800 Polyester 
Desmopan 192 Polyester urethane 
Hytrel 4069 Polyether ester 
Elastollan WYO 1388-5 Polyurethane 
C) Piston over a 
polypropylene carrier 
Silicone Silicone 
 
Each combination of design and/or material was tested in triplicate. All of the raw 
weight loss data is presented in tables of Appendix-I. 
4.2.2.1.2 Results and discussion 
The effect of piston material on in vitro release rate for various materials is shown 
graphically in Figure  4.6 to Figure  4.7.  
Figure  4.6 show the cumulative weight loss versus time of double silicone O-ring 
and solid silicone pistons. 
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Figure  4.6. Cumulative weight loss over time for: a) double silicone O-ring pistons b) solid 
silicone pistons. 
 
Both double silicone O-ring piston (Figure  4.6a) and solid silicone (Figure  4.6b) 
piston materials showed a typical and anticipated release profile. In both cases, all 
devices performed well despite a small release variation among the devices in the 
case of double O-ring silicone piston. Small gas bubbles were observed in the 
formulation in the case of the solid silicone pistons. These gas bubbles were 
attributed to the presence of a possible small leakage of gas between the barrel 
and the piston. However, these gas bubbles were negligible, as they were not 
growing much in size to cause any spontaneous discharge of the formulation.  
Neither of the two pistons delivered the entire payload contained in the EMIDs 
possibly due to friction caused by the tight fit between the piston and the barrel. 
Figure  4.7 shows the cumulative weight loss over time of various pistons over a 
polypropylene carrier. These pistons were made of santoprene (a-e) and 
polypropylene (f) materials. The material compositions of the pistons from Figure 
 4.7g-l (Silicone, Reflex 123E/Elastollan WYO 1388-5, Thermoflex (65A 1-
800)/Hytrel 4069 and Desmopan 192) were silicone, polyurethane, polyester, 
polyester urethane, respectively.  
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Figure  4.7. Cumulative weight loss over time for pistons over a polypropylene carrier 
containing a) santoprene (8211-35) + 10% polypropylene; b) santoprene (8211-75) + lube; c) 
santoprene (201-73); d) santoprene (8211-87A); e) santoprene (8211-87A) + 10% 
polypropylene; f) polypropylene pistons; g) silicone; h) reflex 123E; i) thermoflex (65A 1-
800); j) hytrel 4069; k) desmopan 192 and l) elastollan WYO 1388-5 piston. 
 
All the santoprene piston materials (Figure  4.7a-e) showed slip stick phenomenon 
with some degree of variation among them. Slip stick behaviour produced non-
zero order of release profile due to the inconsistency of piston motion within the 
barrel, which in turn causes inconsistency of delivery rate of the payload over 
time.  
For one device of samples represented in Figure  4.7a did not move at all due to 
piston sticking in the barrel (device # 2). This was checked by ensuring the 
pressure build up in the back chamber and tested at end of the experiment.  
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From Figure  4.7b and c it can be seen that all devices functioned despite showing 
signs of slip stick and some release variation among them. For one device of 
samples represented in Figure  4.7d did not move (device # 2) despite showing 
weight loss (apparently due to improper sealing between the piston and the barrel, 
because gas was seen to move past the piston and cause spontaneous discharge of 
the formulation).  
From Figure  4.7e it can be seen that one out of the three pistons (device # 1) failed 
to move at all due to the piston becoming stuck. In addition, an inadequate seal 
between the piston and the barrel created gas leakage into the formulation 
chamber for one of the two working devices but this did not affect the weight loss 
profile.  
None of the three polypropylene pistons moved (Figure  4.7f), despite one of them 
showing a linear weight loss versus time. This piston (device # 3) showed gas 
leakage between the piston and the body, which caused spontaneous formulation 
discharge.  
Polypropylene carrier pistons showed the highest friction of all (due to the fact 
that none of the three pistons moved at all), followed by santoprene (8211-87A) + 
10% polypropylene pistons. On the other hand, it can be seen that all the pistons 
in Figure  4.7g-l did not exhibit any slip-stick characteristics, possibly due to their 
less coefficient friction compared to the pistons made of either santoprene or 
polypropylene materials. 
One out of three devices performed well (device # 3) in Figure  4.7g for the 
silicone rubber with piston carrier. The other two had improper sealing between 
the piston and the barrel. Gas leakage from the back chamber went through the 
formulation to cause spontaneous discharging. One device became completely 
exhausted by day 5 (device # 2). Formulation also leaked into the back chamber 
near the gas cell.  
In Figure  4.7h all three devices for Reflex 123E piston material showed the 
desired profile and performed well. From Figure  4.7i it can be seen that for 
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Thermoflex (65A 1-800) one out of three (device # 3) had gas leakage due to 
improper sealing between the piston and the barrel. This caused a slight increase 
of discharge of the formulation. The improper sealing was due to the piston and 
its carrier breaking into parts. However, two of the three pistons performed 
despite some release variation between them. 
From Figure  4.7j it was observed that for Hytrel 4069 piston two out of the three 
devices (devices 1 and 2) had gas leakage into the formulation due to improper 
sealing between the piston and the barrel. One device became completely 
exhausted by day 3 (device # 1) due to gas leakage from the back chamber that 
went through the formulation causing a dramatic spontaneous discharge. In 
addition, one (device # 2) out of two failed devices caused formulation leakage 
into the back chamber. One out of the three pistons performed well.  
From Figure  4.7k it was observed that for Desmopan 192 piston one (black 
diamond) out of three had gas leakage between the piston and the barrel due to 
improper sealing between them. Two out of the three pistons performed well 
giving very similar release profiles.  
From Figure  4.7l it can be seen that for Elastollan WYO 1388-5 piston all three 
devices performed well giving very similar release profiles compare to silicone 
pistons (Figure  4.6). It appears to be a very good material for this purpose.  
However, none of the pistons (Figure  4.7) delivered the entire payload contained 
in the EMIDs perhaps due gas diffusion through the body wall, resulting in 
progressively lower internal pressure acting on the piston (see Section 4.2.6). The 
total amount of the payload delivered varied among the piston materials (i.e., 
Thermoflex (65A 1-800) versus santoprene (8211-87A) + 10% polypropylene for 
18g versus 7g) perhaps due to the coefficient frictional difference of their 
materials. Therefore, pistons made of santoprene or polypropylene materials were 
not recommended for further study due to the slip stick behaviour or high friction 
inheritance. Table  4.2 summarises piston performance including the 
presence/absence of slip-stick behaviour, function and release rate of the initial 
linear portion of the release profile of the tested pistons. 
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Table  4.2. Summarised overall effect of piston material, slip-stick behaviour, function and 
release rate of initial linear portion of the slope of the tested pistons. 
Piston type Piston Material  
(Trade name) 
Graph  
displays 
slip-stick 
behaviour
Yes or No 
Function Slope 
(g/Hour, 
Mean ± 
SD) 
Original type Double O ring silicone piston No **** 2.0  ± 0.2 
Santoprene (8211-35) + 10% polypropylene Yes * 2.4 ± 0.2 
Santoprene (201-73) Yes * 2.2± 0.2 
Santoprene (8211-75) + lube Yes * 1.8 ± 0.6 
Santoprene (8211-87A) Yes * 1.9 ± 0.6 
Santoprene  (8211-87A) + 10% polypropylene Yes * 1.0 ± 0.6 
Reflex 123E No *** 1.6 ± 0.1 
Polypropylene Possibly * -2.4 
Thermoflex 65A 1-800 No *** 2.7 ± 0.4 
Desmopan 192 No ** 1.6 ± 0.6 
Hytrel 4069 No ** 2.1 ± 0.4 
Elastollan WYO 1388-5 No **** 2.2 ± 0.1 
Piston over  
polypropylene
carrier 
Silicone No ** 2.6 ± 0.5 
Other types Solid silicone No **** 2.0 ± 0.0 
****Excellent; ***good; **poor; *very poor. –none of the pistons moved despite weight release. 
Double O-ring silicone, Elastollan WYO 1388-5 and solid silicone pistons were 
deemed to be amongst the best pistons tested and all performed well with a 
smooth release profile (no slip-stick behaviour), and allowed for a consistent rate 
of release (2.0 ± 0.2, 2.2 ± 0.1 and 2.0 ± 0.0 g/day, respectively) for the initial trial 
period.  
Consideration of the above results leads to the conclusion that double O-ring 
silicone pistons may be the preferred material and design for optimum device 
performance. This type had demonstrated smooth motion (no slip-stick 
characteristics), producing good rate of release. In addition, the double O-ring 
silicone pistons were in abundance compared to other materials. Therefore, further 
study was focused on this piston. However, it is recognised that not all possible 
materials and designs were tested in this study, and that there may indeed be even 
more beneficial combinations that could be used in future work and/or any 
commercial development of this product.  
After piston material selection (double O-ring silicone piston), the effect of 
resistors on the release of the EMID was investigated. 
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4.2.3 Determination of the effect of electrical resistance on in vitro 
release rate 
4.2.3.1 Methods 
The effect of electrical resistance on in vitro release rate was determined using the 
weight loss method. Polypropylene EMIDs covered in tinfoil containing 2% 
HPMC gel, were fitted with resistors of various resistances (4.7, 270, 560, 750, 
1000 and 1300 Ohms). The use of the selected resistors can make possible to 
monitor the rate of release of the payload from the EMID between hours and 
weeks (Table  4.3). Experiments were conducted at 40ºC/75%RH and release rate 
was monitored for 25 days (4.7 Ohms for hours). The pistons used in the study 
were the silicone double O-ring type. Each combination of design and/or material 
was tested in triplicate.  
4.2.3.2 Results and discussion 
Figure  4.8 shows the effect of resistor values between 4.7 and 1300 Ohms on the 
delivery rate profile of EMIDs covered with tinfoil. Each of the curves in Figure 
 4.8 has a similar (hyperbolic) shape except in the case of the 4.7 Ω resistor (the 
entire payload had been exhausted within 4-5 hours). Table  4.3 shows the initial 
slope of the delivery rate for each resistor. The main differences among the 
resistors are a difference in the initial slope (Table  4.3 and Figure  4.8). 
Table  4.3. Effect of resistor values on the initial slope of delivery rate of the EMID 
(Mean±SD, n=3). 
Resistor value 4.7 Ω 270 Ω 560 Ω 750 Ω 1000 Ω 1300 Ω 
Delivery rate (g/day) 166.2 ± 6.1 6.3 ± 0.2 3.0 ± 0.4 2.2 ± 0.3 1.6 ± 0.1 1.2 ± 0.1 
 
The final asymptote for each of the curve also varies with difference resistance 
values (Figure  4.8). Lower resistor lead to a cumulative rate loss profile, which 
tended towards linearity until a plateau is reached when the entire payload had 
been exhausted and the piston, has reached the end of its travel. On the other hand, 
a high resistance (which is expected to provide a lower rate of gas production) 
clearly show a much slower initial rate and more obvious curvature. What is more, 
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the final asymptote corresponds to a much lower accumulated weight loss, with 
the piston not moving the whole length of the barrel.  
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Figure  4.8. Effect of resistance on the release profile of EMIDs covered with tinfoil. 
 
The different release rates of the formulation delivery are explained by the 
different resistors that control the gas production rate according to Equation  4.2 
(Ohm’s Law). 
R
VI =  Equation  4.2. 
 
Where the current (I) is directly proportional to the voltage (V) and inversely 
proportional to the resistance (R).  
Given that, the total gas production from a battery should be independent of the 
resistance one might expect that the only difference will be in the rate of weight 
loss, not the absolute total loss (Cross, 2002). The clear discrepancy here suggests 
that in these systems, all of the gas is not always converted to payload expulsion. 
This in turn implies some loss of gas, either by leakage or by some other 
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mechanism. Great care was taken to ensure there were no gas leaks from any 
source, and the most obvious explanation for gas loss is that the hydrogen being 
generating in the gas chamber can in fact escape via diffusing through the walls of 
the barrel. This phenomenon is described in more detail in section 4.2.6, but 
suffices to say, the rate of gas diffusion, or rate of loss of gas through the barrel, 
would be proportional to the exposed surface area behind the piston, and this 
means that the diffusion effect will become steadily more important as the size of 
the gas chamber increases.  
The only reliable way to compare the effect of resistance is to consider only the 
initial slopes of each of the lines in Figure  4.8 as in the early time the surface area 
of barrel available for diffusion is very small, and one can reasonably expect that 
all of the generated gas will be reflected in piston travel. Applying Equation 4.1, 
the reciprocal of the initial rate versus resistance was plotted to investigate if there 
is any correlation between the rate and the resistance. From Figure  4.9 it was 
found a linear relationship between the reciprocal initial linear portion of the 
release rate and the resistor values (R2 ≥0.998).  
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Figure  4.9. Effect of resistors on the reciprocal of the initial rate of the EMID. 
 
The rate of release of the payload from the EMID can be predicted (between 4.7 
and 1300 Ohms range) by interpolating the regression line equation for a known 
resistor (Figure  4.9). 
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The effect of body composition on the delivery of the EMID was also investigated. 
4.2.4 Determination of the effect of body material on in vitro 
release rate 
4.2.4.1 Methods 
The effect of body material on in vitro release rate was determined using the 
weight loss method. Polypropylene EMIDs with and without tinfoil covering and 
high density polyethylene containing 2% HPMC gel were fitted with a 750 Ohms 
resistor. Experiments were conducted at 40ºC/75%RH and release rate was 
monitored for 25 days. The piston material used in the study was the silicone 
double O-ring type. Each combination of design and/or material was tested in 
triplicate.  
4.2.4.2 Results and discussion 
The effect of polymer type on the formulation release is shown in Figure  4.10. 
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Figure  4.10. Effect of body composition of HDPE (▲) PP with tinfoil ( ) and PP (♦) on 
EMID delivery rate profile. 
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Body material was found to influence delivery rate profile from the EMID. A near 
linear release rate was shown by HDPE until complete exhaustion coincident with 
the piston reaching the end of the barrel. The small weight change observed over 
the final 10 days was thought to be due to water evaporation from the residual 
payload remaining in the orifice housing.  
In contrast, both PP barrels gave non-linear and non-exhaustive release profiles, 
although, the one with the tinfoil coating was similar to the HDPE device than the 
uncoated one. It is believed (see section 4.2.6) that this phenomenon is another 
demonstration of gas diffusion through the body wall, resulting in progressively 
lower internal pressure acting on the piston and therefore a reduced delivery rate. 
Covering the PP body of the insert with tinfoil appears to have inhibited gas 
diffusion to some extent, but did not completely prevent it.  
Further supporting evidence of gas diffusion of leading to the having different 
profile release rates found from EMID fabricated from HDPE and PP polymers is 
shown in Table  4.4. The gas permeability was lower for HDPE than for PP 
polymer. 
Table  4.4. Gas permeability differences between PP and HDPE plastics. 
Gas permeability1([mm cm3/cm2(cm Hg) x 1010] Polymer 
N2 CO2 O2 
PP 4.4 92 28 
HDPE 3 45 10 
1(http://www.dynalabcorp.com/files/Use%20and%20Care%20of%20Plastics.pdf). 
This table indicates that gas permeability values for N2, CO2 and O2 are always 
higher in the case of PP material compare to HDPE polymer. 
Based on these findings, HDPE polymer was selected as the best available body 
material for the EMID. 
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4.2.5 Gas diffusion 
It was apparent that the EMID manufactured from PP material have non-linear 
and non-exhaustive release profiles possibly due to gas diffusion through the 
polymer. Therefore this experiment was carried out to evaluate possible of any 
gas diffusion through the PP EMID. 
4.2.5.1 Method 
In order to investigate gas diffusion through the PP EMID, experiments were 
conducted using two devices (active and control PP EMIDs) which were fully 
immersed in water. Another active device manufactured from HDPE was also 
made for comparison. Each active EMID (PP or HDPE) was loaded with a gas 
cell and a resistor (270 Ω). The EMIDs were inserted into three separate bottles. 
The three bottles were subjected to ultrasound to remove any dissolved gas in the 
water for 10 minutes. The bottles were placed on the bench (with lids on) and 
observed regularly to see any gas bubbles appearing on the surface of the EMIDs. 
Images were taken at appropriate times (e.g., when piston reached at the head of 
the EMID within seven days) to show the gas diffusion of PP EMID (Figure  4.11).  
4.2.5.2 Results and discussion 
There were no gas bubbles seen with either the control or the active HDPE EMID. 
On the other hand, the PP active EMID became covered in gas bubbles, the 
number of which increased over time. These gas bubbles are clearly seen in 
Figure  4.11. 
The gas bubbles observed from this experiment, together with the previous release 
rate profile shown by PP EMID covered with tinfoil from the previous experiment 
(Figure  4.10) (steeper linear release profile compare with PP no tinfoil on) 
provide supporting evidence of the concept of gas diffusion. Putting tinfoil on the 
PP EMID reduced the gas diffusion problem, in a manner not dissimilar to using 
other plastic materials (e.g., HDPE) which are known to be less prone to gas 
diffusion. 
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Figure  4.11. Control, HDPE and PP showing gas bubbles on EMID manufactured from PP 
material. 
4.2.6 Analytical method to measure drug release from EMID 
During technology development studies described in the previous sections, weight 
loss or piston travel measurements were the simplest and most appropriate ways 
to measure the drug release rate from EMID. However, any product that might 
result from this research will need to demonstrate compliance with a variety of 
pharmaceutically accepted procedures. 
An establishment of an in vitro drug release method is a key parameter that is 
used to assess in both the formulation development and quality control of a final 
product. The USP Apparatus 1 (basket method) and 2 (paddle method) are the 
most widely used by which the pharmaceutical industry monitors drug release 
from controlled release products. Up to this date, there has been no critical 
assessment of any methods to determine the release of formulation from the 
EMID. Therefore, a pharmaceutical acceptable test procedure using the USP 
paddle method was evaluated in comparison with the simple physical measure 
used above.  
Control HDPE 
PP
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4.2.6.1 Preparation of formulations used in vitro drug release method 
The drug/gel formulations used in the drug dissolution in vitro release method 
comprised a gel comprising dexamethasone (0.5 mg/mL) dissolved in 2% HPMC 
in a 10% v/v of ethanol/water continuous phase. 
The gel was prepared by dissolving 0.15 g dexamethasone in 30 mL of ethanol 
(SDA, Mobil, NZ). Next, 270 mL of water was added while stirring vigorously 
using a blade mixer. Then 6.0 g of HPMC was added slowly to the mixture and 
stirred for 7 to 8 hours. This formulation was used as the payload for series of 
EMIDs in the dissolution method. 
4.2.6.2 Establishment of in vitro drug release method 
The in vitro release from an electronic insert was conducted using a Hanson 
Dissolution Testing Apparatus (Section  3.2.2). The paddle method with some 
modifications was used (Figure  4.12 and Figure  4.13). The method involved a 1 
litre nominal capacity flask that contained the receptor phase (500 mL of degassed 
10% alcohol/pH 5.0 phosphate buffer). The 10% of the alcohol in the release 
media composition was to achieve sink conditions for the drug solubility. 
Experiments were conducted at 39ºC with the receptor phase stirred at 100 rpm 
using a paddle stirrer positioned 25 mm from the bottom of the flask. A specially 
designed lid was manufactured to hold the EMID in the same position on each run 
(Figure  4.12).  
 
Figure  4.12. Lid designed to hold the EMID in the same position on each run.  
  
Sample collection orifice   
Active device holder Paddle hole   
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For this study and for comparison with other measurements, all EMIDs were 
made with PP barrels coated with tinfoil. Prior to mounting the insert into the 
holder of the lid, the wings of the EMID were cut off. The outlet of the insert was 
initially positioned 60 mm from the bottom of the flask (fully immersed in the 
release medium).  
The final physical set-up is shown in Figure  4.13. 
 
 
Figure  4.13. The final experimental set-up for the in vitro drug release test. 
 
To perform a run 30 g of the dexamethasone formulation was loaded into each of 
six replicate PP EMIDs covered in tinfoil. A resistor (4.7 Ω) was used to control 
gas production in each. This resistor value was chosen since it resulted in full 
expulsion of the EMID contents within 4-5 hours, thereby ensuring the test could 
be completed in a working day. Initially the samples were taken over 5 hours, but 
then routinely taken at 0, 0.5, 1.0, 1.5, 2.0, and 3.0 hours. This represents over 
70% of the drug release from the EMID and yet avoids any complication which 
might result from accumulation of drug around the outlet orifice. A 1.0 mL 
sample was taken at each time point and analysed for drug concentration using a 
UV spectrophotometer monitored at 242 nm. The analytical UV method is 
previously described in Chapter Three (Section  3.2.3.1). 
For the initial 5 hour tests, the cumulative amount of drug dispensed from the 
EMIDs versus time was plotted between 0 and 5 hours, to examine the rate of 
Sleeve 
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release profile (slope). This showed a curved end of the release profile due to the 
piston reaching the end of the EMID and causing a full exhaustion of the material 
contained in EMID Figure  4.14.  
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Figure  4.14. Extended run up to EMID exhaustion using the in vitro drug release method 
(Mean ± SD, n=6). 
As is clearly seen in Figure  4.14, the amount of the drug dispensed at 4 and 5 
hours was very similar (13.7 ± 0.7 mg and 14.5 ± 0.3 mg) and the rate of release 
profile reached plateau values. This was lowering the slope values (tables of 
Appendix-J) and therefore, the last two sampling points (4 and 5 hours) were 
omitted from further work.  
The cumulative amount of drug dispensed from the EMIDs versus time was 
plotted between 0 and 3.0 hours, to determine the slope and linearity of release 
(R2). The mean slope of six replicates and coefficient correlation were 3.6 
mg/Hour and 0.998, respectively.  
The rate of release of drug from the EMID can be calculated from this data, 
knowing the known concentration of drug in the payload. For instance, 3.6 mg of 
dexamethasone was dispensed in an hour from the payload of 0.5mg/mL drug 
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concentration. This indicates 7.2 mL/hour for the release rate from the EMID (e.g., 
the slope value divided by the drug concentration in the payload). 
4.2.6.3 Effect of external and internal parameters on release rate of the 
EMID 
The effect of stirring speed, paddle position, temperature, pH of the release media, 
alcohol strength and volume of the release media on drug release from the PP 
EMID covered in tinfoil was investigated. The vertical position of the EMID 
could be varied and in most cases the outlet orifice was well immersed in the 
release medium (Figure  4.13) but in other cases was just touching or staying 
outside in the release medium. In addition, the effect of the EMID outlet orifice 
position in the release medium was also investigated. Table  4.5 shows the 
variables and the values used in the study. 
Table  4.5. The parameters and their ranges used in vitro drug release method. 
Parameter Tested value 
10 Paddle distance from the bottom of the flask (mm) 
25 
Immersed  
Touching Position of EMID relative to the release media (mm) 
Outside 
35 Temperature (ºC) 
39 
Not degassed Degassing the dissolution medium 
Degassed  
1.60 
5.0 pH of the release media 
7.4 
25 Composition of the release media (%alcohol) 
50 
50 Stirring speed (rpm) 
150 
500 
750 Volume (mL) 
1000 
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4.2.6.3.1 Data analysis  
All data were analysed as described above by using linear regression and 
conversion from cumulative amount to an absolute release rate. The release rate 
results obtained from all parameters were statistically compared using a single 
ANOVA variance method.  
4.2.6.4 Results and discussion 
4.2.6.4.1 Effect of environmental parameters on release rate  
Zero-order release rates from the EMID determined under various external and 
internal parameters in the in vitro drug release method are shown in Table  4.6. In 
this study there were no EMID failures. 
Table  4.6. Results for the different variables investigated in vitro drug release method 
(Mean±SD, N=6). 
Parameter Value Average rate of release
(mL/hour ± SD 
10 7.3 ± 0.3 Paddle distance from the bottom of the flask (mm) 
25 7.2± 0.3 
Immersed  7.3 ± 0.3 
Touching 7.3 ±0.3 Position of EMID relative to the release media (mm)
Outside 6.9 ± 0.4 
35 7.2 ± 0.5 Temperature (ºC) 
39 7.4 ± 0.5 
Degassed 6.9 ± 0.4 Degassing 
Not degassed 7.6 ± 0.7 
1.60 7.8 ± 0.7 
5.0 7.3 ± 0.3 pH of the release media 
7.4 7.2 ± 0.2 
25% SDA 7.7 ± 0.5 Composition of the release media (%alcohol) 
50% SDA 7.5 ± 0.4 
50 7.2 ± 0.3 Stirring speed (rpm) 
150 7.2 ± 0.5 
500 7.0 ± 0.3 
750 7.3 ± 0.4 Volume (mL) 
1000 7.3 ± 0.2 
 
There are no statistically significant differences among any of the tested 
parameters. This indicates that the rate limiting step factor in the EMID was the 
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rate of gas production (i.e., driving mechanism) which is in turn controlled by the 
rate of gas (oxygen and/or hydrogen) produced (see Figure  4.8) during electrolysis 
which is proportional to the applied current (Bunt et al., 1998).  
Since gas production is independent of external factors, the release rate from the 
insert also remains independent of external factors.  
The in vitro drug release method was complex and involved analytical equipment. 
Previously simpler methods (weight loss and piston travel) were used to measure 
the release rate of EMIDs. It is important to demonstrate that the simpler methods 
gave results consistent with the drug release method. Therefore, in addition to the 
in vitro release method, four other methods were investigated. 
4.3 Other in vitro release tests for EMID 
The four alternative methods included assessing weight loss, weight dispensed, 
piston and rod travel. 
4.3.1 Preparation of payload used 
The formulation was the same as for the in vitro drug release method but with the 
exclusion of drug and alcohol content. The payload was a 2% w/v HPMC gel in 
water (Section  4.2.6.1).  
4.3.2 Establishment of the other methods 
The release rate from PP EMID’s covered in tinfoil containing 4.7 Ω resistors was 
monitored with each of the above methods. In each case, the EMID was loaded 
with 30 g of 2% HPMC gel and experiments were conducted at 40ºC/75%RH in 
an oven (Contherm Cooled Incubators, Contherm Scientific Ltd, New Zealand). 
The release of gel monitored using the different methods at selected time points (0, 
0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 3.5 hours) by measuring the cumulative weight loss 
(g), amount released (g), piston movement (cm) or rod travel distance (cm). The 
amount released or distance moved versus time (hours) was plotted and converted 
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to release rate using appropriate parameters such as the payload density and 
physical dimensions of the EMID to determine the rate of release. For instance, to 
allow comparison between these four methods and in vitro drug release method, 
all release rates were expressed in the same units (slopes were expressed in 
mL/Hour). Therefore, the release rates for weight loss and weight dispensed were 
converted from g/hour to mL/hour by multiplying the density of the 2% HPMC 
gel (1.02 g/mL) whereas, for the piston travel and rod travel methods, the rates 
were converted from cm/hour to mL/hour by multiplying by the cross sectional 
area of the EMID (3.14 cm2).  
4.3.2.1 Methods  
4.3.2.1.1 Weight loss 
Weight loss involves the measurement of the weight loss of the EMID over time. 
4.3.2.1.2 Piston travel  
This involved the measurement of the piston position relative to a fixed point 
within the EMID over time. 
In order to evaluate piston position along the barrel a very small window was cut 
along the length of the EMID in the tinfoil to allow the piston to be seen without 
significantly compromising the gas diffusion and its travel distance measured 
(Figure  4.15).  
 
Figure  4.15. PP EMID covered in tinfoil showing a window along the length of the EMID in 
the tinfoil to allow the piston to be seen. 
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4.3.2.1.3 Weight dispensed  
This involves regular collection and weighing of gel dispensed from the EMIDs. 
EMIDs were arranged to lie horizontally over the edge of collection bottles in 
which the dispensed gel was collected and weighed.  
4.3.2.1.4 Rod travel 
This involved determination of the distance of travel of a rod that had been 
inserted into the barrel through the release orifice and which was touching the 
piston. The rod was protruding through the release orifice while maintaining 
contact with the piston. The protruded length of the rod was measured relative to 
the orifice of the EMID over time. 
4.3.2.2 Results and discussion 
Each method gave linear (≥0.998) dependence of release versus time (Figure  4.16-
Figure  4.17) and provided similar release rate values (Table  4.7).  
An example of typical weight loss and weight dispensed release profile is shown 
in Figure  4.16. The mean slope for six replicates for each case was 6.7 and 6.5 
g/hour for weight loss and weight dispensed, respectively.  
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Figure  4.16. Typical cumulative weight loss and weight dispensed in vitro release test of  
EMID (Mean ± SD, n=6). 
Chapter Four 
166 
An example of typical piston and rod travel release profile is shown in Figure  4.17. 
Mean slopes for six replicates were 2.20 and 2.05 cm/hour for piston and rod 
travel, respectively. 
Piston travel
0
5
10
0 1 2 3 4
Time (Hours)
C
um
ul
at
iv
e 
tr
av
el
 d
is
ta
nc
e 
(c
m
) Rod travel
0
5
10
0 1 2 3 4
Time (Hours)
C
um
ul
at
iv
e 
tr
av
el
 d
is
ta
nc
e 
(c
m
)
Figure  4.17. Typical cumulative piston and rod travel in vitro release test of EMID (Mean 
±SD, n=6). 
These alternative release assessment methods provided similar estimates to the in 
vitro drug dissolution for the release rate of the formulation from the EMID (each 
method was shown to produce results that correlated well with the in vitro 
dissolution  method) (Table  4.7). 
Table  4.7. Summarised rate of release (mL/Hour) of EMID by different methods. 
Replicate # In vitro drug 
dissolution* 
Weight
loss 
Weight
dispensed
Piston 
travel 
Rod 
travel 
1 6.3 6.1 6.3 6.8 6.0 
2 7.0 6.7 7.0 6.7 6.7 
3 7.2 7.2 6.6 6.2 5.9 
4 7.0 7.0 5.9 6.3 6.3 
5 7.1 6.6 7.0 6.2 6.7 
6 6.5 6.8 6.1 6.7 6.8 
Release rate (mL/Hour, Mean ±SD) 6.9 ± 0.4 6.7 ±  0.4 6.5 ± 0.5 6.5 ± 0.3 6.4 ± 0.4
Statistical analysis P = 0.23 
*EMID was positioned outside of the release media. 
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The statistical comparisons of the release rate of HPMC gel from the EMID 
demonstrated that there was no significant difference among the different methods 
used (P = 0.23) (Table  4.7). Each method provides a reliable estimate of the 
release rate of the EMID. The way in which the EMID works means that there is 
always an “initiation” period, during which the battery function is changing from 
gas (oxygen) consumption to gas (hydrogen) generation and also it takes a while 
for the gas pressure to build up to move the piston. During this time, graphs of 
release rate over time will exhibit some form of a lag phase (initiation phase). In 
order to reduce the demand on the in vitro drug dissolution apparatus, and to 
reduce as far as possible the numbers of samples need for further analysis, all 
EMIDs tested in this way were subjected to a short period of pre-observation, 
before being inserted in to the bath. In this case, once it was established that 
material was being extruded through the orifice, the excess material was wiped 
from the surface and the EMID place into the bath. It was at this point in time that 
a zero reference point was established. With all the alternative methods, zero time 
was taken as the point at which the gas chamber was sealed. The end result is that 
the in vitro drug dissolution data points clearly progress from the origin, whereas 
graphical data for the other methods all demonstrate a lag phase, which was 
ignored in the calculations. Typical example of curve showing a lag phase for the 
other methods is shown in Appendix-K. All five methods developed were 
compared in terms of ease of use, cost, time, automation capability, need for 
analytical equipment, reproducibility, limitations and need for consumables. The 
results and comparison are shown in Table  4.8. 
Table  4.8. Comparison between different in vitro release methods for the EMID. 
Method Criteria 
In vitro drug 
dissolution 
Weight 
loss 
Weight 
dispensed 
Piston 
travel 
Rod 
travel 
Ease of use Many set up steps Easy 
Need for analytical 
equipment  UV spec Balance Calliper 
Cost Expensive Low 
Time  Extra time for sample analysis Real time 
Automation capability Yes Possibly Yes Possible 
Reproducibility Very good Good 
Limitation None EMID must be clear  None 
Consumables drug and release media N/A 
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All methods provided a similar estimate for the rate of formulation release. 
However, in terms of operation and set-up, the in vitro drug dissolution method 
was relatively complex and involved expensive analytical equipment. The 
remaining four methods were much simpler to perform and did not involve 
complicated set-ups or expensive equipment. The conclusion that can be drawn 
from this study was that release rate determinations for the EMID did not need to 
be performed using the complex and expensive in vitro drug dissolution 
equipment. Reliable estimates of the release rate could be determined by much 
simpler and less expensive methods. The simplest, cheapest and easiest method 
proved to be weight loss (Table  4.8). 
4.4 Physical characterisation of the EMID manufactured 
from HDPE 
Although the early work of this thesis was based on the EMID manufactured from 
PP, observation of the PP polymer highlighted the need to replace this with an 
alternative plastic material. HDPE material was chosen for further study because 
of its lower gas diffusion properties and near linear release rate of the formulation 
over time (Section 4.2.5). The complete description of the EMID (e.g., retention 
wings and drive mechanism) manufactured from PP EMID (original insert) was 
previously described in Section  4.2. As well as changing the plastic, the 
opportunity was taken to modify the wing design shape to rounded wing tips 
(Figure  4.18) because the EMID manufactured from PP caused severe damage on 
vaginal mucosa membranes. This was attributed to abrasions caused by not having 
rounded end wing tips for the PP EMID.  
The EMID insert manufactured from HDPE was manufactured using rounded 
wing tips (Figure  4.18). 
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Figure  4.18. Close up of wing shape of EMID manufactured from HDPE. 
 
To compare PP and HDPE EMIDs, the original 2% HPMC formulation was used 
as a payload (Section  4.3.1). Additionally, in the HDPE studies, the opportunity 
was taken to explore the effect of varying the HPMC concentration in the payload. 
4.4.1 Methods 
4.4.1.1 Retention mechanism and site safety determination 
Since a different plastic (HDPE) from PP was used to make this EMID, in vivo 
characterisation was carried out to investigate the retention mechanism and safety 
at the site of administration. This involved monitoring whether the EMID remains 
in the animal during the length of treatment without damaging the vaginal mucosa 
membranes. 
The EMIDs were placed into the vagina of 12 cattle and monitored for 10 days. 
The retention rate and site safety of the EMIDs were monitored during the 
treatment. Cows underwent a visual inspection of the vagina on days 5 after 
removal of the EMIDs. If there was no damage on the mucosa, they were 
reinserted. On day 10, all animals underwent another visual vaginal inspection for 
any mucosal damage.  
The EMID manufactured from HDPE was retained reasonably well (at the half 
way of the length of the treatment) but caused a high incidence of vaginal damage 
(Section 4.5.2.1.1). This led to a modification of the EMID retention mechanism, 
which involved cutting the wings off, and attaching the EMID to a commercially 
Wings 
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available CIDR™-B as shown in Figure  4.19. These resultant devices were 
observed in 30 cattle over 16 days. 
 
 
Figure  4.19. Picture of the EMID manufactured from HDPE attached to a commercially 
available CIDR™-B. 
 
Due to a poor retention rate (Section 5.4.2.1.2) of the modified HDPE EMID 
strapped onto a loaded CIDR™-B, a further modification of the EMID retention 
mechanism was made. This involved attaching blank PCL wings (Supplied by 
InterAg) to the EMID after removal of the original wings (Figure  4.20). The 
wings were manually attached to the EMID using epoxy resin. The retention rate 
and site safety of this design were tested in 12 cows for 10 days. 
 
 
Figure  4.20. HDPE EMID with attached PCL wings. 
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EMIDs containing 2% HPMC gel were fitted with a 750 Ω resistor (this resistor 
was expected to provide a complete release of the payload material over 10 days). 
The piston material used in the study was the silicone double O-ring type. Cows 
underwent a visual inspection of the vagina after 5 days involving removal of the 
EMIDs. EMIDs were reinserted into the cows after examination.  
4.4.1.2 Preparation of payload formulations 
Formulations of 1, 2 and 3% w/v HPMC were prepared by weighing appropriate 
amounts of HPMC (9, 18 and 27 g), adding slowly to 900 mL water in a beaker 
and leaving to be stirred for 7 to 8 hours at room temperature using a star blade 
mixer (Heidolph, Nicholas Watson Victor Ltd, Germany).  
In addition, three 4% w/v HPMC gel formulations containing 5 mg/mL, 15 
mg/mL and 25 mg/mL progesterone were used in a drug release evaluation study. 
Each of these formulations was manufactured by first mixing a known amount of 
progesterone and water in a beaker using the star blade mixer and the slow 
addition of the HPMC until a uniform suspension product was achieved.  
All formulations were left to stand at room temperature for two days prior to 
loading EMIDs to ensure complete removal of any gas bubbles from the payload. 
The gas bubbles were formed during the manufacturing of the formulation. 
4.4.1.3 Effect of different viscosity and different orifice size on release 
profiles of the EMID 
It is apparent that cows move during their grazing time. They acquire different 
postures such as standing, running, sitting, jumping, mounting, etc. All these 
activities create a movement, which may disturb and shake the EMID payload and 
thus disturb the release profile. In addition, it is expected that the viscosity of the 
payload and the size of the outlet orifice of the EMID may affect the release 
profile. For instance, a large orifice EMID containing water (as a payload) is more 
likely to lose the payload compared to a high viscosity payload and small orifice 
EMID, when both the EMIDs are introduced by similar movements. The modified 
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EMID manufactured from HDPE attached to a commercially available CIDR™-B 
as shown in Figure  4.19, was used. 
The aim was to investigate the effect of orifice diameter and gel viscosity 
(%HPMC) upon in vivo release rate of the payload. 
Using the modified insert, in vivo release rate was determined by administering 
EMID’s into the vaginas of cows and removing them at specified (daily) time 
points. Upon removal, the EMIDs were washed, dried and then weighed. In 
addition, the piston position was also measured. The EMID’s were then re-placed 
into the vagina of the same cow where they remained until due for removal. 
In practice, the recovery times were staggered to accommodate animal welfare 
considerations. On removal, the EMIDs were cleaned and inspected. The 
inspection process included weighing and noting piston position prior to re-
insertion. The EMID’s were removed for analysis then re-inserted 5 times over 16 
days, with all EMID’s being removed on day 16.  
The interaction between viscosity and orifice surface area on in vivo release rate 
was determined. HDPE EMIDs contained either water or HPMC gel at 1, 2 or 3% 
and were fitted with a 1000 Ω resistor (this resistor is expected to provide a 
complete release of the payload material over 15 days). Release rate was 
monitored for 16 days. The piston material used in this study was the silicone 
double O-ring type. Orifice surface areas were altered by changing the diameter of 
the outlet orifice of the large reservoir of the EMID (Figure  4.21). This was 
achieved by either removing the central cross-likes structure or inserting a sleeve 
into the orifice. The resultant orifice surface areas were then 0.354 (large) or 
0.194 (small) cm2 compared to the original 0.22 cm2 (medium). Each of the four 
formulations (water, 1, 2 and 3%HPMC) were tested using these orifice sizes. All 
combinations were tested in duplicate for water and 3%HPMC whereas triplicate 
measurements were used for 1 and 2%HPMC. Any technology failures and the 
causes were carefully observed and recorded.  
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0.220 cm2
Sealed outlet orifices for 
small compartments 
 
Figure  4.21. Outlet orifice area of a normal EMID. 
 
4.4.1.4 Drug release evaluation (progesterone dose titration study)  
Ovariectomised (ovex), non lactating cows aged between 3 to 4 years were 
enrolled from a herd of 14 animals that were located at Dexcel, Hamilton, NZ. 
The cows weighed between 500 and 700 kg.  
The three formulations containing 5 mg/mL, 15 mg/mL and 25 mg/mL 
progesterone were used in the study. Each formulation was tested in quadruplicate 
EMIDs manufactured from HDPE which had attached to blank PCLwings (Figure 
 4.20) and containing 30 g of the formulation. This resulted in three treatments 
each with a total expected progesterone load of 150, 450 and 750 mg per EMID. 
All EMIDs were fitted with a 750 Ω resistor. These were administered into the 
vagina of 12 cattle for 8 days. The progesterone plasma concentration of the 
treated ovex cows was monitored over time. 
Plasma samples were taken at 1, 2, 3, 4, 5, 6, 7 and 8 days and 24 hours post 
removal. The blood samples were collected in evacuated tubes containing heparin. 
Plasma was separated by centrifugation (1500 x g for 15 min) and stored at or 
below -12oC for subsequent progesterone analysis. Concentrations of 
progesterone in plasma were determined by direct radioimmunoassay using a 
commercial solid phase I125 label (Coat-a-Count, DPC, Los Angeles, California, 
USA). 
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4.4.2 Results and discussion 
4.4.2.1 Retention rate and safety determination of the EMID  
4.4.2.1.1 HDPE EMID 
The EMID manufactured from HDPE was retained reasonably (80%) well but 
caused a considerable of vaginal damage. This resulted in a decision to terminate 
the study on day 5. 
4.4.2.1.2 Modified insert strapped with CIDR™-B 
The animal experiment retention rate of the EMID was poor throughout the study 
period. Only 13 out of 30 EMIDs were retained throughout the study period. The 
poor retention was due to a number of factors, some of which might be due to 
mechanical complication such as increased size and weight (i.e., too bulky) of the 
EMID strapped with CIDR™-B. Therefore, the second round of this study was not 
conducted. 
4.4.2.1.3 Second modification of EMID with attached PCL wings 
Retention at day 5 was 100% and all vaginal inspections found no observations to 
report. By day 10, four of the EMIDs had lost their tails. The EMIDs that did not 
lose their tails showed little reaction by day 10, of the EMIDs that had lost their 
tail there were minor irritations observed. 
Subsequently, during “drug evaluation trial”, poor retention was again observed 
using the HDPE EMIDs attached to PCL wings. In this case, it was recognised 
that the wings were in a “Y” shape, not the “T” shape used previously. Only six 
cows retained the EMIDs during the treatment of progesterone dose titration.  
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The retention rate data for each EMID over an eight day insertion period is shown 
in Table  4.9. 
Table  4.9. The retention rate for each EMID dose in ovex cows. 
EMID insert dose (mg/mL) Number inserted Number retained Retention rate 
5 4 1 25 
15 4 2 50 
25 4 3 75 
 
The lower retention rate of this trial compared to the previous experiment 
indicates attaching the PCL wings to the EMID was not reproducible between the 
sequencial trials. Some explanation of this could be some possibility due to small 
changes in wing orientation (changes from the original T-shape to a Y shape), 
leading to the EMID’s beocoming dislodged from the animal. It appears that the 
angle of the wings to the body must be maintained close to 90º, rather than 
expanding to 120° as was seen with a number of the EMID’s in the dose titration 
work. 
4.4.2.2 In vivo release rates using different viscosities and orifice sizes 
Only 16 EMIDs were retained in the cows for a sufficient period to collect EMID 
weight and piston position data for further analysis. A plot of the EMID’s 
cumulative mass against time (Figure  4.22) shows that EMIDs followed the same 
trend and achieved a similar mass loss. However, the low viscosity payload 
EMIDs with a large or medium orifice resulted in loss of the payload material 
(Figure  4.22a). This loss occurred within the first 4 days of the insertion period. 
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Figure  4.22. Cumulative weight loss of the EMIDs during the insertion period of different 
viscosities and orifice sizes.  
Plots of cumulative piston travel distance versus time show different sensitivities 
of the measuring systems compared to the weight loss method. Figure  4.23 shows 
most of the EMIDs followed similar trends and achieved a similar piston travel 
distance. The daily piston travel rate (or weight loss) was clearly not linear for the 
whole insertion period. The piston travel data suggests a fast initial rate, followed 
by a slower and possibly steady state rate. On the other hand, the weight loss data 
may indicate an initial lag followed by a more steady rate. 
The piston travel versus time profile demonstrates an independence of the outlet 
orifice and the viscosity of the payload on the release rate. The piston travel 
represents more the driving mechanism of the EMID but it cannot reflect whether 
the EMID lost its payload. The weight loss method may be used reliably to 
measure the performance of the EMIDs when low viscosity and large orifice size 
EMIDs are used, since, this method directly measures what contains the EMID at 
specified time point. 
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Figure  4.23. Individual piston position within the EMIDs during the insertion period of 
different viscosities and orifice sizes. 
Because of the design limitation (relating to animal ethics issue) together with the 
non-linearity exhibited by both the weight loss and piston travel methods, there 
are insufficient data for reasonable analysis.  
4.4.2.3 Progesterone dose titration study 
Table  4.10 shows the results of the progesterone concentration in plasma at steady 
state for the treated cows. The progesterone concentration over time shows that 
each of the three doses produced different responses in the plasma profiles from 
the ovex cows. It was expected that higher doses would produce higher plasma 
progesterone responses (Table  4.10). The individual cow progesterone plasma 
profiles over time are presented in figures of Appendix-L. 
Table  4.10. Concentration of progesterone in plasma at steady state for the treated cows for 
each of the 3 doses used (Mean ± SD). 
5mg/mL 15 mg/mL 25 mg/mL Progesterone 
plasma 
concentration 
(ng/mL)  
Cow 1) 0.38 ± 0.20, 
 
Cow 2) 1.42 ± 0.10 Cow 1) 2.03 ± 0.71 
Cow 1) 3.7* ± 0.81 
 
Cow 2) 3.30 ± 0.98 
 
Cow 3) 2.3 ± 0.84 
*on day 6 outlier point was excluded. 
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None of the doses showed what is known as a burst release (a characteristic of 
initial progesterone CIDR™-B release profile) phenomenon.  
It is expected that progesterone suspension is dispensed from the EMID outlet 
orifice into the vaginal lumen of the cow. Then, progesterone partitions from the 
dispensed material into the vaginal fluids and from there into the mucosa, then the 
submucosa to the blood stream. The larger the area exposed to the progesterone 
absorption, the larger the amount of progesterone absorbed and permeated 
through the membrane would be. Therefore, it seems that the limiting factor of 
plasma progesterone levels is distribution of the suspension in the vaginal lumen 
solubility of progesterone. With this EMID, unlike a standard CIDR™-B, the drug 
is released only at one end. Therefore, only a small area of mucosa may have been 
exposed to an unevenly distributed progesterone suspension. 
In addition, the dose with the higher concentration (25 mg/mL) would have a 
higher concentration gradient of progesterone between the dispensed material and 
the mucosa membrane in the vaginal lumen. This higher concentration would 
favour a high permeation of progesterone compared to lower dose progesterone (5 
or 15 mg/mL). Each of the three doses showed sharp decline of progesterone 
plasma levels after 24 hours of EMID removal. This is explained by the short 
biological half-life of progesterone (Rathbone & Macmillan, 2004). 
25 mg/mL doses led to plasma progesterone fluctuating between 2-5 ng/mL 
during the treatment except for one occasion. Any progesterone blood levels 
greater than 2 ng/mL can induce oestrous synchronisation among the dairy cows 
after the removal of the device (Rathbone et al., 1998). The EMID demonstrated a 
sustained release of progesterone up to 8 days. However, the retention mechanism 
of the EMID needs to be improved.  
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5 Stability testing 
5.1 Introduction  
Stability testing of all pharmaceutical products is crucial in determining their shelf 
lives. An active pharmaceutical ingredient must remain stable during handling, 
formulation, storage and administration of the drug product. The purpose of 
stability testing, as described by the International Conference on Harmonisation 
(ICH, 2003), is to produce evidence on how the quality of a drug product changes 
with time under the influence of a variety of environmental parameters such as 
temperature, humidity and light, and enables recommended storage conditions, 
retest periods and shelf lives to be established. 
Various formulations used in the EMID, namely the progesterone suspension, 
oestradiol-17β tablets and a blended cloprostenol powder which have been 
previously developed (Bunt et al., 2001; Bunt et al., 1999; Burke et al., 1999, 
respectively) were manufactured and exposed to elevated temperature and 
humidity conditions (40°C/75%RH) for 4 weeks, during which time, the chemical 
and physical stability of each of the various formulations were determined. 
Stability-indicating assays were developed for each compound incorporated in the 
EMID (Section  3.4.). All dosage forms were evaluated by assessing their chemical 
and physical stability and the results are reported in this chapter. The analytical 
method should simultaneously identify and quantify the drug of interest as well as 
any degraded products. The appearance of any new peaks present on HPLC 
chromatograms, which were not originally apparent in freshly made samples were 
to be sought as these would reflect the presence of degradation products from the 
stored progesterone suspension, oestradiol-17β tablets and cloprostenol powder 
analysed by HPLC stability indicating assays.  
In addition, the effect of 40°C/75%RH on battery functionality in the EMID was 
assessed. 
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5.2 Methods 
5.2.1 Manufacture and assessment of progesterone suspension 
5.2.1.1 Manufacture of progesterone suspension 
The formulation composition of the suspension investigated in this stability trial is 
listed in Table  5.1. 
Table  5.1. Composition of progesterone suspension. 
Ingredients Content % (w/w) 
Progesterone USP 2.5 
Hydroxypropyl methyl cellulose (HPMC) NF (60 SH 4000) Metolose 4.0 
Distilled water  93.5 
Total  100.0 
 
The formulation was manufactured by first mixing the progesterone and distilled 
water in a beaker using a star blade mixer  (Heidolph, Nicholas Watson Victor Ltd, 
Germany) at 1000 rpm speed followed by the slow addition of HPMC until a 
uniform (lacking of any clear lumps in the suspension) product was achieved. The 
resultant formulation was left to stand at room temperature for two days to ensure 
complete removal of any gas bubbles from the suspension. A thin foam layer is 
formed at the top of the suspension due to gas bubbles moving to the top of the 
suspension. This layer was removed using a spatula, prior to assessment of the 
suspension. 
5.2.1.2 Assessment of progesterone suspension 
A pharmaceutical suspension is a coarse dispersion in which insoluble particles 
are dispersed in an aqueous medium (Attwood, 2002). A measurement of the rate 
of sedimentation of a suspension, the final volume or height of the sediment and 
ease of its redispersion are used to assess the physical stability of a suspension 
(Billany, 2002). 
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A stable suspension is one in which the final volume or height of the sediment 
remains constant and the dispersed drugs retain their initial form and remain 
uniformly distributed for at least the period between shaking the container and 
removing a required amount considering that progesterone suspension is a finely 
distributed and dispersed as insoluble powder progesterone solid particles in 4% 
w/w HPMC gel in distilled water. For the chemical stability study, the drug was 
extracted from the matrix and analysed using the validated HPLC indicating assay. 
5.2.1.2.1 Drug content uniformity 
5.2.1.2.1.1. Selection of extraction solvent  
Drug content was quantified by HPLC after extraction of the progesterone from 
the suspension formulation. Three extraction solvents were investigated for their 
ability to extract progesterone from the suspension formulation: alcohol, 
methanol/water (6:4) solution and 5% HPβCD in distilled water.  
In order to determine the ability of the different solvents to extract progesterone 
from the formulation, a known quantity of progesterone was added to the 
formulation vehicle. Spiked progesterone samples were prepared by incorporating 
a known amount of progesterone (0.1380 g) into 5.3820 g of formulation base. 
The total amount of formulation was quantitatively transferred into a 200 mL 
volumetric flask. The mixture was stirred using a magnetic stirrer flea (50 x 8 mm 
Magnetic Teflon Stirring Bar, Biolab, New Zealand) for 30 minutes. The mixture 
was subsequently subjected to ultrasound (Soniclean Pty. Ltd, Australia) for a 
further 30 minutes. The stirrer was removed and the solution was made up to 200 
mL with the extraction solvent. Finally, the solution was filtered through a 0.20 
μm nylon filter and the filtrate injected onto the HPLC column for analysis.  
The efficiency of the extraction process was determined by calculating the percent 
bias and the percentage recovery using Equation  5.1 andEquation  5.2, respectively 
(where Ct and Ca are theoretical and actual concentrations, respectively) where the 
theoretical concentration of this extract was estimated as 690 μg/mL. 
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% Bias = 100×−
a
at
C
CC  Equation  5.1. 
 
% Recovery = 100×
t
a
C
C  Equation  5.2. 
 
The extraction efficiency was determined by analysis of spiked samples in 
triplicate for each extraction solvent. 
5.2.1.2.2 Appearance 
The appearance of the suspension was assessed visually by noting any changes in 
colour and the presence of any sedimented particles.  
5.2.1.2.3 Suspension physical stability 
The physical stability of the progesterone suspension was assessed by pouring 50 
mL of progesterone suspension into a 50 mL graduated measuring cylinder. The 
suspension was vigorously mixed prior to pouring. In order to prevent evaporation 
of the vehicle, the measuring cylinders were covered with parafilm. 
The suspensions were observed for evidence of sedimentation on standing for 4 
weeks at (40°C/75%RH). Sedimentation was assumed to have occurred, when 
after visual examination, sedimented particles were observed at the bottom of the 
cylinder with the subsequent appearance of clear a supernatant.  
5.2.1.2.4 Manufacturing assessment 
The reproducibility of the manufacturing process was assessed by examining two 
separate batches of product produced on the same day. In addition, the 
consistency of the manufactured product was also evaluated by taking samples of 
known weight (5.5200 g) from bulk batches of the formulation from the top, 
middle and bottom of that batch. These samples were analysed by HPLC as 
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previously described in Chapter Three. The extraction efficiency of extracted 
samples was calculated using Equations 5.1 and 5.2. 
5.2.2 Manufacture and assessment of oestradiol-17β tablets  
5.2.2.1 Manufacture of oestradiol-17β tablets 
Table  5.2 documents the oestradiol-17β tablet formulation that was subjected to 
stability testing.  
Table  5.2. Composition of oestradiol-17β tablet. 
Ingredients Content % (w/w) 
Oestradiol-17β 2.5 
γ-cyclodextrin 3.75 
Lactose 8.75 
Microcrystalline cellulose (MCC) PH 101 9.75 
Magnesium stearate 0.25 
Total weight (mg) 25 
 
The oestradiol-17β and excipients were accurately weighed using a four decimal 
place balance (Sartorius Analytical Balance, Type BP110S, Biolab Scientific Ltd, 
NZ). The drug and excipients (with the exception of magnesium stearate) were 
added to a plastic bag and blended by shaking for 10 minutes. Magnesium stearate 
was added and the blend mixed for a further 3 minutes, following which, tablets 
were manufactured using a TDP Single Punch Tablet Press (STH®, Shanghai 
Tianhe Pharmaceutical Manufacturing Factory, China). A sample of the blend was 
retained for assessment of blend uniformity. 
A single batch of tablets (2400 tablets) was manufactured. The tablets were 
separated and collected in lots of one hundred and allocated a sequential number 
(1 to 24). The humidity and temperature of the room environment during the 
manufacturing process were (62.3-65.0 %RH) and (16.5-16.8ºC) respectively. The 
tablets were stored in plastic bags, in a cupboard at room temperature until they 
were assessed.  
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5.2.2.2 Assessment of oestradiol-17β tablets 
Like any other dosage form, tablets should meet a number of specifications 
regarding their chemical, physical and biological properties. Details of tests and 
specifications for these properties can be found in official monographs in the 
United States Pharmacopoeias (USP, 1994) and some of the qualities that a tablet 
should have include: 
• the correct dose as labelled, 
• a consistent elegant appearance, weight and size, 
• release of drug content in a controlled and reproducible way, 
• be free from any contaminants and micro-organisms that could cause any 
harm to the user/patient, 
• sufficient mechanical strength to withstand fracture and erosion during 
handling, 
• be chemically, physically and microbiologically stable during its lifetime. 
 
The physical and chemical parameters that should be examined during 
characterisation testing of a normal tablet include friability, weight, thickness, 
hardness, disintegration, assay, drug content uniformity and tablet dissolution.  
5.2.2.2.1 Drug content uniformity 
A known amount (0.4500 g) of a placebo blend was spiked with a known amount 
of oestradiol-17β (0.0500 g) in a 10 mL test tube to produce a powder of 
equivalent weight to 20 tablets. This powder was then mixed for 10 minutes using 
a spatula. The powder blend was transferred into a 100 mL volumetric flask by 
rinsing the test tube with the extraction solvent (alcohol). The solution was 
subjected to ultrasound (Soniclean Pty. Ltd, Australia) for 40 minutes. After 
sonification, the solvent was made up to 100 mL with alcohol. The resultant 
solution was then passed through a 0.20 µm filter and analysed using the HPLC 
method. The theoretical concentration of the oestradiol-17β in the resultant 
solution was 500 µg/mL. Three replicate spiked samples were analysed on three 
different days.  
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The same experiment was repeated using 0.2250 g of blend placebo spiked with 
0.0250 g of oestradiol-17β to produce a blend of the equivalent weight of 10 
tablets. The blend was subjected to the same extraction procedure as described for 
the 20 tablet blend. The theoretical concentration of the oestradiol-17β in the 
resultant solution was 250 µg/mL and once again, three replicate spiked samples 
were analysed on three different days. 
In addition, the extraction method was applied to the tablets manufactured as 
previously described to assess if the compaction process had any affect upon 
extraction efficiency. Twenty tablets of oestradiol-17β were weighed, completely 
crushed and subjected to the same extraction procedure described above. The 
theoretical concentration of the oestradiol-17β in the resultant solution was 500 
µg/mL.  
The extraction efficiency for each experiment was calculated using Equations 5.1 
and 5.2. 
5.2.2.2.2 Appearance 
The appearance of the tablets was assessed visually by noting any changes in the 
colour of the tablet and the surface morphology (e.g., smoothness, pitting).  
Tablets from a randomly chosen bag were evaluated to define the standard 
physical properties of the tablets.  
5.2.2.2.3 Friability testing 
Friability was determined using a Model FT440C Friability Tester with a digital 
counter (Key International, Inc., NJ, USA). Twenty tablets were accurately 
weighed and rotated for 100 drop cycles after which they were gently brushed to 
remove any dust from their surface and reweighed. The weight difference at the 
beginning and after testing was used to determine the friability of the tablets.  
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5.2.2.2.4 Tablet weight, thickness, diameter and hardness testing 
The weight of each tablet was measured using a four decimal place analytical 
balance. The thickness of each tablet was measured using digital callipers 
(Mitutoyo, CD-6″ CS, Mitutoyo Corp, Japan). The diameter and hardness of each 
tablet were measured simultaneously using the Erweka tablet hardness tester 
(Erweka GmbH, TBH 210, Total Lab System Ltd, Germany).  
5.2.2.2.5 Tablet disintegration  
Tablet disintegration was determined using a QC-21 disintegration test station 
(Model 1620 USP disintegration baskets 65-620-001, 1000 mL glass beaker 91-
030-036, acrylic water bath 64-700-131, Hanson Research Corporation, CA, 
USA). The disintegration station was operated at a temperature of 37ºC using 800 
mL of water in the glass beaker. The time taken for each lot of tablets (N=6) to 
disintegrate was recorded. The time of which the last tablet disintegrates and falls 
through the mesh was taken as the end point of the disintegration test.  
5.2.2.2.6 Dissolution Testing 
Dissolution testing of oestradiol-17β tablets was conducted in a sealed 200 mL 
glass bottle to prevent evaporation. The dissolution method was developed by 
taking tablets from the randomly chosen bag and assessing the effect of sampling 
time, receptor phase composition, shaking rate and volume of the dissolution 
media on the percent of drug released from a tablet. The final test parameters were 
selected based on the results of these experiments. Because the need of smaller 
volumes of the release media to dissolve 2.5 mg of the active, the widely used of 
compendial apparatus was not considered to conduct the dissolution testing for 
oestradiol-17β tablets. 
The final test conditions selected are listed in Table  5.3. The method involved 50 
mL of 10% HPβCD in pH 7.4 PBS being added to the 200 mL glass bottle and 
equilibrated to 39ºC. The tablet was dropped into the bottom of the bottle at time 
zero and dissolution was conducted in a shaking water bath (Grant Shaking Water 
Bath, Grant OLS 200, Grant Instruments England) at 50 strokes/minute. A sample 
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of the dissolution media was taken after 30 minutes of shaking. The sample was 
filtered using a 0.20 μm nylon filter before HPLC analysis.  
Table  5.3.Dissolution conditions selected for oestradiol-17β tablets. 
Parameter value 
Volume (mL) 50 
Release media composition HPβCD: PBS at pH5.0(1:9) 
Temperature (ºC) 39 
Speed (spm) 50 
Dissolution runt time (minutes) 30 
 
5.2.2.2.7 Manufacturing assessment 
The consistency of manufacturing was assessed by examining samples from each 
of the 24 bags of product that were separated out during manufacture. The tests 
performed were appearance, friability, weight, thickness, diameter, hardness, 
disintegration, dissolution and drug content of the oestradiol-17β tablets. The 
number of samples for each bag was 20 tablets for friability, weight, thickness, 
diameter and hardness tests. For the disintegration test there were 6 sample tablets 
per a bag. Every second bag had 6 tablets and every third bag had 5 tablets for the 
dissolution and the drug content tests, respectively. The results were used to 
calculate the mean value and standard deviation where appropriate. 
5.2.3 Manufacture and assessment of cloprostenol powder  
Thus far, a physicochemical description of cloprostenol has not previously 
covered in this thesis. Therefore, the following is a brief description and 
application of cloprostenol according to British Pharmacopoeia (1993). 
Cloprostenol sodium is a synthetic analogue of dinoprost (prostaglandin F2α) and 
it is used as a luteolytic agent in veterinary medicine. Cloprostenol is an almost 
white amorphous hygroscopic (absorbs moisture from atmosphere) powder. 
Cloprostenol is freely soluble in water, ethanol (96%), and methanol; it is 
practically insoluble in acetone. Cloprostenol should be protected from light and 
moisture as described in BP (Veterinary) 1993. 
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5.2.3.1 Manufacture of cloprostenol powder 
Table  5.4 documents the cloprostenol powder formulation that was investigated in 
this study. 
Table  5.4. Composition of cloprostenol powder. 
Ingredients Content % (w/w) 
Cloprostenol Sodium salt 0.75 
Microcrystalline cellulose (MCC) PH 102 10.25 
Lactose 88 
Magnesium stearate 1.0 
Total weight (mg) 100 
 
The components of the powder formulation were accurately weighed using a four 
decimal place balance. The blend was prepared in a plastic bag using the 
following procedure. Half of the microcrystalline cellulose was blended by 
shaking with the active ingredient for five minutes; the balance of 
microcrystalline cellulose was then added to the blended mixture and was blended 
for a further five minutes; half of the lactose was added to the mixture and 
blended for a further five minutes; the balance of the lactose was then added and 
blended for a further five minutes; magnesium stearate was then added to the 
mixture and blended for three minutes.  
5.2.3.2 Assessment of cloprostenol powder 
5.2.3.2.1 Drug content uniformity 
Drug content was quantified by HPLC assay after extraction of the cloprostenol 
from the powder blend. Cloprostenol was extracted by dissolving a known amount 
(0.1 g) in 9.9 g of deionised water and subjecting the mixture to ultrasound for 40 
minutes. These samples were then passed through a 0.20 μm nylon filter before 
analysis using a validated HPLC method.  
Validation of the extraction method was achieved by analysis of samples derived 
from a spiked blend that was accurately mixed using a mortar and pestle coupled 
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with a geometric dilution of the powders. This was repeated on six separate 
occasions with random samples being taken from the same spiked blend. Three 
different spiked blends were evaluated. The theoretical concentration of the 
cloprostenol in the resultant solution was 75 µg/mL.  
In each case, the extraction efficiency for each experiment was calculated using 
Equations 5.1 and 5.2.  
5.2.3.2.2 Angle of repose 
For a powder dosage form, a measurement of powder cohesion, angle of repose is 
used to determine flow properties of the powder (Staniforth, 2002). The angle of 
repose is formed by the powder poured from a container on to a horizontal surface, 
which makes a conical heap. This is because the particles of the powder stack 
until the approach angle for subsequent particles joining the stack is large enough 
to overcome friction and they slip and roll over other until the gravitational forces 
balances the interparticle forces. The sides of the conical heap formed in this way 
make the angle of repose with the horizontal surface. The angle of repose is a 
characteristic of the internal friction/cohesion of the particles. Angles of repose 
greater than 50º have unsatisfactory flow properties, whereas minimum angles 
close to 25º correspond to having very good flow properties (Staniforth, 2002). 
The angle of repose of the blend was determined by inverting and lifting vertically 
a 10 mL volumetric cylinder, which was previously filled with 10g of the powder 
blend, onto a petridish. This allows the powder to flow freely onto a petridish. The 
diameter and the height of the resultant conical heap of powder were measured to 
facilitate the calculation of the angle of repose (ө) using Equation  5.3.  
)(
)(tan
cmradius
cmheight=θ  Equation  5.3. 
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5.2.3.2.3 Appearance 
The appearance of the powder was assessed visually by noting any changes in 
colour and any aggregation. 
5.2.3.2.4 Manufacturing assessment 
Manufacturing assessment was achieved by taking random samples of known 
weight (0.1000 g) from various regions of the bulk mixture and extracting the 
cloprostenol by the method described in Section 5.2.3.2.1. The extracts were then 
analysed by HPLC and the consistency of drug content over the batch was 
determined. This was performed using five replicates on three different days. 
5.2.4 Manufacture of intravaginal product 
EMID’s (36 devices) were fabricated from HDPE material as described in Section 
4.2.1 for this thesis. Progesterone suspension formulation was added to the large 
chamber, two oestradiol-17β tablets were placed in one of the small compartments 
at the head of the insert and 100 mg of cloprostenol powder was added to the 
other small compartment located at the head of the insert. A gas cell (Varta 4690 
Simatec, Switzerland) was incorporated into the insert, but no resistor was added 
to activate the battery.  
5.2.5 Stability assessment  
A stability trial was conducted under accelerated conditions at 40ºC/75%RH using 
a temperature and humidity controlled oven (Contherm Digital Series, Cooled 
Incubator, Contherm Scientific Ltd, New Zealand). Progesterone suspension, 
oestradiol-17β tablets and cloprostenol powder and complete EMIDs, which 
loaded with associated formulations as described in (Section 5.2.4.1.), were all 
subjected to the stability trial conditions. All samples were stored for 4 weeks and 
samples were taken for analysis at time 0, 1, 2, 3 and 4 weeks. 
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5.2.5.1 Progesterone suspension, oestradiol-17β tablets and cloprostenol 
powder  
Progesterone suspension was stored in 50 mL graduated measuring cylinders, the 
oestradiol-17β tablets were stored in open top plastic pottles and the cloprostenol 
powder was stored in 10 mL graduated measuring cylinders. Table  5.5 depicts the 
tests that were performed at each time point on each dosage form. 
Table  5.5. Stability tests conducted on progesterone suspension, oestradiol-17β tablets and 
cloprostenol powder formulations investigated in this study. 
Formulation Test Method reference Samples at each 
time point 
Appearance 5.2.1.2.2. 2 
Progesterone suspension Suspension physical 
stability 
5.2.1.2.3. 2 
Appearance 5.2.2.2.2. 10 
Friability 5.2.2.2.3. 20 
Weight 10 
Hardness 10 
Thickness 10 
Diameter 
5.2.2.2.4. 
10 
Dissolution 5.2.2.2.2. 6 
Oestradiol-17β tablets in open 
pottles (Type 1 and Type 2 Fast 
and slow disintegration*) 
Drug content 5.2.2.2.1. 5 
Appearance 5.2.3.2.3. 1 Cloprostenol  
Powder Angle of repose 5.2.3.2.2. 1 
*Two groups of the oestradiol-17β tablets were selected fast (Type 1) and slow (Type 2) 
disintegration on the basis of their disintegration time.  
5.2.5.2 EMID product and associated formulations 
Complete EMID’s were stored horizontally on the metal trays of an oven. Table 
 5.6 depicts the tests that were performed at each time point on EMID. 
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Table  5.6. Stability tests conducted on formulations and battery functions of the EMID 
investigated in this study. 
Product Test Method 
reference 
Samples 
at each 
time 
point 
Progesterone drug content and degradation products 5.2.1.2.1. 5 
Oestradiol-17β drug content and degradation products 5.2.2.2.1. 5 
Cloprostenol drug content and degradation products 5.2.3.2.1. 5 
EMID 
associated 
formulations 
Battery function 5.2.5.2.1. 4 
 
5.2.5.2.1 Determination of the effect of storage on the battery 
The effect of storage (accelerated conditions at 40ºC/75%RH) on the battery shelf 
life was tested. At end of the treatment period, a 750 Ω resistor was placed in 
series with the battery, thereby influencing the current and starting the gas 
production as previously described in Chapter Four (Section 4.2.2.1). The rate of 
release of the formulation was determined by the weight loss method as 
previously described in Chapter Four Section 4.2.4.1. A comparison of the rates of 
release of EMIDs using the batteries subjected to the storage was made. 
5.2.5.3 Criteria of stability testing for a veterinary product 
Acceptance criteria of the mean recovery of the active drug in a veterinary product 
should be within the following ranges as shown in Table  5.7 (Australian 
Pesticides & Veterinary Medicines Authority, 2004). The sample matrix, the 
sample processing procedure and the analyte concentration affect the expected 
mean recovery. 
Table  5.7. Acceptable mean recovery of active constituent of a veterinary product. 
% Active/impurity content Acceptable mean recovery (%) 
≥10 98-102 
≥1 90-120 
0.1-1 80-120 
<0.1 75-125 
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In this study, a deviation of greater than or equal to 10% from the labelled claim 
of oestradiol-17β (10%) tablets is regarded unacceptable. Progesterone (2.5%) and 
cloprostenol (0.75%) mean recovery should be within the ranges of 90-120% and 
80-120%, respectively (Table  5.7). 
Stability of progesterone greater than two years old under the accelerated 
conditions at 40°C/75%RH was verified in previous studies on the CIDR™-B 
product (Ogle, 1999). In the CIDR™-B, progesterone is homogenously dispersed 
in a silicone matrix by injection moulding, at a high temperature (190ºC). Despite 
the high temperature, progesterone compound was very stable according to a 
personal communication from DEC International CIDR™-B experts. Likewise, 
oestradiol-17β tablets prepared from extruded solid dispersion process in 60ºC has 
also been found to be a stable product (Hulsmann et al., 2000).  
Previously, progesterone in aqueous suspension, oestradiol-17β in a tablet 
formulation and cloprostenol powder blend in EMID for veterinary application 
have never been investigated for stability. Therefore, a validated stability-
indicating assay was used for each compound (oestradiol-17β, cloprostenol and 
progesterone) incorporated in the EMID to asses the presence of additional peaks 
appearing on the HPLC chromatograms which would indicate decomposition 
(Section  3.4). The dosage forms were regarded as chemically stable products if 
the tested products retained their chemical and labelled claim as well as their 
original physical properties such as appearance, uniformity, suspendibility and 
dissolution after they were exposed to the stability trial. 
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5.3 Results and discussion 
5.3.1 Manufacture and assessment of progesterone suspension 
5.3.1.1 Manufacture of progesterone suspension 
All progesterone suspensions used in this study were successfully manufactured 
using the method described 5.1.2.1.1. The process was successful in terms of the 
criteria used for the assessment.  
5.3.1.1.1 Drug content 
5.3.1.2.1.1. Selection of extraction solvents  
The results of the effect of extraction solvent type on progesterone extraction 
efficiency from spiked samples in 4% HPMC containing 690 μg/mL of 
progesterone is shown in Figure  5.1 for alcohol, mobile phase (60:40 of methanol: 
water) and 5%HPβCD (Mean±SD).  
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Figure  5.1. Effect of solvent type on progesterone extraction recovery from progesterone 
suspension. 
 
Extraction of progesterone from the suspension was shown to be dependant on the 
extraction solvent used (Figure  5.1). Alcohol and the mobile phase were not as 
efficient at extracting progesterone (45 ± 7% and 58 ± 1%, respectively) from the 
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suspension as 5% HPβCD in deionised water. The latter showed an extraction 
efficiency of 98 ± 1%. Therefore, the 5% HPβCD extraction solvent was used for 
further study.  
5.3.1.1.2 Appearance 
All suspensions appeared homogenous and white in appearance after manufacture 
and stored at room temperature for two days.  
5.3.1.1.3 Physical stability 
The defined manufacturing process resulted in an elegant white pharmaceutical 
suspension that appeared uniform. 
5.3.1.1.4 Manufacturing assessment 
Figure  5.2 shows the results of manufacturing reproducibility between two 
batches of progesterone 2.5 % w/w in 4% HPMC and the consistency of the final 
product of these batches. In both batches the average recovery percent of 
progesterone remained the same (100 ± 1) regardless of the sample position 
within a batch or the particular batch. 
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Figure  5.2. Extraction of progesterone from the suspension formulation used in this study 
from different sample positions of 2 different batches using 5% HPβCD as an extraction 
solvent. 
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The batch-to-batch reproducibility of the manufacturing process for the 
progesterone suspension was shown to be consistent.  
5.3.2 Manufacture and assessment of oestradiol-17β tablets  
5.3.2.1 Manufacture of oestradiol-17β tablets 
All the tablets used in the study were successfully manufactured using the method 
described in 5.2.2.1.  
5.3.2.2 Assessment of oestradiol-17β tablets 
5.3.2.3 Drug content 
Figure  5.3 shows the results of extraction efficiency of oestradiol-17β spiked into 
a placebo blend at two different concentrations (500 and 250 μg/mL) on three 
different days. In all three occasions, the extraction recovery was ≥ 97%, which 
shows that almost all drug content in the spiked samples at the two different 
concentrations was extracted efficiently. Therefore, the extraction efficiency of 
oestradiol-17β was very precise and reproducible. 
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Figure  5.3. Extraction efficiency (%) of oestradiol-17β spiked into a placebo blend at two 
different concentrations on three different days. 
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In addition, Table  5.8 shows the extraction efficiency on two occasions of 
oestradiol-17β from 11 tablets each containing a theoretical amount of 2.5 mg of 
oestradiol-17β. On both occasions, the extraction recovery and bias were 103% 
and 3%, respectively, which also indicates that almost all drug content in the 
eleven tablets was extracted efficiently and so confirming that a reproducible and 
relatively precise extraction method for oestradiol-17β tablets had been developed. 
Table  5.8. The extraction efficiency on two occasions of oestradiol-17β from 11 tablets each 
containing a theoretical amount of 2.5 mg of oestradiol-17β. 
 Replicate # Theoretical 
concentration 
(μg/mL) 
Actual 
Concentration 
( μg/mL) 
% Recovery1 % Bias2 
1 259 267 103 3 
2 259 267 103 3 
Mean % Recovery  103 
  SD 0   
1Equation 5.2. 2Equation 5.1. 
5.3.2.3.1 Appearance 
Tablets from the randomly selected bag were white in colour and had a smooth 
surface.  
5.3.2.3.2 Friability, weight, thickness, diameter and hardness test 
Tablets from the randomly selected bag provided an average friability value of 
0.5%. The tablets had an average tablet weight, thickness, diameter and hardness 
values of 26 mg, 2.4 mm, 3.1 mm and 56.8 N, respectively (Table  5.9). 
Table  5.9. Average weight, thickness, diameter and hardness values of oestradiol-17β tablets 
(N=20). 
Parameter Mean ± SD  % RSD Range 
Weight (mg) 26.0 ± 0.2 0.8 25.7 - 26.3 
Thickness (mm) 2.4  ± 0.0 1.0 2.3 - 2.4 
Diameter (mm) 3.1 ± 0.0 0.3 3.1-3.1 
Hardness (N) 56.8 ± 4.6 8.1 50 - 65 
 
The oestradiol-17β tablets from the randomly selected bag showed very precise 
(%RSD ≤0.8%) diameter and weight values (Table  5.9). 
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5.3.2.3.3 Tablet disintegration  
Tablets from the randomly selected bag showed that the disintegration time of the 
oestradiol-17β was 20.6 minutes. 
5.3.2.3.4 Drug dissolution 
Table  5.10 shows the effect of dissolution time on percentage drug release from 
an oestradiol-17β tablet estimated on three different occasions. The sampling 
points were arbitrarily selected for assessment of dissolution from the randomly 
selected bag. The aim was to define the time at which at least 70% of the drug 
content of oestradiol-17β tablet was released under the operated conditions. In 
order to validate the dissolution method, the experiment was repeated on three 
different occasions under the same conditions. This validated method was then 
used to test the drug dissolution profile from the tablets that were subjected to 
accelerated testing. 
Table  5.10. Effect of dissolution time on percentage of drug release from an oestradiol-17β 
tablet estimated on three different occasions. Receptor phase composition = 10% HPβCD in 
PBS at pH 7.4; Shaking rate = 50 strokes per minute (spm); Temperature = 39ºC. 
Day Time (minutes) 
1 2 3 
Average drug release (%) 
0 0 0 0 0 
15 18 19 16 18 
30 33 32 34 33 
60 34 42 42 39 
 
The amount of drug released is affected by the time of exposure of the tablet to 
the release media (Table  5.10). There is a trend of increased percentage of drug 
release from an oestradiol-17β tablet over time.  
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Table  5.11 shows the effect of receptor phase composition on the percentage of 
drug released from an oestradiol-17β tablet after 30 minutes of shaking at 50 spm. 
Table  5.11. Effect of receptor phase composition on percentage of drug release from an 
oestradiol-17β tablet after 30 minutes of shaking at 50 (spm); Temperature = 39ºC. 
Receptor phase composition % released  
2.5% HPβCD in PBS at pH 7.4 23 
10% HPβCD in PBS at pH 7.4 33 
15% HPβCD in PBS at pH 7.4 27 
10% SDA 5 
25% SDA 5 
50% SDA 21 
 
The percentage of drug released from an oestradiol-17β tablet varied with 
different release media compositions. The 10% HPβCD in PBS at pH 7.4 release 
media gave the highest amount released (33%) compared to other release media 
used (Table  5.11). Table  5.12 shows the effect of stirring rate (50 and 100 spm) on 
percentage of drug release from an oestradiol-17β tablet.  
Table  5.12. Effect of stirring rate on percentage of drug release from an oestradiol-17β tablet.  
Stirring rate (spm) % released  
50 27 
100 29 
 
The stirring rate had little or no effect on the percentage of drug released from an 
oestradiol-17β tablet (Table  5.12). 
Table  5.13 shows the effect of the receptor phase volume (50 and 100 mL) on the 
percentage of drug released from an oestradiol-17β tablet. 
Table  5.13. Effect of receptor phase volume (50 and 100 mL) on percentage of drug release 
from an oestradiol-17β tablet.  
Receptor phase volume (mL) %released  
50 27 
100 23 
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The receptor phase volume affected the percentage of drug release from an 
oestradiol-17β tablet. Increasing of the receptor phase volume possibly leads to 
further dilution of the amount dissolved drugs. This would be likely to 
underestimation of the drug concentration (close to quantitation limit) in the 
receptor phase.  
Tablets from the randomly selected bag provided an average (N=6) dissolution of 
27 % drug released (Table  5.14). 
Table  5.14. Percentage drug released of oestradiol-17β from tablets. 
Bottle number % release 
 
1 20 
2 22 
3 29 
4 36 
5 27 
6 27 
Average 27 
SD 6 
% RSD 21 
 
There is a relatively high variation of percentage release of oestradiol-17β among 
tablets obtained from the randomly selected bag (Table  5.14). This inconsistency 
of drug release profile of the tablets from the same bag could possibly be due to 
the lack of precision of compressive loading applied on the tablets during 
manufacturing.  
5.3.3 Manufacturing assessment of oestradiol-17β tablets 
5.3.3.1 Appearance 
All of the 20 tablets tested in each bag (24 bags) were white in colour and had a 
smooth surface. The appearance of these tablets was tested against the appearance 
of oestradiol-17β tablets from the randomly selected bag.  
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5.3.3.2 Friability test 
Weight loss in all bags before and after the friability test varied between 0 and 
0.6% and did not exceed 0.6% in any bag. Therefore, the friability test of all bags 
did not differ from the friability (0.5%) of the randomly selected bag as previously 
described.  
5.3.3.3 Tablet weight, disintegration and hardness testing 
The average weight varied between 25 and 27 mg for all oestradiol-17β tablets 
from all bags except bags 2, 3 and 17 (Figure  5.4). Also, the oestradiol-17β tablets 
(N=20) from the same bag showed a small weight variation. The percentage RSD 
of the oestradiol-17β tablets from all bags was smaller or equal to 3.3% except 
bags 2 and 3. 
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Figure  5.4. Oestradiol-17β tablet hardness, weight and disintegration values across all bag 
numbers (Mean±SD). 
 
The average hardness for all of the tablets from the 24 different bags varied 
between 37.9 ± 8.4 and 57.1 ± 3.1 Newtons. Tablets within one bag also showed a 
variable range of hardness values. For instance, the tablets from bags 3 and 20 
varied between 21 and 57 versus 52 and 59 Newtons, respectively. A pattern of 
hardness seems to have occurred during a manufacturing run such that after an 
initial drop, the hardness of the tablets appeared to gradually become harder with 
time (Bag 17 was regarded as an outlier).  
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Since the tablets were manufactured by manually turning the press of the machine, 
the dwell times of the punches in the die would be different resulting in different 
compression characteristics, and therefore this might have caused inconsistent 
compressibility of the tablets reflected from their hardness. 
Figure  5.4 also shows the tablet disintegration results. The tablets from all bags 
showed variable disintegration times for the oestradiol-17β tablets from the 24 
different bags (RSD of 57%). The disintegration time (minutes) of the oestradiol-
17β tablets in the 24 different bags varied between 3.4 and 23 minutes. Tablet 
disintegration appeared to vary from bag to bag throughout the manufacturing 
process with little or no obvious trend. The pharmaceutical reasons for changes in 
tablet disintegration between tablets include poor blending and incomplete mixing 
of the disintegrants and changes in compaction pressure (Aulton, 2002). In this 
study, inconsistent compressibility loading during tablet manufacturing may affect 
disintegration time of the tablets. 
The disintegration data resulted in the batch being divided into two types of 
tablets which are Type 1 (Bags 5-12) which were characterised by a fast 
disintegration with a disintegration time of less than 5 minutes and Type 2 (Bags 
1-3, 13, 15, 16, 18-24) which were characterised by a slow disintegration with a 
disintegration time of greater than 15 minutes. A third type was also identified, 
which displayed an intermediate disintegration time between 5-15 minutes (Bags 
4, 14 and 17) but these were not used for further study. 
Figure  5.5 shows the average diameter and thickness of tablets for each bag. The 
diameter remained constant (3.0 mm) for all oestradiol-17β tablets. This was not a 
surprise as the inside diameter of the die remains the same during manufacturing, 
the tablet diameter is also expected to be unchanged. The average thickness varied 
between 2.3 and 2.5 mm for all oestradiol-17β tablets in all bags except bags 1, 2, 
3 and 17. Also the oestradiol-17β tablets (N=20) from the same bag showed small 
thickness variation. The percentage RSD value for thickness was smaller or equal 
to 2.8% for the oestradiol-17β tablets from all bags. It is noteworthy that the 
thickness trend is very similar to that for the weight of the tablets. Possibly, some 
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changes of compaction pressure of the punches were applied during production of 
tablets from bags 1-3 and 17. 
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Figure  5.5. Oestradiol-17β tablet thickness and diameter values across all bag numbers 
(Mean±SD). 
 
5.3.3.4 Drug dissolution 
Table  5.15 shows the results of percentage dissolution release of oestradiol-17β 
tablets from 12 different bags (six tablets per bag). The tablets from 12 bags 
showed variable percentage dissolution release of the oestradiol-17β tablets 
(between 22±9 and 69±11 %) from the tested bags (RSD of 57%). The oestradiol-
17β release of the tablets from all bags was greater or equal to 40% content except 
the tablets from bags of 21 and 23. Also, the oestradiol-17β tablets from within 
the same bag showed variable percentage dissolution release of the oestradiol-17β 
tablets (RSD of 7% and 43%). From Table  5.15 it can be seen that the fast 
disintegrating tablets from bags between 5 and 11 released at least 62% of their 
drug content. The slow disintegration tablets from bags between 1-3 and 11-23 
released 45% or less of their drug content. The difference in percentage 
dissolution of oestradiol-17β tablets is probably due the different disintegration 
rates. For instance, the faster disintegration tablets are expected to release more 
drugs than the slow disintegration tablets under the same conditions. As 
previously explained in Section  5.3.3.3, the method of manufacture could also 
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affect the disintegration times and subsequently dissolution rates of the tablets. In 
addition, an inadequate mixing of the tablet blend could result in non-uniform 
distribution of the active and therefore this may result in variable dissolution rates. 
Table  5.15. Percentage dissolution of oestradiol-17β tablets from 12 different bags. 
Replicate # Bag number 
  1 2 3 4 5 6 
Average % release 
(Mean ±SD) 
% RSD 
 1 31 48 38 52 35 66 45 ± 13 29 
 3 55 62 35 33 19 37 40 ± 15 38 
 5 75 79 - 61 53 76 69 ±  11 16 
 7 58 49 70 71 97 66 68 ±  16 24 
 9 64 63 65 54 66 61 62 ±  5 7 
 11 70 71 70 61 47 53 62 ± 10 16 
 13 40 47 49 71 53 32 49 ± 13 27 
 15 72 56 56 52 59 18 52 ± 18 35 
 17 38 65 47 46 46 57 50 ± 10 19 
 19 43 55 43 42 40 30 42 ± 8 20 
 21 19 23 27 8 20 36 22 ± 9 43 
 23 20 22 29 36 27 27 27 ± 6 21 
 
It was concluded from Table  5.15 that the drug release was not constant across all 
the tested bags. This was attributed to inadequate mixing used to combine all the 
ingredients and the likely presence of segregation of the disintegrants.  
5.3.3.5 Drug content 
Figure  5.6 shows the results of percentage label claim of oestradiol-17β tablets 
from eight different bags (five tablets per bag). The tablets from the tested bags 
showed similar percentage of label claim between 93 and 106.4% of the 
oestradiol-17β tablets. Also, the tablets from the same bag showed an acceptable 
deviation (RSD ≤10%) from the label claim of the oestradiol-17β tablets. The 
overall percentage label claim of the oestradiol-17β tablets is 98 ± 4% for all 
tested bags, which is very promising. Since, the tablets were crushed and the 
active ingredient was completely dissolved in the receptor phase, their drug 
content is expected to be recovered. 
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Figure  5.6. Oestradiol-17β content in tablets from a range of bags that cover the 
manufacturing run. 
 
It was concluded from Figure  5.6 that the drug content was constant for the 
representative bags from the manufacturing run. 
5.3.4 Manufacture and assessment of cloprostenol powder  
5.3.4.1 Manufacture of cloprostenol powder 
All cloprostenol powders used in the study appeared successfully manufactured 
using the method described 5.1.2.1. 
5.3.4.2 Assessment of cloprostenol powder 
5.3.4.2.1 Drug content of cloprostenol blend 
Figure  5.7 shows the extraction efficiency of cloprostenol from a spiked blend 
manufactured using a mortar and pestle on three different days.  
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Figure  5.7. Effect of intra-day and inter-day extraction reproducibility on the extraction of 
cloprostenol from the powder blend. 
 
Assessment of the manufactured blend revealed that it had uniform cloprostenol 
content (Figure  5.7). A reproducible extraction procedure for cloprostenol was 
developed and validated for which drug extraction efficiency was about 80% 
(80±2, 83±3 and 80±4%, for the three different days) of the expected theoretical 
value. This lower recovery of cloprostenol was attributed to an extraction problem.  
5.3.4.2.2 Angle of repose 
The angle of repose of the fresh blend was determined to be 31˚.  
5.3.4.2.3 Appearance 
The appearance of cloprostenol was white. No aggregation of the fresh blend was 
noted.  
5.3.4.2.4 Manufacturing assessment 
The cloprostenol content of the manufactured blend from five different regions of 
the mixture on three different days are shown in Figure  5.8. The cloprostenol 
powder manufactured using geometric mixing in a plastic bag resulted in 
inconsistency of the drug extraction efficiency (83±19, 90±16 and 84±15% for the 
three different days). The higher standard deviation shows inconsistent drug 
Chapter Five 
207 
content uniformity of the powder mixture. An inadequate mixing of the blend 
could result in non-uniform distribution of cloprostenol and therefore different 
samples of the blend might have different drug load and subsequently variable 
assay results. Proper blending and prevention of drug segregation are required for 
a successful manufacturing process (Wu et al., 2000). It is a fact that formulation 
of low dose drugs can be very challenging and problems related to content 
uniformity may arise. This is likely due to the use of a plastic bag to mix the 
powders and lower drug dose (0.75% w/w). Variability of the drug content 
uniformity is due to inadequate distribution of low dosage drugs in powder 
(Greaves, Beasley, & Swarbrick, 1999). This inadequate homogeneity 
encountered with compositions containing lactose is due to the migration of the 
potent low dose drug that disrupts to achieve even distribution of the drug through 
the mixing. Shaking in a plastic bag was found to be an inadequate preparation 
method of cloprostenol powder.  
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Figure  5.8. Effect of intra-day and inter-day extraction reproducibility on the extraction of 
cloprostenol from the powder blend. 
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5.3.5 Stability assessment of progesterone suspension, oestradiol-
17β tablets and cloprostenol powder 
5.3.5.1 Progesterone suspension 
5.3.5.1.1. Appearance and progesterone suspension physical stability 
The presence of any discoloration or sedimentation of the suspension was 
considered to indicate the physical stability of the product under operating 
conditions. All suspensions appeared white and did not discolour at any sample 
point (Table  5.5). The suspensions appeared homogeneous throughout the 
investigation. All suspensions remained physically stable. No sediment was 
observed and no supernatant occurred in any of the samples at any sample point. 
It was concluded that the progesterone suspension remained physically stable 
upon storage. This was due to the fact that the suspension contained a high 
concentration of suspending agent which produced a very viscous continuous 
phase preventing particle sedimentation. 
5.3.5.2 Oestradiol-17β tablets  
The previous tablet characterisation experiments elucidated that the tablet 
appearance, friability, weight, diameter and drug content were found to be 
relatively constant between different bags prior to the stability study. 
Disintegration time and percentage drug released varied among the bags. Two 
types of tables were selected, fast (Type 1) and slow disintegration (Type 2), on 
the basis of their disintegration time.  
5.3.5.2.1 Appearance 
All tablets appeared white and had a smooth surface at all sample points (Table 
 5.5). The appearance of the tablets did not change upon storage. There was no 
evidence of any surface changes implying that the elevated temperatures and 
humidity did not affect the visual appearance of any of the tablets. 
Chapter Five 
209 
5.3.5.2.2 Friability 
Table  5.16 shows the friability of Type 1 and 2 tablets investigated. The tablet 
weight loss due to the friability test is insignificant. The friability value not greater 
than 1.0% is acceptable (USP, 1994). Therefore, the storage conditions do not 
appear to affect the susceptibility of the tablets to abrasion.  
Table  5.16. Friability of Type 1and 2 tablets investigated in this stability study. 
Friability Sample time (weeks) 
 0 1 2 3 4 
% weight loss(Bags of 5, 7 and 8) 0.2 1.0 0.7 0.2 0.6 
% weight loss (Bags of 13, 15 and 19). 0.4 0.2 0.0 0.1 0.3 
5.3.5.2.3 Weight 
Tablet weight for both Type 1 and Type 2 oestradiol-17β tablets was observed to 
remain constant during storage (Table  5.17). Therefore, any potential absorption 
of water during storage was insignificant compared to the weight of the whole 
tablet. Table  5.17 shows the average weight (mg) and tablet weight precision 
(%RSD) of Type 1(fast) and Type 2 (slow) disintegrating tablets investigated in 
this stability study. 
Table  5.17. Average weight (mg) and tablet weight precision (%RSD) of Type 1and Type 2 
tablets. 
Tablet types Parameter Sample time (weeks) 
Types  Weight (mg) 0 1 2 3 4 
Mean 26.0 26.3 26.3 26.1 26.0 Type 1 (5, 7 and 8 bags) 
%RSD 2.8 1.0 2.0 2.0 2.0 
Mean 26.6 26.6 26.6 26.8 26.2 Type 2 (13, 15 and 19 bags) 
%RSD 1.4 1.3 1.4 0.7 1.0 
 
Both Type 1 and 2 tablets showed very close weight value. The average weight 
variation is similar for each type (RSD ≤2.8%).  
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5.3.5.2.4 Hardness 
Table  5.18 shows the average hardness of Type 1 and Type 2 tablets. 
Table  5.18. Average hardness of Type 1 and Type 2 tablets investigated in the stability study. 
Tablet types Parameter Sample time (weeks) 
Types  Hardness (N) 0 1 2 3 4 
Mean 42 41.1 42.0 37.9 37.3 Type1 (5, 7 and 8 bags) 
%RSD 9 11.8 11.2 9.7 12.5 
Mean 47 46.3 44.9 43.7 44.4 Type 2 (13, 15 and 19 bags) 
%RSD 8 12.4 8.2 8.1 12.9 
 
Tablet hardness for both Type 1 and Type 2 oestradiol-17β tablets was observed 
to decrease during storage. The percentage RSD fluctuates between 8 and 12% for 
the tested periods. Also hardness values of Type 1 tablets differed from Type 2. 
Both the Type 1 and 2 tablets showed some variation among them. However, 
overall this data suggested that there was no significant change in the tablet 
hardness on storage (Table  5.18).  
5.3.5.2.5 Thickness Diameter 
Average thickness and diameter of Type 1 and 2 tablets investigated in the 
stability study did not show any difference for the same type or between the two 
types. Tablet thickness for both Type 1 and Type 2 oestradiol-17β tablets was 
observed to remain constant during storage. This indicated that if any moisture 
penetrating the tablets when exposed to elevate humidity conditions, did not 
produce any swelling and did not significantly affect the thickness of the tablet.  
5.3.5.2.6 Dissolution 
The effect of storage on percentage release of oestradiol-17β tablets is shown in 
Table  5.19 for both types of tablets. The percentage drug released appear constant 
with time, and drug dissolution appears independent of storage. It can be seen 
from Table  5.19 that the general trend is for the Type 1 tablets to have a greater 
percentage drug release than the Type 2 tablets (≥69 versus ≤54%). A similar 
trend of percentage drug release was observed from the tablets prior to stability 
trial.  
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Table  5.19. Percentage released (%) of Type 1 and 2 tablets investigated in the stability study. 
Tablet types Parameter Sample time (weeks) 
Types  Dissolution (% ) 0 1 2 3 4 
Mean 69 76 74 78 76 Type1 (5, 7 and 8 bags) 
%RSD 6 7 10 13 21 
Mean 51 48 40 54 45 Type 2 (13, 15 and 19 bags) 
%RSD 15 55 18 27 21 
 
The overall increase of drug release from the tablets subjected to the storage may 
have been due to an initial reaction to the humidity that remained constant after an 
initial exposure. Initial exposure may have impelled some absorption of water that 
resulted in a reaction with one of the components of the tablet causing them to 
bind more strongly with time, thereby affecting the dissolution of the tablets. 
Table  5.20 shows the average drug content of Type 1 and 2 tablets. The average 
drug content varied between 91-99% and 94-104% for Type 1 and Type 2 tablets, 
respectively.  
Table  5.20. Average drug content of Type 1 and Type 2 tablets investigated in the stability 
study. 
Tablet types Parameter Sample time (weeks) 
Types  Drug content (% ) 0 1 2 3 4 
Mean 97 93 91 99 98 Type1 (5, 7 and 8 bags) 
%RSD 8 9 4 5 6 
Mean 100 102 95 104 94 Type 2 (13, 15 and 19 bags) 
%RSD 4 8 4 7 5 
 
The percentage RSD value is lower than 10% at any sample point for each type. 
The storage did not affect on the drug content the tablets contained in open pottles. 
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5.3.5.3 Cloprostenol powder 
5.3.5.3.1 Appearance 
No colour changes were observed in any of the samples at any sample point.  
5.3.5.3.2 Angle of repose 
The angle of repose of the cloprostenol samples was determined at all four sample 
points. It was observed that as the storage time increased, lumps appeared in the 
powder. For comparison purposes, the angle of repose of the samples in the 
presence of the lumps and after breaking the lumps was also determined.  
The angle of repose at the four sampling times before and after breaking the 
lumps is presented in Table  5.21. The angle of repose of the clumped powder was 
greater than 25º at any sampling point. The declumped samples produced an 
acceptable angle of repose (approximately 25º).  
Table  5.21. Effect of storage on the angle repose of cloprostenol powder before and after 
breaking the lumps. 
Angle of repose Week one Week two Week three Week four 
Clumped 
samples 
34.1 29.8 45 31.2 
Declumped 
samples 
21.8 24.8 24.8 24.8 
Difference 12.3 5 20.2 6.4 
 
During storage the cloprostenol powder blend did not appear to change colour, but 
clumps of powder developed upon storage. The angle of repose was affected by 
the presence of clumps that formed on storage of the powder under accelerated 
conditions. The angle of repose was therefore determined both before and after 
destroying the clumps to make the powder blend homogenous in consistency. The 
angle of repose was variable and few conclusions can be drawn from this data. It 
is expected that the release of the drug from the powder and therefore from the 
delivery device would be affected by its ability to flow easily and freely. 
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Therefore, the ability of the drug to flow easily and freely would be expected to be 
affected by formation of the clumps.  
5.3.6 Stability determinations of the whole EMID 
EMIDS were successfully manufactured as previously described in Chapter Four. 
The complete EMID is assessed and the test procedures were described in Table 
 5.6 as previously described. 
5.3.6.1 Progesterone drug content and degradation products in the 
EMID 
The effect of storage conditions on the progesterone suspension contained inside 
the EMID and exposed to 40ºC/75%RH for four weeks is shown in Figure  5.9.  
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Figure  5.9. Effect of 4 weeks storage on progesterone content in the EMID. 
 
The progesterone average percentage labelled claim recovery is within the 
acceptable range of 90-110% of the expected value at any time point of the 4 
weeks study (Figure  5.9). There was an initial drop in progesterone content in the 
3-week sample followed by a relatively stable period for the remaining week. 
There was no evidence of any degradation products and no extraneous peaks were 
seen on the chromatogrammes suggesting that no chemical degradation had 
occurred due to the storage conditions (Figure  5.10). Due to the large standard 
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deviation (±10) associated with the 3 and 4 week samples that this average value 
may not be at all significantly different to the samples of the remaining weeks.  
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Figure  5.10. Effect of 4 weeks storage on progesterone peak chromatogram (i.e., week 4 
sample). 
 
The stability indicating assay showed no degradation products for stored 
progesterone samples. This is in agreement with literature which states that 
progesterone is very stable product (Ogle, 1999). The standard deviation of ±10 
associated with samples of week 3 and 4 are possibly due to a change in the actual 
content of the suspension. It could be that progesterone starts to interact with 
polymer (HDPE) and the drug is partitioning into polymer chains or progesterone 
is interacting with the santoprene bung /piston material. 
5.3.6.2 Oestradiol-17β tablets drug content and degradation products in 
the EMID 
The amount recovered (%) compared to what is claimed on the label of the 
oestradiol-17β tablets contained within the EMID showed a slow decline upon 
storage (Figure  5.11). A trend shows that both Type 1 and Type 2 tablets followed 
the same profile of the drug content recovery in the samples of week 3 and 4. The 
Type 1 tablets showed a bit more pronounced decline than the Type 2 tablets with 
larger standard deviations. Within the EMID the tablet may absorb moisture and 
the drug that was in the solid state of the surface of the tablet would go into 
solution. The drug then may leak into the larger reservoir of the EMID from the 
solution or partition into the small seal rubber plastics and HDPE polymer. The 
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drug from the softer tablets is more likely to dissolve than the drug from the 
harder tablets. It was noted that some tablets (N=2) were found to be mushy or 
partially dissolved during recovery of the oestradiol-17β tablets contained in the 
EMIDs. This probably happened when a seal between the santoprene bung and 
the walls of the small compartments of the EMIDs was not attained and the 
moisture from the larger reservoir could leak into the small compartments. This 
would dissolve the tablets ingredients, which could leak into the larger reservoir 
of the device.  
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Figure  5.11. Effect of 4 weeks storage on the percentage of label claim for oestradiol-17β 
tablets contained inside an EMID. 
 
The average drug recovery of oestradiol-17β from the tablets was not affected by 
storage with the mean recovery of oestradiol-17β remaining in the acceptable 
range of 90-110% of the expected value. Additionally, there was no evidence of 
any degradation products or any extraneous peaks seen on the chromatogrammes 
suggesting that no chemical degradation had occurred due to storage conditions 
(Figure  5.12). However, the assay value of the product proved that using 
oestradiol-17β tablets in EMID is feasible. 
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Figure  5.12. Effect of 4 weeks storage on oestradiol-17β peak chromatogram (i.e., week 4 
sample). 
This follows on from previous work on oestradiol-17β tablets manufactured from 
solid dispersion using melt extrusion at 60ºC, which were also found to be stable 
(Hulsmann et al., 2000). 
5.3.6.3 Cloprostenol drug content and degradation products in the 
EMID 
The appearance of clumping is significant and indicates a possible adverse 
behaviour that could be detrimental to the EMID upon storage. It is noteworthy 
that recovered cloprostenol samples formed a rod shaped structure due to the 
shape of the small compartment of the EMID. Therefore, formation of 
cloprostenol powder clumps in the EMID would be expected. The mean recovery 
of cloprostenol remained in the acceptable range of 80-120% of the expected 
value (Figure  5.13). 
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Figure  5.13. Effect of storage on the percentage of label claim for cloprostenol powder 
contained inside an EMID. 
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There was a slow decrease of percentage drug content observed for cloprostenol 
powder in the samples stored for 3 and 4 weeks. The decrease was however, much 
greater in week 4 compared to week 3. However, no extraneous peaks were seen 
on the chromatogram suggesting that no chemical degradation had occurred 
(Figure  5.14).  
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Figure  5.14. Effect of 4 weeks storage on cloprostenol peak chromatogram (i.e., week 4 
sample). 
 
Therefore, due to the large standard deviation associated with stored samples, the 
average value may not be at all significantly different to the 4 week samples. The 
larger standard deviation of cloprostenol was due to poor powder mixing and 
lower drug dosage. The average drug recovery of cloprostenol from the powder 
was not affected by the storage. 
5.3.6.4 Effect of storage on battery functions in the EMID 
All 16 gas cells worked well and showed that the gas cell was stable under the 
tested conditions (Table  5.22). The release rate of every individual gas cell 
remained the same (3 g/day) and exhibited a linear correlation of ≥0.996 when the 
cumulative weight loss was plotted against release time.  
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Table  5.22. Cumulative weight loss of progesterone suspension (g) versus release time (days) 
using batteries that had been stored for 4 weeks in an EMID at 40ºC/75%RH. 
Day of release Week one Week two Week three Week four 
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 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 1 1.8 1.5 1.6 2.4 1.8 1.7 1.5 1.8 1.8 1.9 2.2 1.7 1.5 1.6 1.8 1.8 
 2 5.5 5.1 5.2 5.2 5.6 5.5 5.2 5.5 5.6 5.5 6.5 5.4 5.4 5.4 5.6 5.3 
 3 9.1 8.2 8.1 8.7 8.9 8.9 8.4 8.8 8.8 8.8 10.3 8.9 8.9 8.9 8.9 8.8 
 4 12.3 11.2 11.2 12.1 12.1 12.2 11.3 12.1 12.1 11.8 13.8 12.2 12.3 12.2 12.1 12.3 
 5 15.8 14.2 14.2 15.6 15.3 15.8 14.4 15.3 15.2 15 17.2 15.4 15.5 15.4 15.2 15.1 
 6 18.5 16.8 16.8 18.6 17.9 18.5 17.1 18 17.8 17.6 20.3 18.1 18.5 18 18 17.9 
 7 21 19.1 19.1 21.5 20.5 21.3 19.6 20.6 20.2 20.1 23.1 20.7 21.3 20.6 20.5 20.4 
 Slope (g/day) 3.2 2.9 2.9 3.2 3.1 3.2 2.9 3.1 3.0 3.0 3.4 3.1 3.2 3.1 3.1 3.1 
 R2 0.9960.9960.9960.9980.996 0.996 0.996 0.997 0.996 0.997 0.997 0.9960.9960.9950.9970.996
 
Table  5.22 shows the constant formulation release over time of all tested devices. 
This indicates that the battery is operating optimally and as good as fresh batteries. 
In this thesis (Section 4.2.4), the release rate of the fresh battery at 750 Ω was 3 
g/day for HDPE EMID. The battery function was not affected by the storage. 
5.4 Conclusion 
Progesterone suspension, oestradiol-17β tablets and cloprostenol powder 
formulations subjected to accelerated testing outside of the EMID were found to 
be chemically stable. There was a tendency of a slow decrease in drug content of 
progesterone and oestradiol-17β contained in the EMID during the last two weeks 
of storage. However, this was not of concern as the overall percentage of the drug 
recovered was within acceptable range. Different compartments of the EMID 
should be properly sealed to prevent any cross contamination between different 
formulations. The Cloprostenol powder formed some clumps, which may affect 
the drug flow from the powder. The battery was found to be stable upon storage.  
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6 Conclusions and recommendations for future work 
6.1 Conclusions 
A simple method using tools made in-house was developed to manufacture PCL 
membranes with defined thicknesses. An in-vitro steroid permeation technique 
was developed and validated using side-by-side cells with PCL membrane. 
Dexamethasone analogues, oestradiol-17β and oestradiol benzoate and 
progesterone were found to be easily absorbed and permeated through PCL.  
Excised mucosa was found to be permeable to the tested steroids with some 
differences in degree of permeation. Dexamethasone acetate, dexamethasone 
isonicotinate and dexamethasone dipropionate that their ester group attached on 
carbon position 21 were susceptible to ester hydrolysis. Dexamethasone valerate 
did not show any sign of hydrolysis. Progesterone followed by dexamethasone 
acetate and dexamethasone valerate showed higher permeability coefficients 
through vaginal mucosa compared to other dexamethasone analogues. Both the 
steroid molecular weight and solubility affected the rate of permeation. The 
permeation rate increased with increasing the solubility of a specific steroid. 
Conversely, the rate of the permeation and permeability coefficients decreased 
with increasing the molecular weight of the steroid. 
The permeation rate data generated using the selected PCL model membrane 
could not predict the permeation rate of selected steroids across excised vaginal 
mucosa in side-by-side cells. However, the use of the PCL membrane might assist 
in allowing for discrimination among steroids dosage forms.  
UV and HPLC analytical methods were developed and validated for 
characterising the tested steroids. In both methods, assays were shown to be linear 
within the stated range, precise and accurate. In addition, the HPLC stability 
indicating assays for progesterone, oestradiol-17β and cloprostenol were 
developed and validated. All the assays of HPLC stability assays were also shown 
to be linear within the stated range, precise and accurate. Progesterone suspension, 
oestradiol-17β tablets and cloprostenol powder formulations were successfully 
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manufactured and tested. Extraction solvents were developed for their ability to 
extract progesterone from the suspending agent, oestradiol-17β from the tablet 
matrix and cloprostenol from blended powder.  
Weight loss was found to be the simplest, cheapest and easiest method to measure 
the release rate from the EMID. The body and piston materials were found to 
influence delivery rate profile from the EMID. A high density polyethylene 
polymer was identified as the most ideal body material for the insert. Likewise, 
double O-ring silicone, Elastollan WYO 1388-5 and solid silicone pistons were 
found to be amongst the best pistons tested, as they did not show any slip-stick 
behaviour and demonstrated a consistent rate of release for the initial trial period.  
The santoprene piston materials showed slip stick phenomenon with some degree 
of variation amongst them. Polypropylene carrier pistons showed the highest 
friction of all, followed by santoprene. Both santoprene and polypropylene 
materials showed a very poor performance. 
In addition, the viscosity of the payload and orifice size was found to influence 
delivery rate profile from the EMID. The low viscosity payload with a large or 
medium orifice EMID resulted in loss of the payload material and thus disturbs 
the release profile. 
The EMID can provide adjustable or versatile drug release profiles. The rate of 
release of the formulation from the EMID can be modified by controlling the rate 
of the gas production from the gas cell. Additionally, different drug 
concentrations in the formulation can produce different responses in the blood 
profiles. The EMID product including the battery and associated formulations was 
found to be stable upon storage.The EMID (manufactured from high density 
polyethylene polymer) produced a good response of blood profile from cows, 
which were treated with the complete EMID containing formulated progesterone, 
but it showed a low retention rate.  Once the retention mechanism for the EMID is 
improved, the device would have potential for commercial application in induced 
calving and oestrous control of cattle via the intravaginal route. 
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6.2 Recommendations for future work 
The EMID needs further improvement of its retention mechanism in order to stay 
in the animal. Not all possible materials and designs were tested in this research, 
and there may indeed be even more beneficial combinations of various 
components, construction materials and configurations of EMID that could be 
used in future work and/or any commercial development of this product. Further 
research is needed to find a lower gas permeability polymer than HDPE to get a 
more linear release profile for long periods of time, and to do further testing of 
Elastollan WYO 1388-5 and solid silicone pistons with different body materials. 
A low viscosity payload with a large or medium orifice should not be used for 
animal trials as this resulted in loss of the payload material. Different 
compartments of the EMID should be properly sealed to prevent any cross 
contamination between different formulations. 
It is recommended that further animal trials are conducted using dexamethasone 
acetate formulation or dexamethasone valerate loaded into EMID for induced 
calving per vaginum administration. Also, it is recommended to screen flux of 
dexamethasone acetate or valerate (in suspension perhaps in 4% HPMC) through 
excised membrane using side-by-side cells. In addition, the same formulations 
could be administered into animals to produce drug blood responses and to 
investigate if there is an in vitro and in vivo correlation for the recommended 
steroids. This could lead a finding of an inexpensive in vitro system simulating 
and mimicking the barrier function of diffusion conditions in animals. 
Further work for the EMID might be measuring pulsing precision of the 
secondary pistons to monitor the release of oestradiol-17β and cloprostenol 
together with progesterone for oestrous control to ensure that the EMID performs 
an immediate release of oestradiol, a sustained release of progesterone and a 
delayed release of a PGF at the appropriate times. 
The EMID could also be explored for use as an intraruminal drug delivery system 
for livestock animals as the device would be expected to be retained in a closed 
volume. 
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Appendix-A.The average thickness measured from over 
five points of the PCL membrane segments. 
Table of thickness of the PCL membranes. 
Membrane Measurement position 
  1 2 3 4 5 
Average 
(µm) 
SD 
(µm) 
1 150 150 140 150 150 148.0 4.0 
2 140 140 140 140 140 140.0 0.0 
3 150 150 140 145 145 146.0 3.7 
4 140 140 140 145 140 141.0 2.0 
5 145 145 145 145 145 145.0 0.0 
6 150 150 140 140 145 145.0 4.5 
7 140 140 135 142 142 139.8 2.6 
8 140 140 138 140 140 139.6 0.8 
9 138 140 140 140 140 139.6 0.8 
10 140 140 138 140 140 139.6 0.8 
11 140 140 140 140 140 140.0 0.0 
12 135 142 140 140 142 139.8 2.6 
13 140 140 145 135 140 140.0 3.2 
14 138 140 145 135 140 139.6 3.3 
15 142 142 145 140 145 142.8 1.9 
16 145 135 135 142 140 139.4 3.9 
17 155 142 130 145 145 143.4 8.0 
18 150 135 135 140 140 140.0 5.5 
19 140 140 140 140 140 140.0 0.0 
20 135 142 140 140 142 139.8 2.6 
21 145 142 140 145 142 142.8 1.9 
22 145 135 135 142 140 139.4 3.9 
23 150 140 135 140 140 141.0 4.9 
24 140 145 145 145 140 143.0 2.4 
25 148 150 140 142 145 145.0 3.7 
26 145 140 140 150 142 143.4 3.8 
27 150 135 130 148 148 142.2 8.1 
28 140 140 135 135 140 138.0 2.4 
29 150 135 130 148 140 140.6 7.6 
30 142 150 145 140 140 143.4 3.8 
31 145 145 140 140 145 143.0 2.4 
32 140 135 140 140 140 139.0 2.0 
33 140 140 140 140 140 140.0 0.0 
34 140 140 140 140 140 140.0 0.0 
35 150 150 140 145 150 147.0 4.0 
36 142 135 140 148 140 141.0 4.2 
37 145 140 130 135 140 138.0 5.1 
38 135 135 140 140 145 139.0 3.7 
37 149 152 149 140 150 148.0 4.1 
38 144 145 145 155 146 147.0 4.0 
39 150 150 142 140 150 146.4 4.5 
40 150 142 150 150 152 148.8 3.5 
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41 150 140 140 150 150 146.0 4.9 
42 145 145 152 150 148 148.0 2.8 
43 150 155 140 140 150 147.0 6.0 
44 152 142 138 150 148 146.0 5.2 
45 145 150 140 135 142 142.4 5.0 
46 135 148 150 140 145 143.6 5.5 
47 135 138 148 150 142 142.6 5.7 
48 150 140 140 148 145 144.6 4.1 
49 145 138 140 150 145 143.6 4.2 
50 140 150 150 145 150 147.0 4.0 
51 145 145 150 150 148 147.6 2.2 
52 140 142 150 150 148 146.0 4.2 
53 148 142 140 150 145 145.0 3.7 
54 142 152 152 145 150 148.2 4.0 
55 140 145 139 132 140 139.2 4.2 
56 150 150 145 150 150 149.0 2.0 
57 145 142 135 130 140 138.4 5.3 
58 130 145 142 135 145 139.4 6.0 
59 140 140 142 150 142 142.8 3.7 
60 135 150 145 135 145 142.0 6.0 
61 140 140 148 150 145 144.6 4.1 
62 140 140 148 150 140 143.6 4.5 
63 145 150 148 145 150 147.6 2.2 
64 145 140 148 150 145 145.6 3.4 
65 140 150 150 145 148 146.6 3.8 
66 135 130 140 148 140 138.6 6.0 
67 145 148 140 138 145 143.2 3.7 
68 150 140 140 150 145 145.0 4.5 
69 145 150 140 145 150 146.0 3.7 
70 142 138 145 150 140 143.0 4.2 
71 145 152 150 145 150 148.4 2.9 
72 140 135 140 150 140 141.0 4.9 
73 145 150 140 140 145 144.0 3.7 
74 148 140 140 150 145 144.6 4.1 
Average (µm) 143.5 142.8 141.5 143.6 144.0 143.1 0.9 
SD (µm) 5.1 5.4 5.2 5.4 3.8 5.0 0.6 
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Appendix-B. The average thickness measured from over 
nine points of the silicone membrane segments. 
Table of Average thickness of the membrane segments of silicone membranes manufactured 
by DEC Manufacturing. 
Sample  No.1 No.2 No.3 No.4 No.5 No.6 No.7 No.8 No.9 No.10 Average STD.DEV.
1 185 160 110 120 125 150 130 115 160 150 140.5 23.0 
2 175 180 135 120 115 135 135 130 140 150 141.5 20.3 
3 150 200 175 130 130 110 155 135 130 140 145.5 24.6 
4 180 150 125 135 150 140 180 150 140 120 147.0 19.1 
5 165 155 155 145 190 160 190 125 170 170 162.5 18.6 
6 175 160 175 165 205 175 180 135 150 140 166.0 19.7 
7 145 120 120 170 185 185 175 170 140 130 154.0 24.6 
8 125 120 125 135 160 160 150 165 130 130 140.0 16.1 
9 140 115 140 145 180 150 160 160 120 160 147.0 18.6 
Average 160.0 151.1 140.0 140.6 160.0 151.7 161.7 142.8 142.2 143.3 150.0 8.3 
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Appendix-C1. Dexamethasone permeation throuugh PCL 
silicone (~150 μm), and synthetic skin (50 μm) 
membranes membrane  
Table of Raw data for permeation of Dexamethasone through PCL membrane. 
Run number Time of sample points 
(hours) 
Cumulative amount of dexamethasone permeated 
(μg) 
1 4.25 5.96 
 21.97 47.56 
 28.89 64.50 
 46.06 106.43 
 52.89 122.94 
 69.89 164.98 
 76.89 180.13 
 99.64 234.33 
 123.64 291.85 
 142.64 343.07 
2 4.25 5.04 
 21.97 38.77 
 28.89 50.99 
 46.06 82.85 
 52.89 96.40 
 69.89 129.67 
 76.89 141.42 
 99.64 183.32 
 123.64 229.40 
 142.64 269.40 
3 4.00 6.57 
 21.33 46.30 
 45.33 105.06 
 67.83 156.31 
 71.13 160.90 
 74.25 169.81 
 92.00 215.73 
4 4.00 4.76 
 21.33 38.84 
 45.33 83.81 
 67.83 128.41 
 71.13 135.22 
 74.25 144.84 
 92.00 183.26 
 
Table of Raw data for permeation of Dexamethasone through silicone membrane. 
Run number Time of sample points 
(hours) 
Cumulative amount of dexamethasone permeated (μg) 
1 27.17 2.91 
 48.03 4.72 
 74.37 7.35 
 95.70 9.10 
 119.62 11.12 
 142.37 13.19 
2 27.17 3.53 
 48.03 5.32 
 74.37 8.18 
 95.70 10.14 
 119.62 12.48 
 142.37 15.47 
3 22.00 5.67 
 46.00 7.13 
 70.33 9.71 
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 94.08 13.44 
 120.58 15.76 
 167.66 18.49 
4 22.00 4.59 
 46.00 5.72 
 70.33 8.31 
 94.08 11.60 
 120.58 12.88 
 
167.66 15.86 
 
Table of Raw data for permeation of Dexamethasone through synthetic skin membrane. 
Run number Time of sample points 
(hours) 
Cumulative amount of dexamethasone permeated (μg) 
1 21.88 2.30 
 46.63 4.10 
 70.05 4.67 
 94.80 6.25 
 117.75 8.00 
2 21.88 2.56 
 46.63 4.91 
 70.05 5.60 
 94.80 6.68 
 117.75 10.12 
3 23.63 1.60 
 47.72 3.39 
 72.63 4.49 
 96.00 5.51 
 122.42 6.27 
 144.42 7.08 
4 23.63 1.71 
 47.72 2.78 
 72.63 4.92 
 96.00 6.42 
 122.42 7.00 
 144.42 8.72 
 
Appendix-C2. Dexamethasone acetate permeation 
throuugh PCL silicone (~150 μm), and synthetic skin (50 
μm) membranes membrane 
Table of Raw data for permeation of Dexamethasone acetate through PCL membrane. 
Run number Time of sample points 
(hours) 
Cumulative amount of dexamethasone acetate  permeated (μg) 
1 4.25 4.42 
 21.87 50.21 
 29.20 72.74 
 46.12 124.45 
 53.17 144.12 
 70.79 191.47 
 77.54 202.14 
 95.46 257.44 
117.88 321.29 
125.52 344.89 
 
142.27 386.16 
2 4.25 4.54 
 21.87 54.08 
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 29.20 77.61 
 46.12 135.22 
 53.17 158.70 
 70.79 216.17 
 77.54 236.38 
 95.46 292.05 
 117.88 353.85 
 125.52 377.29 
 142.27 425.99 
3 5.50 6.80 
 21.92 76.80 
 28.59 90.53 
 46.75 134.32 
 69.42 193.38 
 77.17 214.22 
 94.59 260.01 
 118.17 309.23 
Table of raw data for permeation of Dexamethasone acetate through silicone membrane. 
Run number Time of sample points 
(hours) 
Cumulative amount of dexamethasone acetate permeated 
(μg) 
1 21.92 10.39 
 49.17 20.33 
 72.92 28.43 
 95.42 35.82 
 117.75 44.42 
 141.25 51.81 
2 21.92 10.15 
 49.17 21.78 
 72.92 29.66 
 95.42 39.09 
 117.75 46.50 
 141.25 55.08 
3 21.920 10.29 
 46.750 17.16 
 69.420 28.77 
 94.590 37.22 
 118.170 45.93 
 142.670 54.11 
Table of Raw data for permeation of Dexamethasone acetate through synthetic skin 
membrane. 
Run number Time of sample points 
(hours) 
Cumulative amount of dexamethasone acetate permeated 
(μg) 
1 24.00 1.79 
 47.75 3.95 
 71.92 6.12 
 96.67 7.47 
 121.25 10.10 
 143.42 11.83 
2 24.00 3.31 
 47.75 5.44 
 71.92 7.11 
 96.67 8.29 
 121.25 10.11 
 143.42 11.83 
3 19.88 2.92 
 43.92 3.43 
 70.63 4.77 
 94.22 6.53 
 119.80 8.65 
 143.63 10.56 
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Appendix-D. The cumulative amount of the steroids 
permeated through excised mucosa over time 
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Figures of curves of the cumulative amount of progesterone, dexamethasone, dexamethasone 
acetate eter and dexamethasone dipropionate ester permeated through excised mucosa over 
time. 
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Appendix-E. Accuracy and precision of the UV assay 
Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for dexamethasone. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 3.93 3.96 3.90 3.93 0.024 0.62 -1.75 4 μg/mL 
2 3.99 4.16 3.75 3.97 0.17 4.24 -0.83 
1 29.07 29.63 29.93 29.54 0.36 1.21 -1.52 30 μg/mL 
2 29.62 29.72 29.67 29.67 0.041 0.14 -1.10 
1 39.47 38.99 38.78 39.08 0.29 0.74 -2.30 40 μg/mL 
2 40.53 39.40 39.85 39.93 0.46 1.16 -0.18 
 
Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for dexamethasone acetate. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 4.19 4.17 4.17 4.18 0.009 0.23 4.42 4 μg/mL 
2 4.06 4.14 4.17 4.12 0.046 1.13 3.08 
1 29.62 29.99 29.82 29.81 0.151 0.51 -0.63 30 μg/mL 
2 29.45 30.02 29.85 29.77 0.239 0.80 -0.76 
1 40.44 40.02 39.82 40.09 0.258 0.64 0.23 40 μg/mL 
2 40.18 39.92 39.85 39.98 0.142 0.36 -0.04 
 
Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for dexamethasone isonicotinate.. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 4.14 4.25 4.0 4.13 0.102 2.48 3.25 
4 μg/mL 2 4.05 4.25 4.06 4.12 0.092 2.23 3.00 
1 29.7 29.89 30.02 29.87 0.131 0.440 -0.433 
30 μg/mL 2 29.75 30.2 30.02 29.99 0.185 0.617 -0.033 
1 40.11 40.17 40.11 40.13 0.028 0.070 0.325 
40 μg/mL 2 40.17 40.04 39.89 40.03 0.114 0.286 0.083 
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Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for dexamethasone valerate. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 4.48 4.50 4.43 4.47 0.03 0.76 11.73 
4 μg/mL 2 4.42 4.45 4.29 4.39 0.09 2.01 9.64 
1 30.07 30.48 30.39 30.31 0.22 0.71 1.04 
30 μg/mL 2 29.93 30.37 30.48 30.26 0.29 0.95 0.87 
1 40.09 39.04 39.71 39.61 0.53 1.34 0.98 
40 μg/mL 2 39.66 39.75 39.54 39.65 0.11 0.27 0.88 
 
Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for dexamethasone diproprionate. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 4.36 4.10 4.23 4.23 0.106 2.51 5.75 
4 μg/mL 2 3.99 3.92 4.23 4.05 0.133 3.28 1.17 
1 29.71 30.07 30.49 30.09 0.319 1.06 0.30 
30 μg/mL 2 29.82 29.96 30.24 30.01 0.175 0.58 0.022 
1 39.93 40.29 40.09 40.10 0.147 0.37 0.26 
40 μg/mL 2 39.96 39.74 40.02 39.91 0.120 0.30 -0.23 
 
Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for progesterone. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 3.80 4.35 4.31 4.15 0.250 6.03 3.83 
4 μg/mL 2 3.84 4.41 4.39 4.21 0.264 6.27 5.33 
1 15.35 15.73 15.32 15.467 0.187 1.21 3.11 
30 μg/mL 2 15.17 15.69 15.24 15.367 0.230 1.50 2.44 
1 20.09 20.99 20.14 20.41 0.4130 2.02 2.03 
40 μg/mL 2 20.16 21.08 20.08 20.44 0.4537 2.22 2.20 
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Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for oestradiol benzoate. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 4.22 4.2 4.04 4.22 0.160 3.80 5.59 
4 μg/mL 2 4.16 4.22 4.18 4.24 0.060 1.35 5.97 
1 14.5 15.31 15.16 14.99 0.350 2.35 -0.069 
30 μg/mL 2 14.57 15.22 15.28 15.02 0.320 2.15 0.149 
1 20.49 20.25 20.01 20.25 0.200 0.97 1.25 
40 μg/mL 2 20.46 20.31 20.14 20.34 0.170 0.84 1.68 
 
Table of Inter-day reproducibility of accuracy and precision of the lower, middle and high 
range for oestradiol-17β. 
Concentration 
(μg/mL) 
Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 10.02 10.67 9.86 10.18 0.350 3.44 1.83 
4 μg/mL 2 9.89 10.54 9.90 10.11 0.304 3.01 1.10 
1 30.26 29.81 30.16 30.08 0.193 0.64 0.26 
30 μg/mL 2 30.40 29.65 30.10 30.05 0.308 1.03 0.17 
1 39.99 39.27 40.00 39.75 0.342 0.86 -0.62 40 μg/mL 
2 40.06 39.17 39.93 39.72 0.393 0.99 -0.70 
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Appendix-F. The quantitation limit of the UV assay 
Table of the UV quantitation limit for dexamethasone. 
Concentration (μg/mL) Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias
1 1.14 1.02 1.05 1.07 0.07 6.10 7.02 1 μg/mL 2 1.11 1.04 1.06 1.07 0.03 3.26 6.71 
1 2.17 2.07 2.09 2.11 0.05 2.58 5.57 2 μg/mL 2 2.17 2.08 2.09 2.11 0.05 2.29 5.57 
1 3.23 3.11 3.11 3.15 0.07 2.13 5.06 3 μg/mL 2 3.23 3.11 3.16 3.17 0.06 1.96 5.50 
 
Table of the UV quantitation limit for dexamethasone acetate. 
Concentration (μg/mL) Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias
1 1.09 1.06 1.12 1.09 0.03 2.88 8.88 1 μg/mL 2 1.12 1.07 1.15 1.11 0.04 3.71 11.18 
1 2.24 2.09 2.17 2.17 0.07 3.42 8.28 2 μg/mL 2 2.18 2.12 2.14 2.15 0.04 1.64 7.29 
1 3.18 3.07 3.17 3.14 0.06 2.01 4.71 3 μg/mL 2 3.23 3.15 3.22 3.20 0.05 1.46 6.73 
 
Table of the UV quantitation limit for dexamethasone isonicotinate. 
Concentration (μg/mL) Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias
1 0.77 0.72 0.75 0.75 0.03 3.61 -25.19 1 μg/mL 
2 0.78 0.70 0.75 0.74 0.04 5.70 -25.82 
1 1.84 1.74 1.79 1.79 0.05 2.83 -10.32 2 μg/mL 
2 1.80 1.72 1.81 1.78 0.05 2.87 -11.22 
1 2.83 2.77 2.81 2.80 0.03 0.97 -6.56 3 μg/mL 
2 2.84 2.74 2.88 2.82 0.07 2.61 -6.07 
 
Table of the UV quantitation limit for dexamethasone valerate. 
Concentration (μg/mL) Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias
1 0.83 0.63 0.76 0.74 0.10 13.56 -25.67 1 μg/mL 2 0.79 0.73 0.76 0.76 0.03 3.91 -24.16 
1 1.83 1.72 1.78 1.78 0.06 3.16 -11.15 2 μg/mL 2 1.83 1.77 1.83 1.81 0.03 1.84 -9.58 
1 2.88 2.64 2.82 2.78 0.12 4.47 -7.36 3 μg/mL 2 2.94 2.78 2.77 2.83 0.09 3.34 -5.61 
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Table of the UV quantitation limit for dexamethasone dipropionate. 
Concentration (μg/mL) Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 1.22 1.18 1.09 1.16 0.07 5.74 16.36 
1 μg/mL 
2 1.25 1.20 1.15 1.20 0.05 4.13 19.66 
1 2.20 2.15 2.15 2.17 0.03 1.42 8.30 
2 μg/mL 
2 2.19 2.12 2.12 2.15 0.04 1.87 7.39 
1 3.20 3.05 3.10 3.12 0.07 2.39 3.91 
3 μg/mL 
2 3.18 3.23 3.06 3.16 0.09 2.86 5.29 
 
Table of the UV quantitation limit for progesterone. 
Concentration (μg/mL) Replicate Day 1 Day 2 Day 3 Mean SD % RSD % Bias 
1 0.64 0.66 0.60 0.63 0.03 4.91 -36.77 
1 μg/mL 
2 0.64 0.64 0.60 0.62 0.02 3.76 -37.57 
1 1.67 1.58 1.60 1.61 0.05 3.00 -19.28 
2 μg/mL 
2 1.66 1.64 1.60 1.64 0.03 1.84 -18.22 
1 2.62 2.56 2.56 2.58 0.03 1.33 -13.96 
3 μg/mL 
2 2.62 2.59 2.60 2.60 0.02 0.62 -13.29 
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Appendix-G. Accuracy and precision of the HPLC assay 
Table of the analysis of accuracy and precision for dexamethasone (N=3). 
Sample concentration 
 (μg/mL) 
Actual 
concentration 
(μg/mL) 
SD % RSD % Bias % Recovery
0.2 0.190 0.000 0.000 5.00 95.00 
2 2.123 0.00 0.222 -6.17 106.17 
4 4.093 0.078 1.90 -2.33 102.33 
 
Table of the Analysis of accuracy and precision validation standards for dexamethasone 
acetate HPLC assay validation (N=3). 
Sample concentration (μg/mL) Actual 
concentration 
(μg/mL) 
SD % RSD % Bias % Recovery
0.4 0.420 0.020 4.76 -5.00 105.0 
2 2.05 0.005 0.244 -2.25 102.25 
5 4.74 0.005 0.106 5.30 94.70 
Table of the Analysis of accuracy and precision for dexamethasone valerate (N=3). 
Sample concentration (μg/mL) Actual 
concentration 
(μg/mL) 
SD % RSD % Bias % Recovery
0.4 0.400 0.020 5.0 0.0 100.00 
2 2.02 0.070 3.47 -1.0 101.00 
5 5.09 0.025 0.492 -1.7 101.70 
 
Table of the Analysis of accuracy and precision for dexamethasone isonicotinate (N=3). 
Sample concentration (μg/mL) Actual 
concentration 
(μg/mL) 
SD % RSD % Bias % Recovery
0.4 0.380 0.007 1.94 0.503 94.97 
2 1.95 0.008 0.388 1.31 97.38 
5 4.74 0.001 0.014 6.51 94.79 
Table of the Analysis of accuracy and precision for dexamethasone dipropionate (N=3). 
Sample concentration (μg/mL) Actual 
concentration 
(μg/mL) 
SD % RSD % Bias % Recovery
0.4 0.400 0.005 1.176 0.004 99.96 
2 2.07 0.006 0.312 -1.774 103.55 
5.0 5.19 0.016 0.315 -4.637 103.71 
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Table of the Analysis of accuracy and precision for progesterone (N=3). 
Sample concentration (μg/mL) Actual 
concentration 
(μg/mL) 
SD % RSD % Bias % Recovery 
0.2 0.180  0.004 2.39 9.83 
2 2.14  0.009 0.42 -6.99 
4. 4.12  0.186 4.53 -2.92 
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Appendix-H. The limit of quantitation of the HPLC assay 
Table of the Data for determination of the limit of quantitation for dexamethasone (N=3). 
Sample concentration (μg/mL) Calculated 
(μg/mL) 
SD % RSD % Bias % Recovery
0.0 0.0 0.0 0.0 00.0 0.0 
0.1 0.0 0.0 0.0 100.0 0.0 
0.2 2.12 0.00 0.22 -6.17 106.17 
 
Table of the Data for determination of the limit of quantitation for dexamethasone acetate 
(N=3). 
Sample concentration (μg/mL) Calculated 
(μg/mL) 
SD % RSD % Bias % Recovery 
0.0 0.0 0.0 0.0 00.0 0.0 
0.1 0.0 0.0 0.0 100.0 0.0 
0.2 0.19 0.11 11 5 95 
0.4 0.40 0.027 2.7 0.0 100 
 
Table of the Data for determination of the limit of quantitation for dexamethasone 
isonicotinate (N=3). 
Sample concentration (μg/mL) Calculated 
(μg/mL) 
SD % RSD % Bias % Recovery
0.0 0.0 0.0 0.0 0.0 0.0 
0.1 0.0 0.0 0.0 100.0 0.0 
0.2 0.0 0.0 0.0 100.0 0.0 
0.4 0.371 0.062 6.2 7.25 92.75 
 
Table of the Data for determination of the limit of quantitation for dexamethasone valerate 
(N=3). 
Sample concentration (μg/mL) Calculated 
(μg/mL) 
SD % RSD % Bias % Recovery
0.0 0.0 0.0 0.0 00.0 0.0 
0.1 0.0 0.0 0.0 100.0 0.0 
0.2 0.0 0.0 0.0 100.0 0.0 
0.4 0.41 0.02 2.1 2.5 97.5 
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Table of the Data for determination of the limit of quantitation for dexamethasone 
dipropionate (N=3). 
Sample concentration (μg/mL) Calculated 
(μg/mL) 
SD % RSD % Bias % Recovery 
0.0 0.0 0.0 0.0 0.0 0.0 
0.1 0.0 0.0 0.0 100.0 0.0 
0.2 0.0 0.0 0.0 100.0 0.0 
0.4 0.37 0.2 2 7.5 92.5 
 
Table of the Data for determination of the limit of quantitation for progesterone (N=3). 
Sample concentration (μg/mL) Calculated 
(μg/mL) 
SD % RSD % Bias % Recovery 
0.0 0.0 0.0 0.0 0.0 0.0 
0.1 0.0 0.0 0.0 100.0 0.0 
0.2 0.19 0.2 2 5 95 
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Table of the Weight loss using Double silicone O-rings silicone piston 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 1.5 1 1.3 
2 4.4 3.5 4.1 
3 7.2 5.6 6.5 
4 9.2 7.2 8 
5 10.6 8.7 9.4 
6 12 9.6 10.2 
7 13.2 10.4 10.9 
8 13.8 11 11.7 
9 14.3 11.5 12.1 
10 15 11.9 12.4 
11 15.4 12.2 12.7 
12 15.6 12.7 12.9 
13 16.3 13.1 13.2 
 
Table of the Weight loss using Santoprene (8211-35) + 10% polypropylene.  
Replicate Time (Days) 
1 2 3 
0 0 0 0 
1 2.4 0.3 2.8 
2 4.8 0.3 5.5 
3 8.1 0.6 8.9 
4 8.1 0.6 9.1 
5 11.6 0.6 13 
6 11.7 0.8 13.1 
7 11.8 0.9 13.2 
8 11.9 0.9 13.3 
9 15.7 0.9 13.3 
10 16 1.1 13.4 
11 16 1.1 13.4 
12 16 1.2 13.5 
13 16.1 1.2 13.5 
 
Table of the Weight loss using Santoprene (201-73). 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 3.7 1.7 2.8 
2 3.8 6.28 5.7 
3 6.7 6.5 5.8 
4 10.5 11.4 9.8 
5 10.6 11.5 9.9 
6 10.7 11.6 9.9 
7 10.9 11.7 14.8 
8 11 11.8 14.8 
9 16.2 11.8 14.9 
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10 16.3 16.9 15 
11 16.5 17 15.1 
12 16.5 17.1 15.1 
13 16.6 17.2 15.2 
Table of the Weight loss using Santoprene (8211-75) + lube. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 1.2 2 3 
2 4.1 5.5 5.9 
3 4.3 5.6 6.1 
4 8.9 10.5 6.2 
5 9 10.6 6.3 
6 9.1 10.7 12.9 
7 9.2 10.8 13 
8 9.2 10.9 13.1 
9 9.3 10.9 13.2 
10 16.2 11 13.2 
11 16.3 11.1 13.3 
12 16.3 11.1 13.4 
13 16.4 11.2 13.5 
Table of the Weight loss using Santoprene (8211-87A). 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 1.7 1.8 0.1 
2 1.8 4.4 2.9 
3 6.1 7 3.1 
4 6.3 9.4 3.2 
5 6.4 11.2 3.2 
6 6.5 13.4 7.5 
7 6.5 15.1 7.7 
8 6.7 16.7 7.7 
9 6.7 20.6 7.8 
10 6.7 20.8 8 
11 6.9 20.8 8 
12 7 20.8 8 
13 7.1 26.3 8.1 
 
Table of the Weight loss using Santoprene (8211-87A) + 10% polypropylene. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 0.3 0.2 0.3 
2 0.3 2.8 2.1 
3 0.4 2.8 2.1 
4 0.4 2.9 5.5 
5 0.5 3 5.6 
6 0.6 7.1 5.7 
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7 0.7 6.8 5.8 
8 0.7 7.3 5.9 
9 0.8 7.4 5.9 
10 0.9 7.5 6 
11 0.9 7.5 6.1 
12 1 7.6 6.2 
13 1.1 7.6 6.3 
Table of the Weight loss using Reflex 123E. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 1.9 1.7 1.4 
2 3.7 3.4 2.9 
3 5.7 5.4 4.6 
4 7.1 6.9 6.1 
5 7.9 7.7 7.2 
6 9.7 9.4 8.2 
7 10.6 10.4 9 
8 11.4 11.1 9.7 
9 12.1 11.8 10.4 
10 12.8 12.5 10.9 
11 13.3 12.9 11.3 
12 13.6 13.4 11.6 
13 14 13.8 13.9 
 
Table of the Weight loss using PP pistons. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 0.3 0.1 1.9 
2 0.4 0.1 4.5 
3 0.4 0.2 6.9 
4 0.5 0.2 9.3 
5 0.6 0.3 11.6 
6 0.7 0.4 14 
7 0.8 0.5 16.5 
8 0.9 0.6 18.4 
9 0.9 0.6 20.6 
10 1.1 0.8 23.4 
11 1.2 0.8 23.9 
12 1.2 0.9 26.1 
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Table of the Weight loss using Thermoflex(65A 1-800). 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 3.9 2.9 3.7 
2 6.7 5.2 7.1 
3 9.5 7.7 10.7 
4 11.8 9.8 13.5 
5 13.6 11.3 15.5 
6 15.3 12.8 18.7 
7 16.8 14.2 21.5 
8 17.4 15 22.6 
9 18.1 15.5 23.4 
10 18.9 16.2 25.7 
11 19.4 16.6 26.4 
12 19.6 16.8 26.6 
13 20.4 17 26.6 
 
Table of the Weight loss using Desmopan 192. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 7.3 1.3 1.2 
2 8.8 2.7 2.6 
3 10.3 4.1 4.1 
4 11.8 5.3 5.3 
5 12.8 6.3 6.2 
6 13.8 7.1 7.1 
7 14.9 8 7.7 
8 15.6 8.9 8.6 
9 16.2 9.3 8.9 
10 23.5 9.7 9.4 
11 23.5 10 10.7 
12 23.6 10.3 10.9 
13 23.6 10.7 12.3 
Table of the Weight loss using Hytrel 4069. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 3.1 3.8 2.5 
2 5.6 6.9 4.4 
3 27.6 9.8 6.3 
4 27.7 11.2 7.9 
5 27.8 11.4 8.9 
6 27.8 13.7 9.8 
7 27.9 15.4 10.7 
8 27.9 16.5 11.4 
9 28 18 11.9 
10 28.1 20 12.5 
11 28.1 20.9 12.8 
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12 28.1 21.6 13.1 
Table of the Weight loss using Elastollan WYO 1388-5. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 2.5 2.6 2.7 
2 4.6 4.9 5 
3 6.8 7.4 7.5 
4 8.8 9.4 9.3 
5 10.2 11.1 11 
6 11.7 12.5 12.6 
7 12.9 13.9 13.9 
8 13.7 14.7 14.6 
9 14.3 15.6 15.3 
10 15 16.5 16.3 
11 15.8 17.2 17 
12 16.1 17.5 17.4 
13 16.5 18 18 
Table of the Weight loss using Silicone rubber piston on piston carriers. 
Replicate 
Time (Days) 1 2 3 
0 0 0 0 
1 3.5 2.6 2.7 
2 6.7 6.2 5.1 
3 10 9 7.6 
4 12.6 11.6 9.4 
5 14.7 30.1 11 
6 17.9 30.2 12.5 
7 20.6 30.2 13.4 
8 22.8 30.2 14.2 
9 24.9 30.2 14.7 
10 25.4 30.3 15.6 
11 25.6 30.3 15.9 
12 26.7 30.3 16.2 
13 26.8 30.3 16.3 
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Effect of the range time of the release on the slope value of the in vitro drug release method.  
Time 
(Hours) Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 Mean SD 
0 0 0 0 0 0 0 0 0 
0.5 1.95 2.2 1.95 1.85 1.9 1.6 1.9 0.2 
1 3.75 4.2 3.65 3.75 3.45 3.6 3.7 0.3 
1.5 5.5 6 5.8 5.9 5 5.5 5.6 0.4 
2 7.35 7.95 7.6 7.8 6.6 8.0 7.5 0.5 
3 10.5 11.45 11.2 10.65 9.65 11.0 10.7 0.6 
4 13.65 14.4 14.45 13.75 12.45 13.6 13.7 0.7 
  
  
  
  
  
  
  
  
  5 14.2 14.95 14.9 14.35 14.55 14.3 14.5 0.3  
   
Convert using the slope vale  (mg/Hour) divided by the drug concentration in the payload (0.5 mg/mL) 
mg/Hour Range mg/Hour 
Mean 
(mg/Hour) SD mL/Hour 
Slope 0-5 3.0 3.1 3.2 3.0 2.9 3.0 3.0 0.1 6.1 
Slope 0-4 3.4 3.6 3.6 3.5 3.1 3.5 3.4 0.2 6.9 
Slope 0-3 3.5 3.8 3.7 3.6 3.2 3.8 3.6 0.2 7.2 
Slope 0.5-5 2.9 3.0 3.1 2.9 2.9 2.9 2.9 0.1 5.9 
Slope 0.5-4 3.3 3.5 3.6 3.4 3.0 3.5 3.4 0.2 6.8 
Slope 0.5-3 3.4 3.7 3.7 3.6 3.1 3.8 3.6 0.3 7.2 
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Appendix-K. An example of the other In vitro release 
methods 
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Figure of the typical example of curve showing a lag phase for the other methods.  

Appendices 
L-1 
Appendix-L. Individual cow progesterone plasma profile 
over time of the dose titration study. 
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Progesterone formulation at 15 mg/mL
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Progesterone formulation at 5 mg/mL
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